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Thesis Summary 
Models of Alzheimer’s disease (AD) have provided useful insights into the 
pathogenesis and mechanistic pathways that lead to its development.  One emerging 
idea about AD is that it may be described as a hypometabolic disorder due to the 
reduction of glucose uptake in AD brains.  Inappropriate processing of Amyloid 
Precursor Protein (APP) is considered central to the initiation and progression of the 
disease.  Although the exact role of APP misprocessing is unclear, it may play a role in 
neuronal metabolism before the onset of neurodegeneration.  
 
To investigate the potential role of APP in neuronal metabolism, the SHSY5Y 
neuroblastoma cell line was used to generate cell lines that stably overexpress wild 
type APP695 or express Swedish mutated-APP observed in familial AD (FAD), both 
under the control of the neuronal promoter, Synapsin I.  The effects of APP on glucose 
uptake, cellular stress and energy homeostasis were studied extensively.  It was found 
that APP-overexpressing cells exhibited decreased glucose uptake with changes in 
basal oxygen consumption in comparison to control cell lines.   
 
Similar studies were also performed in fibroblasts taken from FAD patients compared 
with control fibroblasts.  Previous studies found FAD-derived fibroblasts displayed 
altered metabolic profiles, calcium homeostasis and oxidative stress when compared to 
controls.  As such, in this study fibroblasts were studied in terms of their ability to 
metabolise glucose and their mitochondrial function.  Results show that FAD-derived 
fibroblasts demonstrate no differences in mitochondrial function, or response to 
oxidative stress compared to control fibroblasts.  However, control fibroblasts treated 
with Aβ1-42 demonstrated changes in glucose uptake.  This study highlights the 
importance of APP expression within non-neuronal cell lines, suggesting that whilst AD 
is considered a brain-associated disorder, peripheral effects in non-neuronal cell types 
should also be considered when studying the effects of Aβ on metabolism. 
 
 
Key words: Alzheimer’s disease, glucose, mitochondria, SHSY5Y cells, human dermal 
fibroblasts 
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Chapter 1: Introduction to Alzheimer’s disease 
1.1 Overview of Alzheimer’s disease 
Dementia is defined as a substantial loss in intellectual abilities such as memory that 
impedes everyday functions.  Alzheimer’s disease is the most common form of 
dementia, making up to between 50 to 70% of dementia cases.  It is estimated that 
currently 44.4 million people suffer from AD worldwide, with this figure estimated to rise 
to 135.5 million by 2050 (International, 2013), if no effective treatments or cures are 
found.  
 
AD was first described by Dr Alois Alzheimer in 1908, after observing the symptoms of 
a patient with progressive memory impairment, changes in behaviour (including 
paranoia, delusions) and progressive decline in the ability to use language.  Post-
mortem brain examination of the patient revealed protein aggregates, which he termed 
‘plaques’ and ‘tangles’ (Hippius and Neundörfer, 2003).  However, it was Fischer 
(Fischer, 1907) who is credited to be the first to report plaques.  In the late 1960s, the 
work of Blessed, et al, (1968) led to AD becoming widely accepted as the most 
common basis for senile dementia (Blessed et al., 1968, Kang and Muller-Hill, 1990, 
Arai et al., 1991). 
 
Studies have attempted to define the pathogenesis of AD by observing and describing 
the two major structural hallmarks of the plaques and tangles (see Figure 1.1).  Kidd et 
al (1964) and Terry et al (1963) utilised electron microscopy to study the two types of 
lesions.  A number of studies have noted significant degeneration of neurons 
responsible for synthesising acetylcholine, as well as irregularities in the dopaminergic, 
glutaminergic and the inhibitory γ-aminobutyric acid (GABA) systems (Ellison et al., 
1986).  These observations strongly suggested that AD is the consequence of highly 
heterogeneous cell degeneration.  The study of the composition and origin of the 
plaques and tangles also became central to studies of AD.  However, current research 
18 
 
suggests that these lesions may only serve as pathological hallmarks observed late in 
disease.   
 A      B 
 
Figure 1.1 Image of the characteristic plaques (A) and neurofibrillary tangles (B) found 
in AD brain (Images attributed to Wikimedia Commons, https://common.wikimedia.org). 
 
1.2. Symptoms and disease pathology 
AD patients experience a range of symptoms including cognitive changes, memory 
loss and behavioural changes (Selkoe, 2001a).  The significant loss in memory function 
is largely attributed to massive neuronal cell and synapse loss in preferential brain 
regions. Cholinergic neurons are specifically affected (Mesulam, 2004), and are 
characterized initially by synaptic dysfunction that precedes neuronal death (Mattson, 
2004).  These symptoms represent the later stages of AD, in which behavioural 
changes become evident due to death of neurons in key regions. 
 
It is believed the lateral entorhinal cortex (LEC) is implicated in early AD.  LEC 
dysfunction in preclinical AD is detected by functional magnetic resonance imaging 
(fMRI) (Khan et al., 2014b).  The LEC is considered a gateway to the hippocampus, 
which plays a vital role in learning and consolidation for long term memories.  This 
makes the hippocampus especially susceptible to damage in early AD (Mu and Gage, 
2011).  AD has been shown to spread directly from the LEC to other areas of the 
cerebral cortex, especially the parietal cortex, which is responsible for spatial 
orientation and navigation.  Cognitive impairment is associated with synaptic loss in the 
neocortex and the limbic system, which are responsible for higher brain functions such 
as sensory perception, spatial reasoning and learning and memory (McIntosh et al., 
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1998, Miller and Cummings, 2007).  The extensive cell death observed leads to 
extreme shrinkage of the hippocampus and cerebral cortex. 
 
In the early and pre-symptomatic AD stages, degeneration of basal forebrain 
cholinergic nuclei takes place (Mann et al., 1984, Perry et al., 1978).  Neuronal cell 
death is attributed to exposure of cells to abnormal levels of beta amyloid (Aβ) peptide, 
with specific vulnerability of cholinergic basal forebrain neurons (Boncristiano et al., 
2002).  AD brains show hallmarks of apoptosis (Kadowaki et al., 2005, Mattson, 2000, 
Cotman and Su, 1996), such as DNA fragmentation and the activation of Caspase-3, a 
key effector enzyme of the apoptotic cascade (Stadelmann et al., 1999). 
 
Currently, diagnosis of AD is carried out using subjective aptitude exams, which test 
the ability of a person to identify objects and recall events.  The most common test is 
the mini mental state examination MMSE, first established in the 1970’s (Folstein et al., 
1975).  Clinicians can assess the severity of dementia based on the score attained and 
then recommend the appropriate treatment.  However, problems arise from variations 
in test specificity, with the major disadvantage of being unable to distinguish mild 
cognitive impairment (MCI) reliably from dementia and the difficulty in recording 
changes in cases of severe dementia (Lancu and Olmer, 2006).  In reality, 50% to 90% 
of dementia cases may be unrecognised due to the difficulty in distinguishing AD from 
normal aging (Ritchie and Lovestone, 2002). 
 
At present, definitive diagnosis can be only be carried out by post mortem brain 
autopsy to confirm the presence of plaques and tangles.  To date, there are no 
definitive biomarkers for diagnosing AD, but studies into levels of Aβ, total tau and 
phosphorylated-tau 181 taken from cerebral spinal fluid (CSF) have been assessed.  
Samples taken from MCI patients have demonstrated an increase in the level of total 
tau and phosphorylated tau but decreased levels of neurotoxic Aβ1-42 species 
(Hansson et al., 2006).  Sensitivity in these tests was estimated to be at 95% but 
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specificity was lower.  These results are encouraging but still require further validation.  
A current major issue in AD diagnosis is that neuronal degeneration is probably 
advanced to a stage that some current drug treatments may be ineffective (Peterson 
and Goldman, 1986). 
 
Advancements in brain imaging technology may prove useful to diagnose AD.  Imaging 
of AD brains showed decreases in total brain mass (Teipel et al., 2014) with shrinkage 
of the cerebral cortex and hippocampus (Dubois et al., 2007) and severely enlarged 
ventricles, as shown in Figure 1.2).   
Figure 1.2.  Image showing Pittsburgh Compound B (PIB) uptake to visualise amyloid 
in the brain of non-demented patient compared to Alzheimer’s patient brain. (Image 
attributed to Wikimedia Commons, 
https://commons.wikimedia.org/wiki/File:PET_AD.jpg). 
 
Amyloid deposition can be visualised in the brain with the use of Pittsburgh Compound 
B in PET scans (Klunk et al., 2004) (see Figure 1.2).  This technique could aid early 
diagnosis.  PIB is a radioactive thioflavin T analog which binds to beta sheets of 
amyloid, and is currently under development by GE Healthcare as a clinical diagnostic 
tool to assess brain amyloidosis (Landau et al., 2013).  Higher PIB retention has been 
demonstrated in AD patients when compared to controls (Rowe et al., 2007); with PIB 
retention particularly pronounced in the striatum of AD mutation carriers compared to 
sporadic patients/controls (Klunk et al., 2004). 
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The other major protein involved in AD is tau, which can also be imaged with tau-
specific radiotracers.  This technique may provide accurate, reliable and reproducible 
quantitative measures of global and regional brain tau burden (Zhang et al., 2012c).  
Such detailed neuroimaging methods provide a good evaluation of disease 
progression, (as the spread of tangles is a good correlation of AD pathology).  Most 
selective tau imaging tracers focus towards binding paired helical filaments (PHFs) 
(Villemagne et al., 2014).  However, the running costs of using such techniques for 
routine AD screening would likely deter clinicians from frequent use.  
 
Methods to detect early biomarkers for dementia could provide a more high throughput, 
non-invasive and inexpensive alternative.  A blood test is in development, which 
detects peripheral blood lipids profiles, that are associated with the development of 
MCI or AD within 3 years (Mapstone et al., 2014).  The researchers detected preclinical 
AD with 90% accuracy, which was comparable with published CSF studies.  Therefore 
simple blood tests such as these could provide faster and reliable diagnosis of patients 
at risk of developing AD, as well as alleviating the costs of using alternative methods. 
 
Fluorodeoxyglucose tracer positron emission tomography (FDG-PET) imaging detects 
glucose uptake in patients and has been used to study brain metabolism extensively in 
AD (see Figure 1.2).  FDG-PET has been utilised to measure cerebral metabolic rates 
of glucose (CMRglc), an indicator of neuronal activity.  In the AD brain, there are 
regional patterns of CMRglc reductions, with consistent deficits in parieto-temporal 
areas (Krystal, 1987), posterior cingulate cortex (Minoshima et al., 1997) and the 
medial temporal lobes, which encompasses the hippocampus, 
transentorhinal/entorhinal cortex and subiculum) (Mosconi, 2005).  In contrast, fMRI 
scans of the LEC in young healthy individuals show signs of high metabolism (Khan et 
al., 2014a).  Reductions in the activity of key mitochondrial enzyme complexes such as 
the α-ketoglutarate dehydrogenase complex and decrease in the expression of 
glycolytic enzymes and pyruvate dehydrogenase (PDH) complex has also been 
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observed in AD (Yao et al., 2009a).  Reductions in glucose utilisation in the brain as 
well as mitochondrial function appears decades before any symptoms or 
histopathological changes occur, making these metabolic changes useful biomarkers of 
risk of AD (Mosconi et al., 2008a, Reiman et al., 2004).  
  
As discussed in section 3.1.2, there is gradual decline in the energetics of mitochondria 
(production of ATP) as well as increases in production of oxidants and oxidative stress 
In AD.  Aβ has also been shown to interact with mitochondrial proteins including ABAD 
(amyloid-binding alcohol dehydrogenase) and CypD (cyclophilin D), which results in 
altered homoeostasis (Yao et al., 2007).  Carbohydrates are the major respiratory 
substrates in aerobic respiration, with glucose being the predominant energy source.  A 
shift toward the metabolism of ketone bodies away from glucose observed in AD could 
point to attempts by the cell to alleviate bioenergetic deficits and compensate for the 
decline in glucose-driven ATP generation (Hoyer, 1991, Blalock et al., 2004).  Ketone 
bodies produced from fatty acids in the liver, can be converted to acetyl-Coenzyme A, 
which can be fed into the Krebs cycle, by its conversion to citrate, the first compound of 
the Tricarboxylic acid cycle (TCA). 
 
These observations suggest that AD can be considered a result of hypometabolism 
(Mosconi et al., 2008b), with increasing evidence that AD is associated with type II 
diabetes.  In fact, Type II diabetes been shown to cause brain insulin resistance, 
oxidative stress and cognitive impairment (Zhao and Townsend, 2009).  Indeed AD has 
recently been described as “type III diabetes” (de la Monte and Wands, 2008).  
 
1.2.1 Amyloidogenesis 
One of the two major hallmarks of AD is the presence of intraneuronal plaques found 
throughout the brain, but particularly in the limbic and association cortices (Dickson, 
1997).  Such plaques are composed of an amyloid beta (Aβ) peptide core (Gouras et 
al., 2005, Gouras et al., 2000) surrounded by dystrophic neurites, reactive astrocytes 
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and other proteins.  Structurally, these neurites appear dilated and twisted, with cellular 
abnormalities such as engorged lysosomes and numerous mitochondria (Selkoe, 
2001b).  Neurons are known to naturally produce amyloid and release the peptide into 
the intraneuronal space (Haass et al., 1992b), where it is speculated to have important 
physiological functions (see section 1.4).  However, it should also be noted that plaque 
loads poorly correlate with cognitive impairment, which explains the incidence of non-
demented individuals who were found to have plaques post-mortem (Price and Morris, 
1999). 
 
Aβ is derived from a larger precursor protein called the Amyloid Precursor Protein 
(APP), which is cleaved in a complex pathway to generate peptides varying in length, 
ranging from 38 to 43 amino acids in length.  The most neurotoxic peptide form Aβ1-
42, has a higher propensity to aggregate due to the presence of two extra hydrophobic 
amino acids (Kim and Hecht, 2006) than its other forms (Snyder et al., 1994).  Aβ1-42 
and Aβ1-40 peptides found to make up the plaques seen in AD. 
 
During the aggregation process, amyloid initially forms beta sheet structures, which 
then progress to oligomers, fibrils and then plaques (Powers and Powers, 2008).  This 
increase in size can be detected when amyloid aggregates are separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis.  Non-fibrillar monomeric Aβ1-42 
appears at 4kDa, increasing in size as it forms beta sheets (Glenner and Wong, 1984b, 
Masters et al., 1985).  Amyloid plaques within tissue can also be positively stained with 
Congo red dye or Thioflavin T, which bind specifically to the beta sheet structures 
(Miura et al., 2002, Khurana et al., 2005).   
 
APP is located within the cell membranes of neurons, where it is cleaved, allowing the 
release of Aβ peptide into the extracellular space.  The peptide can be internalised by 
neurons, where it is folded into beta sheet sheets that stack together to form fibrils, 
which aggregate to form plaques (Seeman and Seeman, 2011) under pathological 
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conditions.  Three types of amyloid deposits have been identified in AD brains; diffuse 
plaques, senile plaques and cerebrovascular deposits (Morgan et al., 2004a).  The 
development of amyloid deposits can be described in three stages, according to their 
distribution progressing from antero-basal to postero-lateral deposition (Braak and 
Braak, 1991).  
 
Diffuse plaques are considered to occur early in plaque formation (Dickson, 1997).  
They are dispersed throughout the cerebral hemispheres and sparsely within the white 
matter, the striatum and cerebellar cortex.  These plaques are more common than 
senile plaques, and appear as amorphous, spherical, diffuse amyloid deposits 
(Tagliavini et al., 1988).  They are described as pre-amyloid deposits, where amyloid 
exists as non-amyloid aggregates, which do not stain with Congo Red or thioflavin-S, 
and can be found within ‘normal’ aged individuals.  They also do not contain neurites or 
signs of neuronal injury (Serrano-Pozo et al., 2011).  Senile plaques, on the other hand 
consist of a dense amyloid core (Iwatsubo et al., 1994), surrounded by dystrophic 
neurites, commonly containing paired helical filaments (PHFs, see section 1.2.2), 
closely associated to reactive astrocytes and microglia (Mandybur and Chuirazzi, 
1990).  A number of dystrophic neurites do contain tau but also stain positive for 
ubiquitin, which may be a sign of early plaque formation (Morgan et al., 2004a).  
Distinct hallmarks include the presence of butyrylcholinesterase (Guillozet et al., 1997), 
a protein associated with axonal growth cones and several neurotransmitters (Masliah 
et al., 1992).  Axonal sprouting associated with senile plaques is also thought to trigger 
synaptic dysfunction (Arendt, 2001).  Inflammation is evident in the vicinity of plaques, 
due to the presence of acute phase proteins such as antichymotrypsin, interleukin-1 
and interleukin-6 (IL-6) positive activated microglia (Wegiel and Wisniewski, 1990, 
Eikelenboom and Veerhuis, 1996). 
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Amyloid angiopathy can accompany AD, whereby amyloid deposits in cerebral blood 
vessels, in association with senile plaques (Miyakawa and Uehara, 1979).  However, 
cerebrovascular amyloid is also present in non-demented individuals who fail to 
possess the hallmarks of AD.   
 
1.2.1.1 APP Biosynthesis and trafficking 
The importance of amyloid and its precursor in AD has led to many studies on APP 
processing and whether upstream events may be future targets of therapeutic drugs.  
Amyloid Precursor Protein is encoded by the APP gene, which consists of 19 exons 
located on chromosome 21.  There are three main isoforms produced through 
alternative splicing of exons 7 and 8 (Sandbrink et al., 1996); APP751, APP770 and 
APP695 (LaFerla, 2002, Price and Sisodia, 1998, Price et al., 1998).  The two larger 
isoforms contain a 56-amino acid insert known as the Kunitz domain (KPI) (Fig 1.) 
within the extracellular domain, named as it shares homology to the Kunitz serine 
protease inhibitor domain (Price and Sisodia, 1998) but these isoforms when cleaved 
do not produce the amyloid peptide.  Interestingly, increased levels of KPI containing 
APP isoforms have been reported in AD and to be associated with Aβ (Zhang et al., 
2011).  The Aβ peptide is derived from Amyloid Precursor Protein 695 (APP695) 
isoform (Haass and Selkoe, 2007, Vassar, 2005), expressed abundantly within neurons 
(Puig and Combs, 2013, Tanaka et al., 1989) and to a lesser degree within astrocytes 
(Sisodia et al., 1993).   
 
Following transcription of the APP gene within the nucleus, full-length APP mRNA is 
directed to the endoplasmic reticulum for translation into protein by the action of 
ribosomes.  From here, APP continues its journey through to the Golgi apparatus and 
trans-Golgi network (TGN), where APP undergoes post-translational modifications, 
acquiring N- and O-linked sugars quickly after biosynthesis (Annaert et al., 1999).  Full 
length APP is a type I transmembrane protein, consisting of a large extracellular N-
terminal domain, a hydrophobic transmembrane domain and a short C-terminus 
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intracellular domain (Reinhard et al., 2005).  This protein quickly undergoes a series of 
proteolytic cleavages, resulting in a short half-life, estimated to be 20-30 minutes in 
most cell types tested.  APP cleavage results in the secretion of products into vesicle 
lumens and the extracellular space (Kang et al., 1987, Bodovitz and Klein, 1996). 
 
1.2.1.2 APP processing 
APP metabolism within the cell is complex, but has been particularly well-characterised 
for the APP695 isoform in the central nervous system.  Once full length APP is formed, 
it can follow one of two processing pathways, as shown in Figure 1.3, leading to the 
production of fragments, which themselves can influence distinct signalling pathways.  
Figure 1.3.  Diagram showing the two processing pathways in which APP695 may be 
processsed Image attributed to Wikimedia Commons, 
https://commons.wikimedia.org/wiki/File:P3_peptide_synthesis.jpg. 
 
1.2.1.2.1 The amyloidogenic pathway 
The amyloidogenic pathway (associated with AD) leads to sequential APP cleavage  by 
two different enzymes, β-secretase-1 (BACE1) and γ-secretase, resulting in Aβ peptide 
formation and the release of the C-terminal fragment, termed the Amyloid Precursor 
Intracellular Domain (AICD )(Zhang et al., 2012a).  Mutations (in APP, Presenilin 1 
(PSEN1), and Presenilin 2 (PSEN2)) have been identified, which influence APP 
metabolism (see Figure 1.4). Presenilins 1 and 2 encode for subunits that make up part 
of the γ-secretase enzyme complex.  In particular, these pathogenic mutations 
preferentially increase the production of neurotoxic Aβ1-42 (Thinakaran and Koo, 2008, 
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Cole and Vassar, 2007b, Jankowsky et al., 2004) or increase the Aβ40/42 ratio (Haass 
et al., 1995, Selkoe and Wolfe, 2007). 
Figure 1.4. Diagram showing where enzymes act on APP, as well as some of the 
mutations that influence enzyme cleavage.  
 
1.2.1.2.2 Beta-site APP cleaving enzyme 1 
BACE1 is widely expressed throughout the body but is highly active within neurons (Li 
et al., 2006, Czech et al., 2000).  BACE1 is an aspartyl protease, with a single 
transmembrane domain close to the C-terminus and a palmitoylated cytoplasmic tail 
(Benjannet et al., 2001).  It efficiently cleaves membrane bound substrates suggesting 
that the enzyme is likely to be membrane bound or closely associated with a 
membrane protein (Citron et al., 1995, Yu et al., 2000).  BACE1 co-localises to the cell 
membrane of the Golgi Body, Trans Golgi Network and endosomes (Cole and Vassar, 
2007a), where it functions optimally at acidic pH (Pastorino and Lu, 2006).  This is 
further supported by the fact that endosomal dysfunction has been linked with 
Alzheimer’s disease and neurodegeneration (Nixon, 2005).  The cleavage of APP 
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occurs upon APP internalization, which also suggests that BACE1 may be active in 
other cellular compartments in addition to endosomes. 
 
BACE1 acts at the Aspartate +1 residue of the Aβ sequence of APP (Vassar et al., 
1999) generating the amino terminus of Aβ (Figure 1.4 shows the cleavage site in 
APP).  This cleavage releases three fragments, sAPPα, a secreted APP ectodomain, 
and the membrane-bound carboxyl terminal fragment (CTF), C99.  BACE can also 
cleave at Glutamine +11, at Valine-3 or at Isoleucine-6 (Haass et al., 1992b).  The 501 
amino acid sequence of BACE1 contains two aspartic protease active site motifs 
(DTGs).  Mutation of either aspartic acid renders the enzyme inactive (Hussain et al., 
1999, Bennett et al., 2000b).  Site-directed mutagenesis of the amino acids close to the 
cleavage site of full length APP influences the sequence preference for BACE1 (Citron 
et al., 1995).  Substitutions of the residues to larger hydrophobic amino acids (such as 
to leucine and asparagine; observed in Swedish APP) for the methionine or lysine 
residue enhance the efficiency of BACE1 cleavage. 
 
This enzyme has broad substrate specificity, indicating it has other cellular functions.  
In addition to APP, BACE1 cleaves the APP-like proteins 1 and 2 (Eggert et al., 2004), 
low-density lipoprotein receptor LDLR related protein (LRP) (von Arnim et al., 2005), 
the β-subunits (VGSCβ and SCN2b) of sodium gated channels (Wong et al., 2005) and 
neuregulin (NRG1) (Willem et al., 2006).  The study of BACE1 knock outs led to subtle 
side effects, most notably, being more timid and a less exploratory phenotype 
compared to controls (Harrison et al., 2003). 
 
 The only known mammalian homologue of BACE1 is BACE2, which is mapped to the 
DS critical region on chromosome 21.  BACE2 shows only 75% sequence homology to 
BACE1, and is detected at low levels in peripheral tissues (Bennett et al., 2000a).  With 
relevance to AD, it is expressed at low levels in the brain but can cleave APP at the β-
site to produce Aβ in vitro (Abdul-Hay et al., 2012).  Interestingly, other studies have 
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reported BACE2 acting as an alternative α-secretase (Yan et al., 2001) and serving as 
an antagonist to BACE1 (Basi et al., 2003).  Furthermore, BACE2 expression is not up-
regulated to compensate for a lack of BACE1 in knockout mice.  BACE2 function has 
been associated with insulin expression in β-cells of the pancreas, where it modulates 
insulin receptor signalling   
 
1.2.1.2.3 γ-secretase 
γ-secretase is a multi-unit enzyme complex, consisting of: presenilin-1 or -2, nicastrin, 
anterior pharynx-defective 1(APH-1), and presenilin enhancer-2 (PEN-2).  Similarly to 
BACE-1, γ-secretase cleaves a range of substrates, preferentially processing type I 
integral membrane proteins such as Notch, E-cadherins and N-cadherins (Zhang et al., 
2000, Marambaud et al., 2002, Marambaud et al., 2003, Haapasalo and Kovacs, 
2011).  With respect to APP, γ-secretase cleaves at several sites within the 
transmembrane domain of the C-terminal fragment, releasing Aβ peptides ranging in 
length from 38 to 43 residues.  Approximately 90% of secreted Aβ ends in residue 40, 
whereas Aβ42 accounts for 10% under non-pathological physiological conditions.  
Minute amounts of shorter Aβ peptides such as Aβ37 and Aβ38 have also been 
detected (Thinakaran and Koo, 2008).  
 
1.2.2 The non-amyloidogenic pathway 
Non-amyloidogenic processing of APP (see Figure 1.3) is not associated with 
pathogenic phenotypes, and occurs via the action of α-secretase, which cleaves APP 
within the Aβ domain (at the Lysine 16-Leucine 17 bond) thus precluding Aβ peptide 
formation.  Cleavage at this site leads to the generation of soluble APP fragments that 
are associated with a range physiological functions (Haass et al., 1992a).  The second 
cleavage reaction is catalysed by γ-secretase. 
 
1.2.2.1 α-secretase 
α-secretase is a zinc metalloprotease (Roberts et al., 1994), and a type-1 
transmembrane protein (Lammich et al., 1999).  Enzyme activity principally occurs at 
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the plasma membrane (O’Brien and Wong, 2011) but some activity has also been 
observed in the  trans-Golgi (Kuentzel et al., 1993, Epis et al., 2012).  Activation of 
protein kinase C (PKC) causes an increase in α-secretase cleavage of APP by 
promoting transport of APP to the cell surface (Mills and Reiner, 1999).  Members of 
the A disintegrin and metalloprotease (ADAM) family were identified to have associated 
α-secretase activity, specifically ADAM9, ADAM10 and ADAM17, all of which have 
been demonstrated to cleave APP.   
 
The exact identity has been an area of intense research.  ADAM9 knockout mice 
demonstrated no significant differences in Aβ production or the α-secretase cleavage 
product p3 (Weskamp et al., 2002), eliminating this ADAM as being responsible for 
amyloid production in the brain.  Previously, ADAM17 was found to localise to plaques 
and tangles within the hippocampi of AD brains but its expression remains unchanged 
in AD (Skovronsky et al., 2001).  Furthermore, the inhibition of ADAM17 leads to 
decreased production of sAPPα, one of the APP cleavage fragments.  In addition, 
ADAM17-deficient cells retain α-secretase activity (Buxbaum, 1998).  Studies have 
strongly suggested that ADAM10 is the predominant α-secretase produced within 
neurons (Kuhn et al., 2010).  Overexpression of ADAM10 increases α-cleavage whilst 
dominant-negative form of ADAM10 inhibited endogenous α-cleavage activity 
(Lammich et al., 1999).  ADAM10 RNA levels have been found to be significantly 
increased in AD brains (Gatta et al., 2002), strengthening the case of ADAM10 as the 
main candidate for α-secretase activity.  At present, the identity of α-secretase is 
unclear, but may be due to the combined activities of both ADAM17 and ADAM10 
(Nunan and Small, 2000).  
 
Cleavage of APP by α-secretase is similar to processing of the growth factors TGF-α 
and TNF-α and other integral membrane proteins (Werb and Yan, 1998).  The 
mechanism involves a constitutive component and a modulated component, the latter 
of which is activated by PKC (Buxbaum et al., 1993) as well as other second 
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messengers.  Generally, constitutive α-secretase activity occurs in the brain arguably 
due to ADAM17, which is regulated by PKC.  Under basal conditions, α-secretase 
activity is estimated to outnumber β-secretase activity.  Overexpression of ADAM10 
within neurons of the cortex and hippocampus (Marcinkiewicz and Seidah, 2000) leads 
to reduced BACE1 processing of APP and a decrease in amyloid deposition (Postina et 
al., 2004).  Studies such as these suggest that up-regulation of α-secretase activity 
may potentially be of therapeutic value in AD (Postina et al., 2004). 
 
1.2.3 Neurofibrillary degeneration (NFD) 
The second hallmark of AD is the neurofibrillary tangles (NFTs).  NFTs are caused by 
intraneuronal aggregation of hyperphosphorylated protein into structures known as 
paired helical filaments (PHFs) (Kurt et al., 1997).  PHF bundles are principally found 
within pyramidal cells of the entorhinal cortex, hippocampus and the supragranular (II-
III) and infragranular (V-VI) layers of the association cortical areas (Braak and Braak, 
1995).  
 
PHFs are formed from phosphorylated tau (Grundke-Iqbal et al., 1986).  Tau belongs to 
a family of neuronal microtubule-associated proteins (MAPs) whose physiological 
functions are to modulate microtubule network stability, as well as coordinating axonal 
plasma membrane and microtubule processes (Koechling et al., 2010).  The human tau 
gene is found on chromosome 17q21, consisting of 16 exons, encoding for 6 tau 
isoforms as a consequence of alternative splicing of its mRNA.  The relative 
proportions of the various tau isoforms have also been reported in other neurological 
disorders (Gong and Iqbal, 2008). 
 
During neuronal development, tau stabilises microtubules in the axon.  Site-specific 
phosphorylation of the C-terminal repeats of tau dictates its ability to bind and stabilise 
microtubules.  Tau contains an exceptionally high number of putative phosphorylation 
sites (45 serines, 35 threonines and 4 tyrosines) but some sites appear to be 
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preferentially phosphorylated (Chen et al., 2004).  It is understood that tau undergoes 
conformational changes to facilitate differential phosphorylation, resulting in 
dissociation of tau from microtubules (Gotz et al., 2011).  Under pathological 
conditions, hyperphosphorylation at the C-terminal tail and proline-rich regions, located 
upstream of microtubule-binding domains (Liu et al., 2007), leads to tau dissociation 
from the microtubules, resulting in microtubule collapse and accumulation of tau in the 
dendrites.  
 
To date, no tau mutations have been shown to directly lead to Alzheimer’s disease.  
However neurofibrillary tangles appear independently of senile plaques in more than 
two dozen age-related disorders.  Examples include Pick’s Disease (Pickering-Brown 
et al., 2000), Frontotemporal dementia (Rademakers et al., 2004) and parkinsonism 
linked to chromosome 17 (Wray and Lewis, 2010).  These disorders are termed as 
‘tauopathies’, in which tau plays a central role in disease pathogenesis.  It should also 
be noted that whilst tau is usually perceived as a neuronal protein, it is also expressed 
within non-neuronal cells such as  glia and can lead to disorders such as progressive 
supranuclear palsy or corticobasal degeneration (Gotz, 2001). 
 
The progression of tau pathology can be followed using Braak staging (Braak and 
Braak, 1991), which correlates well with disease progression (Archer et al., 2011) in 
relation to cognitive decline and neurodegeneration.  The characteristic spread of tau 
tangles throughout the brain has led to the concept of the ‘tau prion hypothesis’.  This 
hypothesis centres around the idea that tau is an infectious agent capable of spreading 
from cell to cell, in a manner comparable to a prion protein (Reiniger et al., 2011).  
Prion proteins may be misfolded, leading to their aggregation as cellular prion protein in 
the central nervous system and can be removed from source and be injected into 
different tissues where they seed further aggregation and propagate pathology 
(Yanamandra et al., 2013).  It has been shown that the transfer of tau and prion from a 
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mutated animal into another animal brain leads to the formation of tangles and 
infectious prions respectively (Morales et al., 2013).   
 
There are six Braak stages each describing tau affected regions of the brain.  Between 
stages I to II represent clinically silent cases, where no symptoms are exhibited by the 
AD sufferer.  During these early stages, hyperphosphorylated tau is found in the cortex 
but confined to the transentorhinal region.  The next stage of progression is stage II, in 
which there are numerous and denser neuropil threads (NT) in close proximity to the 
transentorhinal region.  NFTs are detected within the Cornu Ammonis (CA) 1 regions, 
found within the hippocampus (Braak and Braak, 1991, Braak et al., 1993). 
 
 
Stage III to IV represents incipient AD, where the presence of tau tangles and neuronal 
death begins to manifest as memory impairment.  Neurons in the entorhinal and 
transentorhinal regions are affected with NFTs with hippocampal involvement.  At stage 
V, the isocortex is severely burdened with tau tangles and by stage VI, all the changes 
in stages V are more prominent with neuronal death observed in the transentorhinal 
and entorhinal layers.  In addition, many neurons of the substantia nigra stain positively 
for tau tangles (Braak and Braak, 1991). 
 
In AD, tau aggregation is considered as a possible response to the disease process 
(Koechling et al., 2010).  Cellular studies have demonstrated that Aβ toxicity is 
dependent upon tau expression (Rapoport et al., 2002).  Furthermore, studies have 
demonstrated the ability of tau to modulate Aβ toxicity.  Indeed, treatment of 
hippocampal slices with Aβ1-42 does not lead to the impairment of long term 
potentiation in Tau-/- mice (Shipton et al., 2011, Roberson et al., 2007). 
 
1.3 The Causes of AD 
The presence of amyloid plaques and tau tangles in AD patient brains are important 
pathologically.  However, as mentioned previously, the presence of plaques in non-
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demented individuals (Price and Morris, 1999) suggests that the plaques themselves 
are not toxic to cells.  Further studies have shown that oligomeric amyloid load is a 
better correlate of dementia symptoms.  However, the presence of NFTs remains the 
best indicator of AD duration and severity (Arriagada et al., 1992).  
 
Other than cases of FAD, a definitive cause for developing sporadic AD has not been 
established, however, a number of risk factors have been identified.  Ageing is the 
principal factor to consider.  Other factors include lifestyle, education (Hofman et al., 
1997, Katzman, 1993, O'Carroll and Ebmeier, 1995, Zhang, 1990, Lindsay et al., 2002) 
and the inheritance of certain genes.  Studies have revealed that more educated 
people or those who continued to learn into adulthood were less likely to develop 
dementia.  This may reflect a compensation mechanism for neurodegeneration early in 
AD, however these individuals show rapid decline in cognitive function at the advanced 
stages of AD (Wilson et al., 2004).  The importance of lifestyle choices such as diet and 
exercise have been demonstrated in providing protection against dementia (Daffner, 
2010).  Physical activity appears to slow down the decline associated with ageing and 
may ameliorate the rate of cognitive decline (Weuve et al., 2004, Larson et al., 2006).  
A Mediterranean diet has been associated with not only reducing the risk of developing 
cardiovascular disease and cancer but also dementia (Scarmeas et al., 2009, 
Scarmeas et al., 2006). 
 
Generally, AD can be classified as being late onset (LOAD), occurring after the age of 
65 or early onset (EAOD), before the age of 65.  The majority of AD cases are 
described as late onset.  In such cases, determination of common factors that lead to 
the development of Alzheimer’s disease is problematic due to the apparent sporadic 
nature of the observed cases.  In comparison, EOAD is associated with inheritance of 
autosomal dominant alleles.  The contribution that genetic factors may play in sporadic 
cases is uncertain.  However, both early and late onset AD are characterised by similar 
pathological phenotypes and may be clinically indistinguishable from one another. 
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1.3.1 EOAD 
Early onset AD (also known as familial AD (FAD)) accounts for between 2 to 10% of all 
AD cases (Morgan, 2011, Selkoe, 2001b) and is genetically linked to genetic 
aberrations in chromosome 21, 14, and 1 where the genes encoding the Amyloid 
Precursor Protein (APP), Presenilins 1 (PSEN1) and 2 (PSEN2) reside respectively. 
 
Subsets of families have been shown to carry point mutations in APP, which causes an 
imbalance in amyloid turnover (Haass et al., 1995), and leads to an increase in Aβ1-42 
production.  Mutations in the Presenilin 1 (PSEN1) and 2 (PSEN2) genes encoding for 
protein subunits that constitute part of the γ-secretase enzyme are responsible for the 
majority of FAD cases (Price and Sisodia, 1998, Berezovska et al., 2005) , some of 
which are shown in Figure 1.4.  Furthermore, the cloning of the presenilin genes 
(Sherrington et al., 1995) has demonstrated that presenilin mutations increase the 
production of Aβ1-42 in humans (De Strooper et al., 1998, Scheuner et al., 1996a) and 
transgenic mice (Duff et al., 1996).  
 
1.3.2 Sporadic AD  
Late onset AD (LOAD) or sporadic AD afflicts patients late in life with incidence mainly 
occurring between the seventh and eight decades.  It is the commonest form of AD, 
contributing to 95–99% of AD cases but has a weaker association with genes than FAD 
cases (Bali et al., 2012).  However, there is speculation that genetic components could 
account for up to 60-70% of all LOAD cases (Hollingworth, 2011), hence identifying 
these genetic factors has proven to be a more challenging issue to tackle.  This also 
complicates how to model sporadic AD in vitro. 
 
Results of several large genome wide association studies (GWAS) have linked novel 
loci associated with LOAD.  These include clusterin (CLU), phospatidylinostol-binding 
clathrin assembly protein (PICALM) (Harold et al., 2009), amphiphysin II (BIN1), 
complement receptor 1 (CR1) (Lambert et al., 2009), bridging integrator 1, ATP-binding 
cassette transporter 7 (ABCA7), membrane-spanning 4-domains subfamily A, CD2AP-
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CD2-associated protein (CD2AP),  CD33 (sialic acid-binding  immunoglobulin-like 
lectin) and ephrin receptor A1 (EPHA1) (Naj et al., 2011).  Genetic variants in triggering 
receptor expressed on myeloid cells (TREM2), which encodes for the triggering 
receptor expressed on myeloid cells has also been linked with an autosomal recessive 
form of EOAD.  Recently, genetic variants in the apoliprotein E receptor (SORL1) have 
been found to have an increased risk of SAD (Young et al., 2015).  Proteins expressed 
from these genes are involved in a variety of different processes shown to have some 
mechanistic relationship with APP/ Aβ.  These will be discussed in the following 
sections. 
 
PICALM is involved in clathrin-mediated endocytosis, where it acts to recruit clathrin 
and adaptor protein complex 2 to regions of site assembly (Tebar et al., 1999).  BIN1 is 
involved in many cellular processes, such as actin dynamics, membrane trafficking and 
clathrin-mediated endocytosis (Pant et al., 2009), which may affect the processing of 
APP and Aβ production or Aβ clearance from the brain. 
 
The other genes appear to be associated with the immune system.  CR1 forms part of 
the complement system, where it binds complement factor C3b and C4b to participate 
in clearing immune complexes.  Amyloid can bind to C3b, which suggests CR1 may be 
involved with Aβ clearance (Thambisetty et al., 2013).  CR1 is also implicated in 
neuroinflammation, which occurs commonly in AD (Crehan et al., 2012).  CD33 
encodes for a cell surface immune receptor, which can bind sialyated glycans.  
Increased expression of CD33 in microglial cells has been observed in AD brain, with 
the number of CD33-immunoreactive microglia correlating with plaque burden (Griciuc 
et al., 2013). 
 
EPHA1 encodes for cell surface receptors which bind to ephrin ligands to modulate cell 
adhesion, synapse formation and plasticity.  EPHA1 is found on CD4-positive T cells 
and monocytes in the cerebrospinal fluid.  Genetic variations in EPHA1 were found to 
37 
 
affect pathological changes in the hippocampus and the lateral occipitotemporal and 
inferior temporal gyri, leading to reduced risk of AD (Wang et al., 2015a).  CD2AP 
encodes for a scaffolding adaptor protein, which regulates cytoskeletal organization.  It 
is believed that CD2AP is associated with increased plaque burden (Liao et al., 2015). 
 
ABCA7 mediates the production of high-density lipoprotein with lipids and 
apolipoproteins.  It binds APOA-I and functions in apolipoprotein-mediated 
phospholipid and cholesterol efflux from cells.  In addition, ABCA7 influences the 
transport of APP through the cell membrane and is involved in host defence.  In 
relation to AD, loss-of-function in ABCA7 is found increase the risk of AD in 
Caucasians (Steinberg et al., 2015). 
 
Clusterin is of great interest as it is co-localised with amyloid plaques.  It is an ATP-
independent molecular chaperone, found to be increased in AD brains (May et al., 
1990), specifically within the pyramidal neurons and non-pyramidal cells of the 
hippocampus and entorhinal cortex, two areas known not to be affected by AD 
(Lidstrom et al., 1998).  Expression of clusterin is highest in the brain, particularly within 
astrocytes (Pasinetti et al., 1994). 
 
Clusterin exhibits broad substrate specificity and can stabilize misfolded proteins (Poon 
et al., 2000), and is activated during endoplasmic stress, in what is known as the 
unfolded protein response (UPR).  When unfolded/ misfolded protein accumulate within 
the ER, the UPR is activated to restore normal cellular function by stopping protein 
translation, degrading misfolded proteins and activating signalling pathways to recruit 
molecular chaperones, whose functions are to aid protein folding.  Should the UPR fail 
to achieve this, UPR results in apoptosis, which may be involved in AD pathogenesis 
(Stutzbach et al., 2013, Cornejo and Hetz, 2013). 
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Astrocytes can secrete clusterin in response to excitatory neurotransmitter kainic acid 
treatment, and ischemic insults.  Clusterin may improve recovery in the brain to such 
stresses (Imhof et al., 2006), thus explaining its co-localisation to amyloid plaques.  
This protein also plays a role in amyloid clearance by binding to megalin receptors 
(Hammad et al., 1997) on the neuronal cell membrane thus facilitating amyloid 
endocytosis (Nuutinen et al., 2009).  It has higher affinity for the shorter Aβ1-40 
peptides than for fibrils and acts to increase Aβ solubility, whilst preventing its 
aggregation (Matsubara et al., 1995).  Although it can prevent Aβ oligomerization and 
enhance fibril formation, a balance in the ratio of clusterin and Aβ peptide is required.  
In addition, clusterin may be found in lipoproteins and functions to regulate cholesterol 
and lipid metabolism, two processes that are perturbed in AD (Calero et al., 2005).  
 
Other independent GWAS studies have identified putative genetic variants in death-
associated protein kinase 1, sortilin-related receptor 1 and low density lipoprotein 
receptor-related protein 6 which are associated with neuronal apoptosis, APP 
trafficking and altered Wnt/β-catenin signalling respectively (Waring and Rosenberg, 
2008).  A large meta-analysis from the AlzGene database reported thirteen additional 
potential AD-susceptibility genes including Angiotensin I converting enzyme, oestrogen 
receptor 1, prion protein mitochondrial transcription factor A as well as tumour necrosis 
factor (Waring and Rosenberg, 2008). 
 
The most influential genetic factor associated with sporadic AD is the apoliprotein E4 
(APOE4) genetic variant which is carried by 15% of the human population (Coon et al., 
2007).  The APOE4 gene mapped to chromosome 19, encodes for a plasma 
lipoprotein which functions to transport cholesterol (Mahley, 1988).  There are 3 known 
alleles; ApoE2, ApoE3 and ApoE4, of which the E4 variant carries an increased risk of 
AD (He et al., 2007), but is not essential for AD to develop.  ApoE is produced and 
secreted in the central nervous system by astrocytes (Ignatius et al., 1986), with levels 
highest in the brain and liver (Elshourbagy et al., 1985).  Levels of ApoE are increased 
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after injury and are increased in neurodegenerative diseases.  In AD, it is localised to 
extracellular senile plaques and intracellular neurofibrillary tangles (Namba et al., 
1991), strongly supporting its role in AD. 
 
The mechanism by which ApoE plays a role in AD pathogenesis is unclear but one 
theory is that APOE4 interacts with a receptor that leads to increase Aβ production.  
Specifically, the receptor APOE2R, expressed in the brain has been shown to alter Aβ 
levels presumably via an unknown binding interaction (Hoe et al., 2005).  Neuro-2a 
cells transfected with the Swedish mutation of APP (SweAPP695) demonstrated a 
twofold increase in Aβ production in the presence of human very low density 
lipoproteins (VLDLs)(where APOE4 is most abundant) but not with LDL and HDL (high 
density lipoproteins) (Huang et al., 2001).  In these cells, the presence of APOE4 may 
stimulate APP internalization and translocation of BACE1 from the cell membrane to 
endosomes. Transgenic animal studies have demonstrated that APOE4 is linked to 
amyloid deposition (Bales et al., 2009, Hartman et al., 2002) but as yet, there is poor 
understanding of the mechanistic relationship between the two.  ApoE has also been 
found to have avid affinity for amyloid (Strittmatter et al., 1993), a finding which was 
confirmed by ApoE immunoreactivity with cerebral and systemic amyloid taken from 
patients (Wisniewski and Frangione, 1992). 
 
1.3.3 The amyloid hypothesis 
At present, the amyloid cascade hypothesis is the most commonly accepted process 
thought to lead to AD pathology.  Indeed, several mutations involved in familial AD 
influence amyloid production.  The conventional view of AD is that the majority of the 
pathology is driven by an increased burden of Aβ in the brain, which can be influenced 
by APP mutations such as the Swedish, London, Indiana and Arctic (see Figure 1.4).  
These different point mutations occur in different regions of the APP gene but all lie 
within or close the Aβ peptide region.  At least 33 mutations within the APP gene have 
been identified to be associated with EOAD (Cruts et al., 2012) and a related disorder 
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of hereditary cerebral amyloid angiopathy (CAA) (Weggen and Beher, 2012).  APP 
duplication can also cause early-onset AD with CAA, as demonstrated by the increased 
incidence AD in individuals with trisomy 21 (who suffer from Down syndrome) (Roizen 
and Patterson, 2003).  Recently, one APP mutation found in the Icelandic population 
which is an A673T substitution affects β-secretase cleavage of APP leading to a fall of 
Aβ by approximately 40% (Jonsson et al., 2012).  This is the only known mutation 
shown provide life-long protection against age-related cognitive decline.  Such 
mutations suggest that therapy directed against β-secretase cleavage need only 
reduce Aβlevels by 40% rather than eliminate its production completely to be effective 
whilst extending lifespan. 
 
 
The Aβ hypothesis states that the Aβ aggregates trigger a complex pathological 
cascade that results in neurodegeneration.  Emphasis on the importance of the amyloid 
hypothesis has been performed in studies using transgenic mice which overexpress 
human APP and mutant tau (Gotz et al., 2001, Lewis et al., 2001).  These mice 
develop plaques before developing neurofibrillar deposits (Selkoe, 2001a).  
Furthermore, expression of human BACE1 in mice led to cleavage of murine APP to 
Aβ 56 and Aβ hexamers.  Mice exhibited AD-like phenotypes from three months of age 
which progressively worsened over time (Plucinska et al., 2014).  It must be noted that 
no human mutations in tau have been found in Alzheimer’s disease.  Furthermore, to 
simulate significant AD pathology in rodents, mutations in both APP and tau are 
necessary.  The increased incidence of AD in Down syndrome humans caused by 
trisomy of chromosome 21 (Glenner and Wong, 1984a) further supports this 
hypothesis.  Such evidence suggests that Aβ is an integral part of the disease and may 
be a more important factor to consider in comparison to tau (Hardy and Selkoe, 2002).  
 
1.4 Pathogenic mechanisms of Amyloid   
The manner in which Aβ aggregates and the particular species of peptide produced is 
vital to consider.  In AD, APP is cleaved to form a range of peptides; of these the Aβ1-
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42 form is strongly associated with neurotoxicity both in vivo and in vitro.  These 
neurotoxic effects lead to gradual impairments in short-term memory and cognition due 
to neuronal dysfunction (Rönicke et al. 2011) and death in the hippocampus, limbic 
system and cerebral cortex (Jhoo et al. 2004).  The mechanism by which neuronal 
death occurs may be due to a number of pathways, some of the key mechanisms will 
be outlined in the subsequent sections. 
 
1.4.1 Calcium homeostasis 
Aβ1-42 has been shown to cause changes in calcium (Ca2+) concentration signals 
when applied to primary cultures of hippocampus or cortex-derived neurons and 
astrocytes (Abramov et al., 2004).  These intracellular signals were limited to 
astrocytes.  Aβ-induced hyperactivity in astrocytes has also been observed in AD mice 
models (Kuchibhotla et al., 2009).  This observation and the lack of response using 
calcium channel inhibitors led to suggestions that Aβ itself might form calcium 
permeant channels in the astrocyte membrane, as a possible pathogenic mechanism 
(Arispe et al., 1993, Bhatia et al., 2000, Abramov et al., 2003).  The changes in 
intracellular calcium levels in astrocytes could impair the astrocyte’s role in supporting 
neuronal viability, leading to neuronal death.  Neuronal death has been confirmed by 
deficits in cholinergic transmission and loss of synaptophysin protein (Morgan et al., 
2004b).  These aberrations are believed to result partly from oxidative stress and 
damage to the membrane.  
 
1.4.2 Aβ-induced excitotoxicity 
Excitotoxicity describes the phenomena in which over-activation of the glutamate N-
methyl-D-aspartate (NMDA) receptor (NMDAR) leads to increases in intracellular 
calcium by directing opening channels and affecting calcium homeostasis.  Elevated 
calcium levels can overactivate several enzymes, such as PKC, calcium/calmodulin-
dependent protein kinase II, phospholipases, and nitric oxide synthase (NOS) (Mark et 
al., 2001).  One of the consequences of excessive stimulation of glutamate receptors, 
is the generation of nitric oxide (NO) and superoxide ions via NOS activation leading to 
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neuronal death.  The release of NO is detrimental to the cell as it can cause 
downstream misfolding, aggregation and mitochondrial fragmentation.  This process is 
one mechanism that underlies Aβ-mediated neurodegeneration with evidence to 
suggest that amyloid itself can bind to the NMDAR (Texido et al., 2011).  In the 
absence of glutamate, Aβ oligomers was found to activate recombinant NR1/NR2A and 
NR1/NR2B receptors (subunits of NMDARs).  In the same study, Aβ oligomers are also 
able to activated native NMDARs with preference to receptors lacking NR2B subunits.  
This observation identified a possible therapeutic target, using antagonists directed 
against NR1/ NR2B receptors (Farlow, 2004).  Clinically, anti-glutamatergic drugs have 
previously been demonstrated to ameliorate symptom severity in cases of moderate-to-
severe AD (Reisberg et al., 2003).   
 
The activation of glutamate receptors mediates many downstream processes such as 
inducing calcium ion influx, calpain activation, and dynamin-1 degradation (Kelly and 
Ferreira, 2006).  Synapses, are structures that are essential to allow the passing of 
electrical signals (in the form of neurotransmitters) between neuronal cells, and are 
highly enriched in calpains  1 and 2  (Perlmutter et al., 1988).  Calpains are calcium-
dependent cysteine proteases with poorly understood functions.  It is known that 
dysregulation calpain activity is leads to tissue damage during ischaemia and brain 
trauma (Goll et al., 2003).  Increased levels of Calpain 2 are found to be associated 
with an increased risk of developing NFTs (Grynspan et al., 1997).  The overactivation 
of calpain is one consequence of high calcium levels (Nixon, 2003), and can indirectly 
modulate APP processing (Siman et al., 1990, Mathews et al., 2002) as well as tau 
phosphorylation (Huang and Wang, 2001).    
 
Another key consequence of excessive activation of NMDARs by amyloid, is the 
inhibition of LTP (Li et al., 2011, Taylor et al., 2008b).  This finding could explain the 
memory loss observed in AD.  Glutamate receptors located at synapses are vital for 
LTP, and also lie upstream of signalling pathways that lead to cell death.  The inhibition 
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of LTP involves a series of kinases, most notably p38 MAP kinase and Jun NH2-
terminal kinase (JNK).  Both enzymes are also associated with tau phosphorylation, but 
inhibitors of these targets do not appreciably reduce neuronal cell death.  The activity 
of Fyn kinase is of great interest and may link both amyloid and tau (Haass and 
Mandelkow, 2010).  Tau is localised to dendrites, where it acts to target Fyn to the 
dendrite, to phosphorylate NMDAR subunit, NR2B (Bhaskar et al., 2005).  This allows 
Fyn to modulate synaptic activity and plasticity.  FYN/hAPP mutant mice exhibit 
impaired neuronal induction of Arc (activity-regulated cytoskeleton-associated protein) 
and spatial memory (Chin et al., 2005).  The importance of tau is illustrated by the fact 
that without tau, excitotoxic signalling does not occur (Hoyos Flight, 2007).  Tau 
reduction (studied with tau -/- mice-derived hippocampal cultures) also prevents the 
inhibition of axonal transport of mitochondria induced by amyloid (Vossel et al., 2010).  
 
1.4.3 Mitoenergetics and oxidative stress  
Cellular metabolism can be described as the process by which cells produce and 
consume energy in the form of adenosine triphosphate (ATP) in order to carry out 
metabolic functions.  There are two main methods by which ATP is generated, one is 
oxidative phosphorylation, which takes place in mitochondria and the other is 
glycolysis, which occurs in the cytosol.  At times of high demand, cells may interchange 
between the two distinct processes to maintain energy homeostasis. 
 
Oxidative phosphorylation is a multi-step process, which involves the co-operation of 
several complexes.  Mitochondria are unique organelles, originating from the symbiotic 
association between a proto-eukaryotic cell and a bacterium (Thrash et al., 2011).  
They have double membranes, are self-replicative, and carry 16.5 kB of DNA, which 
encode for 13 polypeptides that form part of the electron transport chain involved in 
oxidative phosphorylation.  Synapses are highly enriched with mitochondria, where 
they are dynamic and mobile.  Transport of mitochondria from the neuronal body to the 
axon occurs by microtubule-assisted transport (MacAskill and Kittler, 2010) and is vital 
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for not only ATP production but also maintaining calcium homeostasis (Patergnani et 
al., 2011). 
 
Mitochondria are the main source of oxidative stress, in form of free radicals (also 
known as reactive oxygen species (ROS)), such as O-, HO2, H2O2 and RO2 and have 
been implicated in a range of pathologies that include cardiovascular disease, 
diabetes, cancer and neurodegeneration (Raha and Robinson, 2000).  This is due to 
their wide involvement in a range of cellular processes such as fatty acid-oxidation 
(Kunau et al., 1995), cellular signalling (Tait and Green, 2012), apoptosis (Gulbins et 
al., 2003) and heme biosynthesis (Atamna, 2004).  However, it should also be noted 
that these free radicals also play an important roles molecules in cell proliferation and 
survival (Ray et al., 2012a).  
 
1.4.3.1 Mitochondria in AD 
Mitochondrial dysfunction is implicated to play a role in AD pathogenesis.  Neurons 
have a high energy demand that is met predominantly through the electron transport 
chain (glycolysis can be used to provide ATP at a faster rate but is not sustainable).  
Mitochondria also play important roles in calcium homeostasis, signal transduction and 
apoptosis (Abramov et al., 2004, Rottenberg and Scarpa, 1974, Green and Reed, 
1998, Babcock et al., 1997, Brookes et al., 2002).  Therefore, aberrant mitochondrial 
function leads to adverse effects in alterations in energy metabolism, the generation of 
excess free radicals and calcium homeostasis (Davis et al., 1997a).  
 
Amyloid mediated-activation of extrasynaptic glutamate receptors can have detrimental 
downstream effects on mitochondria (Ciani et al., 1996) (Weber, 1999) via the release 
of nitric oxide (NO).  Aβ can stimulate α7 nicotinic acetylcholine receptors to induce 
astrocytic glutamate release, which activates extrasynaptic NMDARs on neurons 
(Talantova et al., 2013).  In response to NMDAR activation, intracellular Ca2+ levels 
rise, which induce nitric oxide synthase activity to produce NO.  NO can then act as a 
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signalling molecule (Garthwaite, 1991); one consequence of which is to activate 
guanylate cyclase to stimulate cGMP formation, eliciting the relaxation of blood 
vessels.  However, excessive NMDAR activation can lead to excess NO, which is a 
potent inhibitor of mitochondrial respiration (Bolanos et al., 1997).  In addition to 
promoting mitochondrial fragmentation, NO competes with oxygen to bind reversibly to 
cytochrome oxidase (Sarti et al., 2012), causing a fall in ATP production and 
sensitization to hypoxia (Brown and Bal-Price, 2003).  NO can also be converted to 
reactive oxygen species such as peroxynitrite, NO2, N2O3, and S-nitrosothiols, which in 
turn interact with key enzymes of the mitochondrial respiratory chain and can activate 
mitochondrial permeability transition, leading to cell death (Le et al., 1995).  The 
importance of free radicals was demonstrated by the delayed progression of cognitive 
impairment in AD patients treated with the antioxidant Vitamin E (Dysken et al., 2014, 
Sano et al., 1997). 
 
Mitochondrial respiration itself is a major source of free radicals.  Free radical 
production is believed to be vital in the initiation and progression of neurodegeneration 
in AD.  These highly unstable molecules may also be generated in response to 
bacterial or viral infection and during the normal oxidative metabolism of substances.  
When levels of ROS exceed the antioxidant capacity of cells, this leads to toxicity and 
cause oxidative injury.  Targets of ROS include mitochondria themselves, membrane 
lipids, proteins and nucleic acids.  ROS is also implicated in other diseases in 
association with atherosclerosis, diabetes and aging (Ray et al., 2012b). 
 
The association of oxidative injury and ROS generation to AD has been demonstrated 
by presence of iron (Fe), copper (Cu) and zinc (Zn) accumulating within the brains of 
AD patients (Exley et al., 2012), as well as elevated levels of peroxynitrite (Smith et al., 
1997), increased expression of heme oxygenase (Smith et al., 1994, Barone et al., 
2012), elevated lipid peroxidase activity (Montine et al., 2002) and high levels of 
hydroxynonenal (Sayre et al., 1997), a lipid peroxidation product.  Metals have long 
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been implicated in Aβ deposition in vivo, where zinc and copper participate in NMDA-
induced activation, and react with Aβ to form amyloid aggregates (Barnham and Bush, 
2008).  These complexes of amyloid: Fe/Cu are considered to be pathologically 
important in AD (Bishop and Robinson, 2004). 
 
1.4.3.2 APP accumulation within mitochondria 
Further evidence for the involvement of mitochondria in AD is that the N-terminal region 
of APP contains a mitochondrial targeting signal, with the positively charged residues 
at positions 40, 44 and 51 revealed as vital components.  In human cortical neurons 
expressing either wild type APP or Swedish APP695, APP was found to be localized 
not only to the plasma membrane, but also to the mitochondria of these cells 
(Anandatheerthavarada et al., 2003).  Furthermore, mammalian cells transfected with 
APP also demonstrate sub-localization of APP to the mitochondria.  The effects of 
APP695 expression have been associated with decreased mitochondrial membrane 
potential, decline in ATP levels and cytochrome c oxidase activity 
(Anandatheerthavarada and Devi, 2007).  
 
Recent studies have observed Aβ accumulation within mitochondria (Lin and Beal, 
2006, Lustbader et al., 2004).  In AD patients and transgenic mice, amyloid 
accumulates gradually within brain mitochondria, causing mitochondrial dysfunction 
energy failure, altered mitochondrial properties and release of ROS.  One particular 
mitochondrial enzyme found to bind Aβ with high affinity is ABAD (Aβ-binding alcohol 
dehydrogenase) (Yao et al., 2011).  ABAD has broad substrate specificity and its levels 
are increased in the cerebral cortex and hippocampus of AD-affected brain regions of 
humans and rodents (Lustbader et al., 2004, Mei et al., 2010, Yan et al., 2010).  Tau 
itself can affect the activity of Complex I of the mitochondrial respiratory chain 
(Swerdlow et al., 2000) and therefore both amyloid and tau can synergistically impair 
mitochondrial functions, contributing to oxidative stress leading and a reduction in 
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energy metabolism (Gotz et al., 2011).  Mitochondrial function in AD will be discussed 
further in Chapter 3. 
 
1.5 The physiological role of APP  
Despite many studies on AD, there is no definitive agreement on the physiological 
function of APP.  APP is widely expressed throughout the body with the APP695 
isoform, being the predominant form in the central nervous system and the peripheral 
nervous system (Golde et al., 1990, Arai et al., 1991, Kang and Muller-Hill, 1990).  
Deletion of the APP gene in mice produces viable offspring but the mice exhibit 
cerebral gliosis, impaired learning and memory and changes in locomotor behaviour.  
In the same study, APP KO mice showed reduced growth throughout adult life 
suggesting that APP plays a role in somatic growth and muscle development 
(Senechal et al., 2008).  This was also reflected in vitro, where fibroblasts expressing 
an antisense APP construct to decrease APP levels exhibited slower growth, a finding 
which was reversed by treating the cultures with APP (Saitoh et al., 1989).   
 
Proteins homologous to APP have been identified in Drosophila, C.elegans and 
mammals (Zheng and Koo, 2006a, Link, 2005, Zheng and Koo, 2006b) but these lack 
the Aβ domain.  Structural studies of APP (see Figure 1.5) have led to the identification 
of several domains such as the growth factor-like domain (Rossjohn et al., 1999) and 
the copper-binding domain, that form part of the E1 and E2 domains (Barnham et al., 
2003).  Indeed, studies have shown that amyloid binds to both Cu and Zn. (Stellato et 
al., 2006).  Evidence of involvement in iron export has also been linked to APP (Duce 
et al., 2010b), as a functional Iron-Responsive Element (IRE) stem-loop exists within 
APP mRNA, which has sequence homology to IREs for ferritin and transferring 
receptor mRNA (Rogers et al., 2002).  Indeed, cytoplasmic free iron levels were found 
to influence APP translation, with APP-/- mice showing vulnerability to iron, leading to 
oxidative stress within cortical neurons (Duce et al., 2010a). 
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Figure 1.5  Diagrammatic overview of the primary sequence of full-length APP, its 
main domains and the residue positions.  
 
 
Other studies have linked APP to roles in regulating synaptic formation and neural 
plasticity (Turner et al., 2003, Thinakaran and Koo, 2008).  An increasing number of 
studies strongly suggest that Aβ plays a role in normal synaptic function.  For 
example, in hippocampal slices, BACE1 activity is increased by synaptic activity but 
Aβ peptides were able to lower excitatory transmission through AMPA (non-NMDA 
type receptor for glutamate) and NMDA receptors, implying a role in homeostatic 
plasticity (Taylor et al., 2008a).  Furthermore, Aβ release has been demonstrated to 
be activity-dependent.  This has been shown for both Aβ1-40 and Aβ1-42 when APP 
was overexpressed following transfection and when produced endogenously 
(Kamenetz et al. 2003).  Interestingly, patients with traumatic brain injury show an 
increase in cerebral amyloid as neuronal function and mental status recover (Brody et 
al., 2008).  In addition, amyloid has been associated with neuronal survival and 
increasing LTP in the hippocampus (Giuffrida et al., 2009). 
 
Full-length APP may function to facilitate cell adhesion and cell-cell interactions due to 
the presence of an RHDS motif (Ghiso et al., 1992).  This region may act like an 
integrin and can be blocked by the RGDS peptide found from within the fibronectin-
binding domain.  APP has previously shown to co-localise with integrins on axonal 
surfaces and interact with laminin and collagen (Storey et al 1996, Breen 1992) via its 
heparin binding domain.   
49 
 
Analysis of the APP primary structure has identified the presence of a YENPTY 
sequence, which contains consensus sequences for a phosphotyrosine binding (PTB) 
domain interaction (Borg et al., 1996).  Proteins like the neuronal X11 and the adaptor 
protein, Fe65 (which forms a complex with AICD) contain PTB domains and are found 
to bind to APP (Borg et al., 1996). 
 
Other APP fragments also display physiological functions.  The N-terminal sAPPα 
fragment has been shown to promote axonal outgrowth (Billnitzer et al., 2013) and 
appears to drive the neuronal differentiation of human embryonic stem cells (Freude et 
al., 2011).  These findings suggest that it may play a neuroprotective role.  
Furthermore, APPα is involved in proliferation of neural stem cells and non-neuronal 
cells (Ohsawa et al., 1999, Pietrzik et al., 1998).  In addition, sAPPα was found to 
increase glucose uptake in neurons (Mattson et al., 1999) and has memory-enhancing 
effects, by increasing LTP (Bour et al., 2004) and facilitates NMDA receptor-mediated 
currents (Taylor et al., 2008b).  AICD fragment has been found to act as a transcription 
factor (Lee et al., 2008a), regulating cell death (Wang et al., 2014b), neprilysin-
mediated Aβ degradation (Belyaev et al., 2009), influencing calcium and ATP 
homeostasis (Hamid et al., 2007) and regulating intracellular trafficking and 
cytoskeletal dynamics (Muller et al., 2007).  
 
Increasing evidence suggests that AD could be defined as a systemic disorder with the 
expression of abnormalities most evident in neuronal tissue.  Several pathological 
changes have been observed outside of the brain, for example, increase in platelet 
membrane fluidity (Zubenko et al., 1987) and changes in membrane protein states 
erythrocytes (Markesbery et al., 1980, Bosman et al., 1991).  Expression of APP 
outside the brain will be discussed in Chapter 4. 
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1.6 The study of AD using models 
AD is an increasingly complex disorder, in which the pathogenic mechanisms have 
been studied using a variety of different models.  Each of these models has provided 
valuable insight into AD pathology as well as the physiological function of APP (section 
1.5).  Here, an outline of the commonly used AD models will be discussed. 
 
1.6.1 Animal models 
Since the discovery of specific genetic mutations and the advancements in molecular 
genetics, scientists have generated a range of transgenic animal models.  Such models 
have demonstrated behavioural effects due to mutant transgene expression, producing 
some of the pathological characteristics seen in human AD.  However, massive 
neuronal cell loss has only been attained in a few mouse strains that express multiple 
transgenes. 
 
The first mouse model to exhibit amyloid plaques was derived from expression of the 
pathogenic V717F APP mutation under a platelet-derived growth factor mini-promoter 
(PDAPP).  These PDAPP mice present with extensive deposits of extracellular 
plaques, astrogliosis and neurite dystrophy (Games et al., 1995), all of which are 
associated with the pathological features of AD.  Other researchers have demonstrated 
similar phenotypes in the Tg2576 strain and the APP23 strain, both of which utilised 
the Swedish APP695 mutation (Hsiao et al., 1996, Gotz and Ittner, 2008).  The Tg2576 
mouse remains the most widely used model of AD.  However, these mice fail to 
demonstrate extensive neuronal death observed in humans (Richardson and Burns, 
2002). 
 
The triple transgenic (3xTg-AD) mouse, which carries the mutant PS1 (M146V), APP 
(Swe) and tau (P301L) transgenes (Oddo et al. 2003) develop plaques and tangles but 
also exhibit synaptic dysfunction including LTP deficits that precedes the appearance 
of plaques and tangles.  These mice are useful to study pathogenic mechanisms and to 
develop therapeutic approaches (Blurton-Jones et al., 2009).  Whilst this model is one 
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of the few to show the majority of pathologies associated with human AD, this is not 
truly reflective of human pathology in which a single mutation is able to induce AD. 
 
Whilst animal models have been useful, AD is only found in humans and higher 
primates, and therefore the use of rodent models should be questioned.  To date, there 
are no animal models which fully recapitulate the human AD pathology without the use 
of multiple mutant gene expression. 
 
1.6.2 In vitro Models 
In addition to animal models, scientists have created a number of in vitro models to 
investigate specific aspects of the disease.  Cultured models provide an easy platform 
to study cells under controlled conditions allowing the investigation of disease 
processes.  Such models also allow for the screening of therapeutic drugs.  However, 
the simplicity of these models do not reflect the complex cellular networks seen in 
tissues, and therefore the results obtained should be treated with caution when 
translating to complex tissues.   
 
1.6.2.1 Transformed cells 
As AD is a neurological disorder, it is natural to use neuronal cells to study such a 
disease.  The SH-SY5Y neuroblastoma cell line, derived from the SK-NSH cell line is a 
common model used because it reaches confluency quickly, and can be easily 
transfected.  In addition, researchers have developed protocols to enhance their 
neuronal differentiation by supplementation with retinoic acid and brain-derived 
neurotrophic factor (BDNF) (Jamsa et al., 2004).  A number of studies carried out using 
this cell line have investigated the effects of mutant PSEN1 (Fang et al., 2006) and its 
effects of intracellular storage (Smith et al. 2002), tau phosphorylation (Löffler et al., 
2012, Huang et al., 2014), the effects of mutant Swedish APP expression (Di et al., 
2010) and the inhibition of Aβ production by Zn (Lee et al. 2009).  Additionally, the 
effects of amyloid on neuronal CRMP-2 phosphorylation (Petratos et al., 2008) and 
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how different APP isoforms lead to different APP metabolites (Belyaev et al., 2010) 
have been studied using this cell line. 
 
Another neuroblastoma cell line that was previously used is the human IMR-32, derived 
from 13 month old male brain.  IMR-32 cells were found to accumulate an intracellular 
fibrillary material which reacts positively for anti-paired helical filament antibodies when 
using in situ immunoelectron microscopy (Neill et al., 1994).  This cell line has also 
been used to study expression and processing of APP.  More recently, the protective 
role of S100b, against Aβ-42-dependent toxicity has also been studied in this cell line 
(Clementi et al., 2013). 
 
In addition, to neurons the brain also contains a number of other cell types such as 
astrocytic cells.  Astrocytic cell lines such as the U373 astrocytoma are useful because 
of their fundamental role within the pathology of AD including protection of neurons 
from excitotoxicity and to allow the study of the effects of reactive gliosis (Beach et al., 
1989).       
  
To investigate toxic effects on heterogenous cultures, co-cultures of different cell types 
have also been used.  For instance, THP-1 (a macrophage like) and SH-SY5Y 
(Messmer and Reynolds 2005) have been co-cultured together.  In addition, co-
cultures of THP-1 and U373 cells (Klegeris et al., 1997) as well as, SH-SY5Y and 
glioblastoma U251-MG cells have been studied (Fujiki et al. 2012).  Whilst co-cultures 
of these cells are useful to investigate how they communicate with each other, they are 
hampered by the proliferative nature of the cells used, making these cultures 
unsuitable for chronic studies.   
 
1.6.2.2 Primary cultures 
Many early AD studies were based on primary cultures and brain slices.  This requires 
careful extraction of animal tissue which is first dissociated and then plated onto either 
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a plastic surface or grown in suspension.  The expression of cellular features and 
plating efficiency is greatly influenced by different factors, which include culture 
environment, tissue type and the dissociation technique utilised (Harry et al., 1998).  
Tissue taken from adult brains are fully differentiated and post-mitotic, which limits their 
effective lifespan in culture.  However, the sources of embryonic rodent brains, which 
contain more neural progenitor cells has provided a solution to this issue.  Whilst these 
tissues may provide useful insights into disease process, inherent species differences 
may impede the relevance of these models. 
 
More valuable and relevant sources of tissue would be those taken from human brain 
biopsies.  In the UK, resource centres have been set up with support from the Medical 
Research Council, Alzheimer’s Research UK and the Alzheimer’s Society.  These 
cellular banks provide valuable yet limited sources of human AD brain tissue, revealing 
key information about late AD pathogenesis; but may be considered of limited use 
when investigating early AD development.  
 
1.6.2.3 Stem cell models of AD 
The issue of producing co-cultures of the different cell types required to simulate the 
complex environment of the brain could be solved by the use of stem cells.  
Undeniably, human embryonic stem cell (hESC)-derived neuronal cultures have 
become an attractive alternative model.  They are human in origin, differentiate into 
multiple cell types found in the brain and can become truly postmitotic.  Despite their 
potential, ES cell studies have been hampered by their inherent ethical issues (de Wert 
and Mummery, 2003).  Such problems have forced researchers to look for alternative 
sources of stem cells.  In 2006, Japanese scientists (Takahashi and Yamanaka, 
2006b), used somatic fibroblasts to create ES-like pluripotent stem cells.  These cells 
came to be known as induced pluripotent cells (iPSCs).  Self-renewing iPSCs can be 
generated from somatic cells from any individual and as they are genetically identical to 
the donor, make them ideal as cell-based models for studying human disorders (Chen 
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and Xiao, 2011).  Indeed, iPSCs have been derived from patients suffering from 
amyotrophic lateral sclerosis, spinal muscular atrophy and familial dysautonomia (Hu et 
al., 2010).   
 
The reprogramming of somatic cells to iPSCs involves the expression of Yamanaka 
factors (Oct3/4, Sox2, Klf4, c-Myc) to induce pluripotency (Takahashi and Yamanaka, 
2006a, Park et al., 2008b).  Cell-to-cell variations do occur in different laboratories 
which can reflect the inefficiency and extensive procedure to produce iPSCs.  
Therefore, when proceeding to generating disease-specific iPSCs, several factors need 
to be considered.  These include the source of somatic cells used, method of cellular 
reprogramming (retroviral or episomal) and the reliability of differentiation protocols to 
produce mature cell types (Mohamet et al., 2014). 
 
With respect to the brain, the development of differentiation protocols to produce 
functional cortical neurons has recently been demonstrated successfully (Shi et al., 
2012b).  iPSCs derived from Down syndrome patient fibroblasts were successfully 
differentiated into neuronal networks (Shi et al., 2012a) to model AD.  This model  
demonstrated detectable AD pathologies over a period of months, allowing the 
researchers to probe into AD development as the cultures age (Livesey, 2012).  
Detecting early changes in cellular responses that precede plaque and tangles would 
allow researchers to find therapeutic drugs to target AD earlier.  This is particularly 
important as current drugs only treat symptoms and not the cause of the disease, 
which most likely lies upstream of amyloid deposition.   
 
Other studies using iPSCs-based neurons have demonstrated the ability to recapitulate 
pathological features of AD in vitro (Israel et al., 2012, Shi et al., 2012a, Qiang et al., 
2011, Sherer et al., 2003, Yagi et al., 2011).  Indeed, iPSC-derived neurons from 
patients with either PSEN1 or PSEN2 mutations give rise to heterogenous neuron 
populations, with increases in Aβ42 secretion but variable expression of tau (Yagi et 
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al., 2011).  These cultures were also responsive to γ-secretase inhibitors, which 
demonstrate the drug screening potential of using such cellular models.   
 
Another cell line which has been used to study AD is the clonally derived, pluripotent 
human embryonal carcinoma NTERA-2 cl. D1 (NT2/D1) (Andrews et al., 1984).  
Retinoic acid treatment differentiates these cells into functional networks of neurons 
and astrocytes, providing a suitable model for human development (Andrews et al., 
1984, Lee and Andrews, 1986, Pleasure et al., 1992).  The neurons and astrocytes 
exhibited morphology and functional properties consistent with these cell types (Hill et 
al., 2012), allowing the use of  such cultures for studying human toxicology/disease 
models (Hill et al., 2008, Woehrling et al., 2007, Hill et al., 2013).  This cell line also 
highlights the importance of incorporating astrocytes into the cultures, which facilitate 
neuronal survival and maturation (Hartley et al., 1999).  Recent work in our laboratory 
(Tarczyluk et al., 2015) demonstrated that NT2-derived neuronal and astrocytic co-
cultures treated with Aβ1-42 display significant changes in metabolism, which is 
reflected in both human brain scans and some animal studies.  In this study, 
hypometabolism was observed in relation to glucose, pyruvate, lactate and glycogen, 
all of which known to provide alternative fuel sources in the brain under different 
conditions.  Such changes also led to a reduction in cellular ATP levels, suggesting 
energy deficiencies could prove detrimental to the brain which has a high energy 
expenditure to facilitate LTP, neurotransmission and combating oxidative stress.  Other 
effects of Aβ1-42 observed was its ability to induce oxidative stress and calcium 
responses and decrease the availability of NAD+, potentially affecting antioxidant 
production, ATP generation and DNA repair. 
 
1.7 Therapeutic targets  
Significant efforts have been made to develop treatments that reduce Aβ production via 
enzyme inhibitors or the use of specific antibodies to target the neurotoxic Aβ 1-42 
species.  Whilst there are numerous avenues of research being investigated, it was 
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estimated that between 2002 and 2012, 99.6 % clinical trials aimed at preventing or 
reversing AD failed (Cummings et al., 2014).  It was considered that this is mainly due 
to treating patients at a point when the disease is too advanced.   As such there is a 
significant effort to improve diagnosis by identifying biomarkers to detect AD earlier. 
 
1.7.1 BACE Inhibitors 
BACE1 is considered to be a therapeutic target for AD because it is the rate-limiting 
step in the Aβ production process (Evin and Kenche, 2007).  BACE inhibitors have 
been developed to inhibit Aβ production, with animal experiments demonstrating a 
reduction in Aβ production.  More recently, a potent BACE inhibitor AZ-4217 was found 
to inhibit soluble amyloid deposition in the Tg2756 mice, with high target selectivity and 
no noticeable side effects (Eketjall et al., 2013).  Currently, another inhibitor AZD3293, 
developed by AstraZeneca will be entering Phase II/III trials in patients with early onset 
AD, after it was found to dose-dependently reduce Aβ levels in cerebrospinal fluid from 
AD and healthy volunteers in Phase I trials. 
 
1.7.2 Anti-Aβ targeting antibodies 
A more direct method of targeting Aβ is to develop anti-Aβ antibodies but success in 
this area has been limited.  Results from clinical trials either failed to show sufficient 
clinical benefit in reducing the number of plaques or patients exhibited severe side 
effects associated with cerebral amyloid angiopathy (CAA, where amyloid is deposited 
in blood vessel walls) including oedema and haemorrhaging in the brain (Castello et 
al., 2014).  
 
A newly developed antibody, mE8 which acts to specifically bind to pyroglutamate Aβ 
(found in amyloid plaques) but not to soluble Aβ has been used (Roh and Holtzman, 
2012).  Pyroglutamate Aβ has its first two N-terminal amino acids of Aβ truncated with 
the following posttranslational conversion of the third amino acid, glutamate to 
pyroglutamate.  This form of Aβ has a higher propensity to aggregate, forming 
oligomers and is more toxic than other amyloid forms.  When mE8 was administered to 
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PDAPP mice (which express mutated APPV717F), it reduced insoluble Aβ levels 
without side effects.  This antibody was also effective in decreasing amyloid plaques 
and insoluble Aβ when given as a preventative treatment.  Better targeted drugs such 
as this antibody may one day prove useful as this approach considers that not all 
amyloid is toxic but may have more critical functions. 
 
1.7.3 Enzyme Inhibitors 
Current treatments used to treat AD only help to ameliorate the symptoms.  These 
treatments concentrate on modulating neurotransmitter levels (either by inhibiting 
acetylcholine release or preventing glutamate-associated excitotoxicity).  Such 
treatments may improve quality of life, but may only be prescribed in those with 
moderate to severe AD.  
 
In the AD brain, degeneration of cholinergic neurons leads to deficiency of the 
excitatory neurotransmitter acetylcholine (ACh), leading to adverse effects in cognitive 
function.  Acetylcholinesterase, expressed predominantly in nervous tissue, 
neuromuscular junctions and plasma, plays a major role in cholinergic transmission.  It 
is a serine-protease which hydrolyses the carboxylic ester of ACh, to produce choline 
and acetic acid, thereby reducing ACh levels.  Therefore, acetylcholinesterase 
inhibitors were developed to reduce the rate at which Ach is degraded.  Currently, only 
donepezil is approved to treat advanced AD, showing cognitive benefits in mild-to 
severe AD (Howard et al., 2012).  However, recently there have been some reports of 
severe side effects involving the breakdown of muscle tissue leading abnormal heart 
rhythms and kidney failure.   
 
Targeting glutamate toxicity is also an approach that has been well-characterised in 
late dementia (Winblad et al., 2002).  The use of the non-competitive NMDA receptor 
antagonist, memantine demonstrated moderate efficacy in treating moderate to severe 
AD (Reisberg et al., 2003).  Memantine binds to the NDMA receptor to inhibit calcium 
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ion influx, thereby prevent the signalling cascade that leads to neuronal excitotoxicity.  
The decline in cognition, function and behaviour in these patients was ameliorated and 
justified its approved use for later stage AD treatment (Robinson and Keating, 2006). 
 
Both of the drugs mentioned above show added benefits when given in combination 
(Lopez et al., 2009).  In addition to these traditional treatments, AD patients can be 
treated with antipsychotic drugs, which are typically prescribed to treat agitation, 
aggression and psychosis.  However, the adverse side effects of sedation and 
Parkinsonism accompanying drug use limit their usage (Ballard and Howard, 2006).  
Despite development of these inhibitors, the efficiency of these drugs was found to 
decrease over time.  As these can only ameliorate the symptoms and not cure the 
patient, the outlook for dementia sufferers remains disappointing.  Sadly there is a 
severe lack of reliable biomarkers that allow clinicians to detect AD symptoms to treat 
patients early in disease.  A recent study investigated the health of cholinergic neurons 
in post mortem brains from people aged 20-95, of both AD patients and healthy 
controls.  Investigators demonstrated the accumulation of Aβ within neurons in patients 
as young as 20 years, decades before the onset of dementia (Baker-Nigh et al., 2015) 
 
1.7.4 Targeting Tau 
Numerous studies have demonstrated the requirement of tau for Aβ-mediated 
neurotoxicity in vitro and in vivo (Roberson et al., 2007, Ittner et al., 2010, Park and 
Ferreira, 2005).  Furthermore, the absence of tau confers some protection against 
excitotoxicity, where tau plays a key role in postsynaptic NMDAR signalling (Ke et al., 
2012).  Therefore therapeutic strategies against tau are currently being developed 
(Gotz et al., 2012).  One approach is to inhibit tau aggregation with low-molecular mass 
compounds (Brunden et al., 2009).  Phase II data showed that methylene blue (MB), 
was reported to inhibit tau aggregation (Wischik and Staff, 2009), although later work in 
tau transgenic fish failed to show improvement (van Bebber et al., 2010).  A study in 
3xTG AD mice fed with MB ameliorated AD pathology by increasing proteasome 
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activity and promoting amyloid clearance (Medina et al., 2011).  These encouraging 
studies provide further incentive to consider MB as a possible future treatment. 
 
Another strategy for targeting tau would be to inhibit tau hyperphosphorylation using 
glycogen synthase kinase 3 beta (GSK-3β) inhibitors.  Two commonly used mood 
stabilizers; lithium and valproic acid (VPA) inhibit this enzyme and were shown to 
reduce tau phosphorylation in animal models.  The anticonvulsant drug, VPA was 
shown to reverse AD pathology in mouse models by reducing amyloid plaques (Noh 
and Seo, 2014).  VPA is a histone deacetylase (HDAC) inhibitor, with age-dependent 
effects on AD mice, by increasing nerve growth factor expression and improving 
cognitive function (Long et al., 2013).  Furthermore, it was shown to inhibit GSK-3β in 
vitro and increase clusterin expression (Chen et al., 1999, Nuutinen et al., 2010).  
Despite showing promise, a long term study in AD patients found no improvement in 
cognitive function with accelerated hippocampal volume.  The use of VPA in patients 
with moderate AD failed to delay behavioural symptoms of psychosis or agitation and 
also cognitive decline.  Its associated side effects of weakness, diarrhoea and tremors 
have detracted clinicians from prescribing VPA routinely to dementia patients (Jahromi 
et al., 2011). 
 
Trials using lithium have shown more potential, reducing tau concentration, 
phosphorylation and amyloid production.  It also reduced axonal degeneration and 
enhance the release of TGF-β1 in cultured neurons and transgenic mice.  Patients with 
bipolar disorder treated with lithium chronically, demonstrated a reduced risk of 
developing dementia (Kessing et al., 2008).  A study carried out in patients with MCI 
found that long term lithium treatment, demonstrated benefits in cognition, with reduced 
levels of phosphorylated tau in CSF.  However, patients with mild AD treated with 
lithium for 10 weeks showed no significant changes in cognitive function.  The side 
effects associated chronic lithium treatment which include increased risk of kidney 
failure have detracted the use of lithium in AD treatment. 
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Despite the extensive efforts spent on understanding AD and its impact on the human 
brain, the drugs treatments discussed so far have not provided any fruitful benefits on 
reversing the brain damage caused by AD.  The increase in life expectancy has led the 
number of dementia cases to increase steadily with no cure in sight.  A suitable 
therapeutic approach that addresses the balance between normal and aberrant levels 
of amyloid is desperately needed.  A key issue to note is at the time of AD diagnosis, 
drug treatments are most likely prescribed at a stage of the disease where the damage 
is irreversible.  Therefore, studies into the events that precede amyloid deposition are 
imperative.  One area of study would be to examine the effects of APP 
overexpression/mutant APP expression in order to study the earliest events that lead to 
cognitive decline.  
 
1.8 Aims and objectives of the study 
The aim of this study was to investigate the role of APP in cellular metabolism.  The 
human neuroblastoma SHSY5Y cell line was used to create stable cell lines that 
overexpressed either Wild type APP695 or APP695 carrying the Swedish mutation.  
 
As APP695 is expressed abundantly in neurons in vivo, this gene was placed the under 
the control of the Synapsin 1 promoter (SynI) ensuring neuronal specific expression in 
the stable cell lines.  Synapsins are a group of neuronal phosphoproteins, which coat 
the cytoplasmic surface of synaptic vesicles and specifically SynI and SynII are only 
expressed in the nervous system, which established the synapsin genes as good 
candidates for an investigation of neuron-specific gene expression (Schoch et al., 
1996).  The advantage of using this neuronal promoter over a viral promoter, such as 
CMV provides increased APP expression at non-toxic levels and is found natively 
within human neurons.  The use of viral promoters gives abnormally high protein 
expression, which would not occur in vivo. 
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The stable cell lines produced were used to study metabolic changes in the cells 
associated with overexpression SweAPP695/ wtAPP695 expression using the 
Seahorse analyser.  Using this technique, measures of mitochondrial function as well 
as investigation of glucose uptake using simple enzymatic assays were performed.  As 
oxidative stress is a common feature associated with AD the ability of cells to respond 
to oxidative insults was tested. 
 
Additionally, in order to investigate the peripheral consequences of APP 
misprocessing, fibroblasts obtained from FAD-patients were studied in terms of their 
metabolic capacity using the Seahorse analyser as well as their ability to cope with 
oxidative stress. 
 
The aims of these studies was to improve our understanding the consequences of APP 
overexpression and its role in not only AD but normal cellular metabolism.  Such 
knowledge may inform the earliest changes that occur in AD and allow investigation of 
the pathways that are perturbed in order to develop novel treatments. 
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Chapter 2: Molecular cloning of APP constructs  
2.1 Introduction to cloning 
2.1.1 Molecular cloning 
Advancements in molecular genetics have allowed researchers to clone genes of 
interest directly into cells in order to study the effects of gene expression.  Since the 
1940’s, major discoveries in DNA structure and replication have allowed scientists to 
determine the specific sequence of genes.  Following the invention of the Polymerase 
Chain Reaction (PCR) (Mullis et al., 1986), new opportunities for cloning and 
sequencing became available.  Cloning of cDNA encoding for a specific protein allows 
researchers to manipulate DNA in order to allow expression in a variety of cell model 
systems.  Furthermore, the identification of pathogenic mutations in humans and 
advances in gene editing have allowed researchers to replicate these mutations in 
vitro, and even produce animal models in which genes can either be knocked in or out. 
 
2.1.2 APP structure 
Determination of the genetic sequence and protein structure of APP has identified a 
number of possible cellular functions.  The APP gene is comprised of approximately 
400kb of DNA, and is spread across 19 exons (Yoshikai et al., 1990).  The gene 
encodes for a number of alternatively spliced APP mRNA products (Price and Sisodia, 
1998) that give rise to 8 known splice variants.  Of the 8 isoforms identified, the 
APP695 isoform is expressed at highest levels in the central nervous system (Kang 
and Muller-Hill, 1990).  This neuronal APP is 695 amino acids in length and is of 
particular relevance to AD.  Nuclear magnetic resonance (NMR) and crystallization 
studies have been utilised to determine APP structure, however no full crystal structure 
has been produced (Gralle and Ferreira, 2007, Xue et al., 2011, Coburger et al., 2013).  
 
APP is a type-I integral membrane glycoprotein, part of a family of proteins, that 
includes APLP1 and APLP2 (Wasco et al., 1992, Sprecher et al., 1993).  The protein 
structure consists of several domains which include a large extracellular domain, a 
hydrophobic transmembrane domain and a short cytoplasmic carboxyl terminus, as 
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shown in Figure 1.5.  Larger APP isoforms also contain the Kunitz-type serine protease 
inhibitor (KPI) domain, located in the middle of the extracellular domain (Ponte et al., 
1988), and is 57 amino acids in length.  APLP1 and APLP2 are the only known 
homologs of APP, sharing 38-51% amino acid homology (Walsh et al., 2007), 
undergoing proteolysis processing similarly to that of APP, but neither have the Aβ 
domain (Cousins et al., 2015).  Expression of APLP2 is found within neuronal and non-
neuronal tissues like that of APP, but APLP1 is largely confined to the CNS (Lorent et 
al., 1995). 
 
Identification of the primary sequence has led to possible functions of APP.  The C-
terminal cytoplasmic tail of APP contains a tetrapeptide sequence, NPXY, required for 
rapid endocytosis of the low density lipoprotein receptor (LDLR) (Chen et al., 1990).  
Deleting this cytoplasmic domain increases secretion of APP (Haass et al., 1993), 
suggestion this region plays some role in APP trafficking.  The Aβ peptide region is 
located near to the C- terminus, (amino acids 597-613) and sits partially outside the cell 
membrane.  Adjacent to this small region is a domain where glycosylation can occur. 
 
The N-terminal region of APP has been characterised substantially.  It is 172 residues 
in length and is conserved amongst the APP isoforms and in its homologues in both 
humans and other species (Daigle and Li, 1993).  This region is rich in cysteines, 
allowing disulphide bond formation, facilitating the formation of a rigid tertiary structure 
(Rossjohn et al., 1999).  This region  bind heparin (Clarris et al., 1997), to the 
extracellular matrix protein fibulin (Ohsawa et al., 2001) as well as to Aβ itself (Van 
Nostrand et al., 2002) and is called the heparin binding domain 1 (HBD1).   
 
The sequence adjacent to the HBD1 has been found to bind Cu2+ and Zn2+ ions in vitro.  
This domain is degraded in vitro possibly due to generation of reactive oxygen species 
(ROS) arbitrated by bound Cu2+ ions.  Three disulphide bonds are present within the 
copper binding site.  Binding of Zn2+ ions can increase APP’s binding affinity to heparin.  
64 
 
However, the residues of this domain are not sufficient to fully chelate Zn2+ suggesting 
that amino acids from a different domain may contribute to metal binding.  Therefore, it 
is likely that the N-terminal region relies on interactions from other APP domains to 
carry out its possible functions.  
 
The central regions of APP contain another heparin binding domain, HBD2 which is 
well conserved and is 179-residues in length.  This domain is followed by a 166-amino 
acid sized segment that is only found in vertebrate APP, and is quickly degraded by 
proteases (Daigle and Li, 1993).  This fragile segment may be less compact in 
conformation whilst the HBD2 forms an α-helical structure (Gralle et al., 2002, Wang 
and Ha, 2004).  APP has also been shown to bind to laminin and collagen in vitro via 
this domain.  F-spondin, a protein associated with differentiation of tissue growth, can 
also bind to these helical regions and can inhibit APP cleavage via BACE1.  The 
central region is also where an N-glycosylation site is located.  Post-translational 
modifications such as glycosylation are important in axonal sorting and secretion of 
APP.  Changes in the glycosylation state of APP lead to decreased secretion of the 
neuroprotective sAPPα (a cleavage product of APP demonstrated to decrease Aβ 
production), with a simultaneous increase in APP deposition within cells (Georgopoulou 
et al., 2001, Obregon et al., 2012). 
 
The Aβ region is where BACE1 and α-secretase cleavage sites are found, and it is 
mutations within this region which influence APP cleavage by β-secretase (as shown in 
Figure 2.2).  The activity of γ-secretase and BACE1 can influence the extent to which 
N-glycosylation and sialyation of APP can occur respectively (Schedin-Weiss et al., 
2014).  Furthermore, APP mutations have been shown to alter N-glycosylation, of this 
protein (Akasaka-Manya et al., 2008). 
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2.1.3 Genetic mutations in APP 
Genetic mutations in the APP and the presenilin genes, that are associated with 
familial (early onset) AD influence the amyloidogenic processing of APP.  Under 
physiological conditions, neurons produce picomolar levels of APP in a regulated 
manner, producing small amounts of Aβ40 that are postulated to modulate synaptic 
activity.  However, familial mutations increase the concentration of Aβ1-40 and the 
toxic species Aβ1-42, which aggregates to form plaques.  The effects of mutations that 
increase the production of Aβ42 are also reflected in sporadic AD (Lippa et al., 1996).  
Both familial and sporadic AD pathologies exhibit severe neuronal loss, as well as the 
presence of neuritic plaques and neurofibrillary tangles.  Clinical features present in 
both forms of AD are also indistinguishable from each other when using PET or MRI 
scans, with the only difference being the age of onset (Duara et al., 1993). 
 
As mentioned in Chapter 1, overexpression of the APP gene, as observed in Down 
Syndrome (DS) patients is sufficient to cause early onset of AD pathology.  An increase 
in Aβ1-42 production leading to the development of plaques has not only been 
observed in DS patient brains, but also in iPSC-derived neurons, which were 
reprogrammed from DS fibroblast cells (Shi et al., 2012a).  In other studies, fibroblasts 
taken from patients with either familial or sporadic AD, reprogrammed into iPSC-
derived neurons, exhibited higher levels of Aβ1-40 (but not Aβ1-42, due to small 
numbers of neurons purified) when compared to non-demented controls.  In addition, 
there was an increase in the phosphorylation of Thr231 (one of the key residues of 
tau), as well as an increase in the activity of glycogen kinase 3β (GSK3β, one kinase 
that phosphorylates tau) implying a direct association between APP processing and tau 
phosphorylation.  This was corroborated by the fact that BACE1 inhibitors decrease 
phosphorylated tau and the activity of GSK3β (Israel et al., 2012).  As the phenotypes 
of both sporadic and familial are similar it suggests that changes in APP processing 
may be very important in the pathology of the disease. 
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2.1.3.1 The Swedish mutation of APP 
The discovery of genetic mutations in the presenilin and APP genes has led to the 
generation of cellular and animal models of AD.  In particular, at least thirty mutations 
in the APP gene have been identified (Table 2.1). 
 
Overexpression of APP can lead to pathological changes as well as early changes in 
cellular metabolism, as shown by the prevalence of dementia in Down syndrome 
patients.  Interestingly, while brain scans of patients with AD and those with preclinical 
AD have demonstrated reduced glucose uptake (Mosconi et al., 2008b) as well as 
mitochondrial dysfunction (Moreira et al., 2010, Wang et al., 2014a), DS brains 
exhibited increased glucose uptake (Lengyel et al., 2006, Balogh et al., 2002).  Despite 
this, Down syndrome patients exhibit increased levels of oxidative stress, with 
decreased levels of mitochondrial components (Nagy et al., 1999, Conti et al., 2007).  
Abnormal mitochondrial activity is also found in DS fibroblasts (Valenti et al., 2011) and 
DS cortical neurons showing increased levels of ROS and lipid peroxidation (Busciglio 
and Yankner, 1995), as well as increased production of Aβ (Shi et al., 2012a)  Hence 
studying these metabolic pathways may reveal key changes in metabolic functions 
associated with APP misprocessing early in AD. 
 
In this project, genetically stable cell lines were generated which express either 
wildtype APP (wtAPP695), to assess the effects of APP overexpression, or the 
Swedish APP mutation (SweAPP695) to assess the effects of increased Aβ-1-42 
production.  These cell lines could then be used to study any changes in metabolism as 
a result of APP expression or misprocessing.  This chapter discusses the steps take to 
construct the genes and the targeting constructs. 
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Table 2.1.  List of known APP mutations, including positions.  Information taken from 
the online Alzheimer Disease and Frontotemporal Dementia Mutation Database 
(http://www.molgen.ua.ac.be/ADMutations/). 
 
The Swedish mutation was originally identified in two families in Sweden (Mullan et al., 
1992), where the average age of onset was 55 years.  This is a double substitution 
mutation leading to a residue change from Lysine to Asparagine and Methionine to 
Leucine at positions 670 and 671 respectively in.  The mutation locus precedes the Aβ 
peptide region of APP, and results in increased production and secretion of Aβ (Haass 
et al., 1995).  Expression of this mutation in vitro leads to an increase in the production 
of Aβ and sAPPβ secretion by 6-8 fold in comparison to wildtype APP expression 
(Citron et al., 1992).  This occurs as the Swedish mutation of APP enhances BACE1 
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cleavage and therefore promotes amyloidogenic processing of APP (Vassar et al., 
1999).  
 
The Swedish mutation has been used to create the well characterised AD mouse 
model (Tg2576) (Elder et al., 2010).  These mice demonstrate increased production of 
Aβ1-40 and Aβ1-42 peptides (Price and Sisodia, 1998) leading to age-dependent 
amyloid pathology, CAA and memory deficits (McGowan et al., 2006, Hsiao et al., 
1996).  In addition, these mice exhibit an increased oxidative phenotype, with an 
increase in the expression of superoxide dismutase 1 (SOD1) (Apelt et al., 2004), 
hemooxygenase-1 (Siedlak et al., 2009) and increased amounts of 4-hydroxynonenal 
compound (Takagane et al., 2015).  In vitro studies using expression of the Swedish 
APP mutation in a neuronal cell line was found to lead to decreased ATP levels (Keil et 
al., 2004, Walls et al., 2012b).  The 5xFAD mouse models which overexpresses the 
human APP695 Swedish , Florida (I716V), London (V717I) mutations and human PS1 
carrying the M146L and L286V mutations exhibit early Aβ deposition, cognitive 
impairment and early signs of significantly reduced levels of brain glucose uptake 
(Macdonald et al., 2014). 
 
Introducing these familial mutations into the cellular genome has enabled researchers 
to create models of AD in order to study AD pathology and the cellular effects of 
wildtype APP overexpression/mutant APP expression on host cells.  This has revealed 
possible mechanisms of APP neurotoxicity.  For example, Aβ peptide production has 
been associated with deficits in energy metabolism, reflecting effects observed in 
human AD patients brains.  As the Swedish APP695 mutation has been well 
characterised in the literature, it was utilised in this study to simulate FAD. 
 
2.1.4 Aims and objectives  
The aims and objectives of this study were to create plasmids expressing APP and to 
test constructs for expression in transfected cell lines.  After ensuring APP production 
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from the cloned sequence in a high level expression vector, stable cell lines were 
produced.  To avoid the excessive production the target protein associated with viral 
promoters which can be toxic to cells, neuronal specific promoters were used.  Initially, 
vectors with neuronal specific promoters and vectors carrying with the wtAPP695/ 
SweAPP695 were constructed.  These vectors were used to create stable cell lines 
using the human SHSY5Y cell line, whereby differentiation of the cells would lead to 
increased APP expression, and therefore increased production of amyloid peptide.  
The expression of mutated APP and overexpression of APP in these cell lines could 
then be compared with untransfected cells to observe whether any significant changes 
in metabolism were associated with increased APP overexpression/ production of Aβ1-
42. 
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2.2 Methods and materials 
All chemicals were molecular biology grade and were obtained from Sigma–Aldrich 
(Poole, UK) unless otherwise stated. 
 
2.2.1 General molecular biology procedures 
2.2.1.1 Preparation of Competent Cells (Rubidium Chloride Method) 
Overnight bacterial cultures were prepared using a single colony of Mach1TR (general 
cloning) or Stbl3 (for cloning viral constructs) E.coli cells to inoculate 10ml of Super 
Optimal Broth (SOB) (2% Bacto Tryptone, 0.5% Bacto Yeast extract, 10mM NaCl, 
2.5mM KCl, 10mM MgCl2, 10mM MgSO4).  On the following day, 0.25% (v/v) 
inoculums were added to sterile SOB media and incubated at 37°C until the cells 
reached the logarithmic phase of growth (determined by an O.D reading of 0.4 at 
550nm).  At this point, the culture was chilled on ice for 30 minutes and then the cells 
pelleted by centrifugation (3000g for 10 minutes at 4°C).  The supernatant was 
removed and the cells re-suspended in ice-cold RF1 Buffer (100mM RbCl, 50mM 
MnCl2 4H2O, 30mM CH3COOK, 10mM CaCl2 2H2O and 15% (w/v) glycerol) at 33% of 
the original volume of media and chilled on ice for 60 minutes.  The cells were then 
pelleted again (3000g for 10 minutes) to allow removal of RF1 buffer.  Cells were finally 
re-suspended in RF2 Buffer (10mM MOPS (3-(N-morpholino) propanesulfonic acid), 
10mM RbCl, 75mM CaCl2 2H2O and 15% (w/v) Glycerol) to prepare for snap freezing in 
liquid nitrogen.  Cells were aliquoted into sterile microcentrifuge tubes and snap frozen 
in liquid nitrogen.  Cells were stored at -80°C until required. 
 
2.2.1.2 Plasmid sequencing 
Sequencing reactions were carried out at the Functional Genomic Facility, University of 
Birmingham (http://www.birmingham.ac.uk/facilities/genomics/about/index.aspx).  As 
chain termination sequencing was used, primers were designed to split the target 
sequences into approximately 700bp sequencing runs.  Typically two to four reactions 
were prepared containing 250ng of plasmid DNA and 3.2pmoles of primer (Eurofins 
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MWG Operon, Ebersberg, Germany) to ensure sequencing of the complete gene 
sequence.  
 
2.2.1.3 Bioinformatics analysis 
Sequencing data was converted into Fasta format and the raw data observed using 
Chromas Lite 2.01 software (Technelysium Pty Ltd, Australia).  Alignments of the 
obtained sequences were made against reference sequences (obtained from the NCBI 
website).  The online Mulitalin (http://multalin.toulouse.inra.fr/multalin/) and EMBOSS 
Matcher (NMBL) (http://www.ebi.ac.uk/Tools/psa/emboss_matcher/nucleotide.html) 
programs were used to confirm the identity of recovered plasmids.  Plasmid maps and 
theoretical cloning were created/carried out using Clone manager 5 (Sci Ed Central, 
NC, USA). 
 
2.2.1.4 PCR 
For PCR reactions using different primer pairs, the optimum annealing temperature of 
the primers was initially determined by gradient PCR.  A PCR mastermix was set up 
containing: 1x Pfu buffer (Invitrogen, Paisley, UK), 200μM dNTPs (Invitrogen, Paisley, 
UK), 0.5pmole/μl of the appropriate forward primer and reverse primer (Eurofins MWG 
Operon, Ebersberg, Germany), 0.5ng/100μl of reaction of DNA template, Pfu enzyme 
(Invitrogen, Paisley, UK) and the remaining volume made up in DNAse/RNAse free 
sterile water. 
 
30μl aliquots of mastermix were dispensed into 0.2ml sterile PCR tubes and the PCR 
reaction was carried out in a Thermocycler PCR machine (Techne).  The primary 
annealing temperature was set to 60°C with a gradient of 20°C as most primers have a 
theoretical melting (Tm) temperature of 55-58°C.  The PCR samples were analysed by 
agarose gel electrophoresis (see section 2.2.1.9). 
 
Once the optimal annealing temperature was established, large scale PCR reactions 
were set up containing 1 x Pfu buffer (Invitrogen, 10x), 200µM dNTPs (Invitrogen, 
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10mM), 0.5pmoles/μl of the appropriate forward primer and reverse primer (Eurofins, 
MWG Operon, Ebersberg, Germany), 0.5 ng of DNA template/100µl reaction, 1.25U of 
Pfu enzyme/100µl (Invitrogen, UK, 5U/μl) and the remaining volume made up with 
sterile water.  50µl aliquots of the mastermix were dispensed into 0.2ml PCR tubes. 
 
The PCR reaction was then set up using the previously determined optimum annealing 
temperature for 30 cycles.  Reaction conditions were generally set out as listed in 
Table 2.1.  For cloning DNA a final extension of 5 minutes was added to the last cycle. 
Step Temperature Duration 
Initial denaturation 95°C 1 minute 
30 cycles of the following steps:  95°C 30 seconds 
Annealing Optimal temperature 30 seconds 
Extension 72°C 2 minutes per 1kb of 
template DNA 
Table 2.2.  Protocol to run PCR. 
 
 
2.2.1.5 PCR Tailing reactions 
To ensure 3’ adenine overhangs were present on PCR products amplified with proof 
reading polymerases, purified products were tailed using Taq polymerase.  Tailing 
reactions were performed in GoTaq Flexi buffer (1x, Promega, Southampton, UK), 
MgCl2 (1.5mM, Promega, Southampton, UK), dATPs (100µM, Bioline, London, UK), 
GoTaq (1U, Promega, Southampton, UK) and 13.6µl of the purified PCR product to 
make up to a total volume of 20µl.  The mixture was then incubated at 72°C for 20 
minutes. 
 
2.2.1.6 TOPO cloning 
Inserts carrying 3’ adenine overhangs were cloned into commercially available pre 
charged Topoisomerase vectors (pCR8 TOPO vector).  TOPO reactions were prepared 
in accordance with the manufacturer’s instructions. 
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2.2.1.7 Transformation of Topo reactions 
2.5µl of the Topoisomerase reaction was transformed into Mach1TR E.Coli (see 
section 2.2.1.16), plated onto spectinomycin agar plates (100µg/ml) using 50µl, 100µl 
and 150µl of inoculated broth to ensure that there was no overgrowth of colonies 
overnight at 37°C. 
 
2.2.1.8 Recombination reaction of TOPO vectors 
To recombine TOPO vectors into the final destination vector, a recombination reaction 
was prepared as recommended in the ViraPower Promoterless lentiviral Gateway Kit 
manual (see appendix).  Briefly, 2µl of LR Clonase II Plus was added to 10fmoles of 
pENTR5’ Syn1 TOPO, 10fmoles of pCR8 wtAPP695/SweAPP695, 20fmoles of 
pLenti6.4 R4/R2 V5 Dest with an appropriate volume of Tris-HCl EDTA buffer (10mM 
Tris-HCl, 1mM EDTA, pH 8.0) added to make the total reaction volume up to 8µl.  After 
the reaction was incubated overnight at room temperature, 1µl of Proteinase K solution 
was added and the reaction incubated at 37°C for a further 10 minutes and then the 
reaction was immediately transformed into Stbl3 E.coli cells (see section 2.2.1.16 for 
protocol).  Transformed bacteria were plated onto LB agar plates containing ampicillin 
(50µg/ml) for selection.  On the following day, colonies were counted and selected for 
further analysis.  
 
2.2.1.9 Agarose gel electrophoresis 
Standard agarose gels were made with Hi-Res Standard Agarose (GeneFlow, 
Lichfield, UK) and 1xTAE buffer (0.04M Tris-acetate, 0.001M EDTA, pH 8.0).  The 
agarose was heated until fully dissolved and once cool enough to pour; 0.5µg/ml of 
ethidium bromide (Sigma-Aldrich, Poole, UK) was added.  The gel was poured into a 
caster with the appropriate sized comb.  5µl of each PCR sample was loaded into wells 
with 6x Mass Ruler loading dye (for large sized PCR products, Thermo Scientific, UK). 
(Xylene cyanol dye (Sigma-Aldrich, Poole, UK) was used for fragments less than 
800bp).  Mass Ruler High Range ladder (Fermentas, Thermo Scientific, UK) and 
MassRuler Low Range Ladder (Fermentas, Thermo Scientific, UK) were also loaded to 
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determine band size.  The gel was run for 1 hour at 100V, after which time the DNA 
was visualised under UV transillumination (using the G: Box HR-16, GENE Sys, 
Syngene, UK). 
 
2.2.1.10 Gel extraction 
To purify PCR products of the appropriate size from low level contaminating bands and 
primers, PCR sample were pooled and then gel purified on 1% Seaplaque™GTG™ 
(Lonza SLS Nottingham, UK).  PCR samples were prepared with 6x loading dye 
(Thermo Scientific, UK) and run in the same well and run for 1 hour at 100V.  
 
Under UV transillumination, the appropriately sized band was excised from the gel 
using a sterile scalpel blade.  Subsequent gel extraction was carried out using the 
QIAQUICK Gel Extraction Kit (QIAGEN, Manchester, UK) in accordance with the 
manufacturer’s instructions (see appendix).  DNA was concentrated through a single 
column and eluted in the minimal recommended volume of sterile water to increase 
DNA concentration. 
 
DNA concentration and purity were determined using the NanoDrop spectrophotometer 
(Thermoscientific, UK).  DNA concentration was determined from absorbance at 
260nm, and the A260 and A280 were noted as an indication of its purity. 
 
2.2.1.11 Restriction Digest 
Restriction enzymes were used in conjunction with appropriate buffers as 
recommended by the manufacturer (NEB, New England, USA).  Typical reactions 
consisted of 10µg vector in a 200µl reaction or 5µg of insert in a 100µl reaction with 2-4 
units of restriction enzymes/µg DNA added.  Reactions were typically carried out at 
37°C for 3-4 hours before being heat-inactivated at 65°C/80°C (depending on the 
enzymes used, NEB double digest software was used to calculate optimal temperature 
and compatibility of enzymes in double restriction digests). 
75 
 
2.2.1.12 PCR clean up 
Digested PCR products were purified using the QIAQUICK PCR Purification Kit 
(QIAGEN, Manchester, UK) in accordance with the manufacturer’s instructions (see 
appendix for protocol).  
 
2.2.1.13 Dephosphorylation of cDNA ends 
Digested DNA vectors were dephosphorylated to remove 5’ phosphates from the 
cohesive ends to prevent self-ligation or concatemerisation of the vector.  Subsequent 
to restriction digest, dephosphorylation reactions were carried out in the appropriate 
restriction enzyme buffer with the addition of Antarctic Phosphatase Reaction Buffer 
(NEB, New England, USA, 10x) at 1/10th of the total digest reaction volume.  Five units 
of Antarctic Phosphatase (NEB, New England, USA) were added and the reaction was 
mixed gently.  The reaction was incubated for 50 minutes at 37°C and then heat-
inactivated for 20 minutes at 65°C. The digested, dephosphorylated vectors were 
subsequently gel purified to remove both the excised fragment and enzymes (see 
section 2.2.1.10).  
 
2.2.1.14 Ligation  
A 3:1 molar ratio of insert to vector was used for ligation reactions unless otherwise 
stated.  Molar concentrations of each purified DNA was calculated assuming the 
average mass of 1bp = 660 Daltons.  Typically 100ng of vector was used for each 
ligation with 3:1 molar ratio of the respective insert. 
 
Ligations were carried out in 20µl reactions containing 100ng of dephosphorylated 
vector, a 3x molar ratio of insert, 1x Ligase Buffer (Invitrogen, 5x), 1 unit of T4 DNA 
Ligase (Invitrogen), with the remaining volume made up with sterile water.  Self-ligation 
reactions in which the insert was omitted were carried out with each ligation.  Reactions 
were incubated at 16°C for 16 hours and subsequently heat-inactivated to stop further 
enzyme activity at 65°C for 20 minutes. 
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2.2.1.15 Agar preparation 
20g of Luria-Bertani broth (LB) (Invitrogen, Paisley, UK) was dissolved in 1L of distilled 
water. Difco Bacto Agar (BD; Oxford, UK, 1.5%W/V) was added and the media was 
autoclaved at 121°C.  Ampillicin sodium salt (Sigma-Aldrich, Poole, UK) stocks were 
prepared at 50mg/ml dissolved in sterile water and sterilised using a 0.2μm filter.  After 
autoclaving, media was cooled to 50oC, and (where required) the respective antibiotic 
stock solution added to achieve the following final concentrations, Ampillicin (50μg/ml), 
Spectinomycin dihydrochloride pentahydrate (Sigma-Aldrich, Poole, UK, 50µg/ml), 
Kanamycin (Sigma-Aldrich, Poole, UK, 40 µg/ml).  The media was then poured into 
sterile Petri dishes (Sarstedt, UK) to set.  LB plates containing no antibiotics were also 
prepared in a similar manner.  
 
2.2.1.16 Transformation 
Ligation reactions were transformed into E. Coli strains Mach1™T1R R (Genotype F
- 
φ80(lacZ)ΔM15 ΔlacX74 hsdR(r
K
-
m
K
+
) ΔrecA1398 endA1 tonA) for the mammalian 
expression vectors (see section 2.2.4 and 2.2.5) whilst Stbl3™ (Genotype F-mcrB 
mrrhsdS20(rB-, mB-) recA13 supE44 ara-14 galK2 lacY1 proA2 rpsL20(StrR) xyl-5 λ-
leumtl-1) were used for viral vectors (see section 2.2.7).  Both bacterial strains were 
obtained from Life Technologies (Paisley, UK). 
 
Ready competent E.coli strains were thawed on ice (15 minutes) whilst 100μl of the 
cells were pipetted into tubes (pre cooled on ice) containing 5μl of the respective 
ligation reaction.  Reactions were mixed by flicking the tubes and were then incubated 
on ice for 30 minutes.  A positive control using undigested plasmid was also carried 
out.  A tube containing cells only was also incubated on ice to ensure cell viability.  
After 30 minutes, all tubes were heatshocked at 37°C for 1 minute and then 
immediately recovered on ice for 2 minutes.  500μl of LB media was added to each 
tube and the cultures were shaken at 200rpm at 37°C (30°C for 70 minutes for viral 
plasmids) for 50 minutes to allow expression of antibiotic resistance markers.  During 
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this time, Ampicillin (or Kanamycin) containing agar plates were air dried by inverting 
them at 37°C to remove excess moisture. 
 
For plating, 150-200μl of each cell suspension was pipetted onto Ampicillin plates and 
spread evenly with a sterile plate spreader.  Tubes containing no vector were plated 
onto LB only plates to determine the growth of cells.  All plates were then incubated 
overnight at 37°C (30°C for viral plasmids). 
 
2.2.1.17 Colony PCR 
Colonies of bacteria derived from transformed bacteria were screened for the correct 
gene insert using colony PCR (primers for each vector are contained in the appendix).  
Sterile universal tubes containing 6ml of LB media with the appropriate antibiotic were 
prepared.  Ampicillin plates were divided into sections with each section labelled for the 
respective colony.  
 
Each colony was picked with a sterile pipette tip and a small amount of bacteria 
scraped into a sterile PCR tube.  The bacteria were then streaked onto a clean section 
of an antibiotic selection plate and the pipette tip was placed into the sterile universal 
tube which was incubated overnight with shaking (200rpm) at 37°C. 
 
PCR mastermix (30µl) was added to each PCR tube, along with a negative control.  
The PCR conditions included an initial denaturation step of 95°C for 2 minutes to lyse 
the bacteria, followed by 30 cycles of, denaturation at 95°C for 1 minute, primer 
annealing at 54°C for 30 cycles and extension at 72°C for 1Kb/minute with a final 
extension of  72°C for 5 minutes.  The PCR reactions were analysed by DNA gel 
electrophoresis (see section 2.2.1.9).  Samples shown to contain the appropriate sized 
band were subject to small scale plasmid isolation (see section 2.2.1.18) using 3ml of 
the 5ml cultures for subsequent sequencing (see section 2.2.1.2). 
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2.2.1.18 Small scale plasmid isolation (miniprep) 
The miniprep procedure was carried out using the QIAQUICK Miniprep Kit (QIAGEN, 
Manchester, UK).  3ml of bacterial culture was centrifuged at 17900 x g to pellet the 
cells.  DNA was extracted in accordance with the manufacturer’s instructions (see 
appendix) and the plasmid DNA was eluted into 50μl of sterile water.  The plasmid 
DNA concentration was determined (see section 2.2.1.10) to prepare for sequencing 
(see section 2.2.1.2). 
 
2.2.1.19 Large plasmid isolation (midiprep) 
Colonies confirmed as containing the correct sequence were picked from the replica 
streak plates (see section 2.2.1.12) and used to inoculate small cultures (30ml LB) with 
the appropriate antibiotic.  After incubation for 8 hours (200rpm) at 37°C, these cultures 
were used to inoculate a larger 200ml overnight culture.  On the following day, the 
optical densities of the cultures were measured to determine the scale up of plasmid 
isolation.  200ml cultures which gave an OD reading of 2 were prepared using a midi 
prep kit whereas, cultures giving OD readings for 6 were prepared using a Maxiprep kit 
to account for the larger amount of bacterial cells and plasmid DNA.  The Machery-
Nagel Endotoxin-Free DNA Purification Kit (Fisher Scientific, Loughborough, UK) was 
used. 
 
2.2.2 Protein expression procedures 
2.2.2.1 Cell lysis 
Cells were washed three times with ice-cold PBS to remove any serum proteins.  
Protein samples were prepared in an appropriate volume of 1X Radio-
Immunoprecipitation Assay (RIPA) buffer (Millipore, Watford, UK) containing Mini 
complete protease cocktail inhibitors (Roche Diagnostics Ltd, West Sussex, UK).  The 
cells were detached with a sterile scraper and transferred into 1.5ml microcentrifuge 
tubes and incubated at 4°C for 30 minutes to ensure complete lysis.  Cell debris was 
pelleted at 10,000rpm at 4°C for 10 minutes and the cell lysate collected.  Cell lysates 
were stored at -80°C.  
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2.2.2.2 The BCA Protein Assay 
To determine the total protein concentration, the Pierce BCATM protein assay kit 
(Thermo Scientific, Paisley, UK) was used (for protocol see appendix).  Briefly, 25µl of 
sample, BSA standard (ranging from 125-2000µg/ml) or assay diluent (BSA-free 
control) were incubated in a 96-well microplate with 200µl of working reagent (50:1, 
Reagent A: B) for 30 minutes at 37°C.  The absorbance was then read at 562nm using 
the Multiscan GO plate reader (Thermo Scientific, Loughborough, UK), and the data 
obtained from Skan It 3.2 (Thermo Scientific, Loughborough, UK).  The protein 
concentration was calculated using the absorbance of a known BSA standard (Pierce, 
Thermo Scientific Loughborough, UK) diluted in identical buffer to the sample tested. 
 
2.2.2.3 SDS-PAGE 
Polyacrylamide gel electrophoresis (PAGE) followed by Western Blotting was 
performed on the protein samples.  SDS-PAGE was performed using the Mini 
Protean® 3 Cell (Bio-Rad Laboratories Ltd., Hemel Hempsted, UK).  Sodium dodecyl 
sulphate polyacrylamide gels were prepared according to the manufacturer’s 
guidelines.  Stacking gels (4% polyacrylamide, made with final concentration of 0.125M 
Tris-HCl, pH6.8, 3.9% w/v acrylamide, 0.1% SDS in deionised water) and resolving 
gels (10% polyacrylamide) were prepared with 0.75mm thick glass plates.  5-10μg of 
cell lysates were denatured in sample buffer at 1x final concentration (deionized water, 
5% glycerol, 12.5mM Tris-HCl pH 6.8, 0.4% SDS, 0.002% bromophenol blue and 1% 
β-mercaptoethanol) for 5 minutes at 95°C and were separated by electrophoresis for 
45 minutes at 200V or until the bromophenol blue reached the bottom of the gel.  
PageRuler Plus Prestained Protein Ladder (Thermo Scientific, Northumberland, UK) 
was included as reference to determine sample protein size. 
 
2.2.2.4 Western Blot Transfer 
Following SDS-PAGE, plates were carefully separated, and the gels equilibrated in 
transfer buffer (25mM Tris, 192mM Glycine, 10% Methanol in deionised water) for 15 
minutes before being transferred onto Nitrocellulose Hybond ECL membranes 
80 
 
(Amersham, GE Healthcare, Buckinghamshire, UK).  The SDS gels and nitrocellulose 
membranes were then sandwiched between four pieces of Whattman cellulose 
chromatography paper and two pieces of sponge, pre-soaked in transfer buffer.  
Transfers were performed using the mini trans-blot electrophoretic transfer cell (Bio-
Rad Laboratories Ltd., Hemel Hempsted, UK) at 30V, 90mA for 16 hours on ice. 
 
2.2.2.5 Immunoblotting  
Nitrocellulose membranes were equilibrated in Tris-buffered saline (TBS) (138mM 
NaCl, 2.68mM KCl, 24.8mM Tris-base in deionized water, pH 8.0) before being blocked 
in TBS-Tween (0.1% Tween)/ 5% powdered milk (Marvel Skimmed Milk, UK) for 2 
hours at room temperature.  
 
Membranes were then incubated in the appropriate primary antibody diluted in 3% 
(w/v) dried milk powder in TBS 0.1% (v/v) Tween on a rolling platform overnight at 4°C.  
On the following day, the membranes were washed six times (5 minutes/wash) in TBS-
0.1% Tween, 3% powdered milk to eliminate excess unbound antibody.  The blot was 
then incubated for 1 hour at room temperature in the appropriate secondary antibody to 
visualise bound primary antibody. 
 
After incubation with secondary antibody, blots were washed a further six times in TBS 
0.1% (v/v) Tween (5 minutes/wash).  Protein-antibody binding was detected on X-ray 
film (CL-XPosure Film, Thermo Fisher Scientific, UK) using the enhanced 
chemiluminescence (EZ ECL Blotting analysis system, Geneflow, Lichfield, UK).  EZ 
ECL was prepared and left to equilibrate for 5 minutes protected from light, before 
being applied to the blots for 1 minute.  Blots were secured in an autoradiography 
cassette (Hypercassette, Amersham, GE Healthcare, Buckinghamshire, UK) between 
two pieces of acetate before exposing to X-Ray film.  X-ray films were exposed to the 
blots until clear protein bands were visible.  Films were developed between 30 seconds 
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to 1 minute (Kodak, Sigma-Aldrich, Dorset, UK), washed thoroughly in water (30 
seconds), and then fixed for 3 minutes (Kodak, Sigma-Aldrich, Dorset, UK). 
 
2.2.3 Protein expression studies 
 
2.2.3.1 COS-7 cell culture 
Monkey kidney COS7 cells (ATCC) were cultured in DMEM with Glutamax (Gibco, Life 
Technologies, Paisley, UK) with 100U/ml Penicillin and 100μg/ml Streptomycin (Gibco, 
Life Technologies, Paisley, UK) and 10% Foetal Bovine Serum (FBS) (Invitrogen, 
Fisher Scientific, UK).  When cells reached 90% confluence, they were washed once 
with Phosphate buffer saline (PBS) without MgCl2/CaCl2 (Gibco, Life Technologies, 
Paisley, UK) and detached using 0.05% Trypsin-EDTA (Gibco, Life Technologies, 
Paisley, UK).  Cells were pelleted at 200g for 5 minutes and the cells re-suspended in 
fresh media.  Cells were split 1:5/1:4 twice a week depending on the rate of growth and 
maintained at 37°C, 5% CO2. 
 
2.2.3.2 Cell Quantification (Trypan Blue Exclusion) 
To quantify the number of living cells, cells were diluted 1:2 with Trypan Blue 0.4% 
solution (Sigma-Aldrich, Poole, UK).  To prepare cells, they were trypsinised, cells, and 
the cells pelleted by centrifugation.  Cells were re-suspended in fresh medium and then 
diluted 1:2 with Trypan Blue.  Cells were counted using average counts from both sides 
of a haemocytometer slide.  
 
2.2.3.3 Preparation of COS7 cells for transfection 
For protein studies, COS7 cells from an 80% confluent flask were trypsinised and the 
trypsin neutralised with fresh media.  Cells were pelleted and then re-suspended in 
fresh media and live cells enumerated using a haemocytometer (see section 2.2.3.2).  
Six-well plates (Corning, MA, USA), were seeded at a density of 2.5 x105 per well to 
ensure 60-90% confluence could be reached for transfection the following day.  To 
perform immunocytochemistry, Poly-D-lysine/ Laminin coated coverslips (BD Biocoat, 
BD Biosciences, Oxford, UK) were placed into 6-well plates prior to seeding.  
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2.2.3.4 COS7 transfection 
Transfections were carried out using Lipofectamine LTX Plus (Gibco, Life 
Technologies, Paisley, UK) in accordance with the manufacturer’s instructions (see 
appendix).  Plasmid DNA (2.5μg/well) was diluted with 500μl of Opti-MEM® I Reduced 
Serum Medium (Gibco, Life Technologies, Paisley. UK) and 2.5μl of Plus Reagent 
added directly to the DNA.  The solution was mixed gently and incubated for 15 
minutes at room temperature.  After 15 minutes, 8.75μl of Lipofectamine LTX reagent 
(as recommended in the manufacturer’s instructions, see appendix) was added to the 
DNA-Plus reagent mixture and the solution incubated for 30 minutes at room 
temperature to allow complexes to form. 
 
As a positive control, cells were also transfected with the Green Fluorescent Protein 
(GFP) expressing plasmid (PAC-GFP-Nuc, Clontech, Saint-Germain-en-Laye 
France).  For protein studies, COS7 cells were transfected in triplicate with either 
SweAPP695 or wtAPP695 expressing plasmids.  As a negative control, untransfected 
COS7 cells were prepared in triplicate and incubated alongside transfected cells.  
Before transfection, the cells were refreshed with 500µl of complete media and 100µl of 
the DNA-lipofectamine complexes were added drop-wise to the wells, and incubated at 
37°C, 5% CO2 until the following day.  The media was then replaced and the cells were 
incubated for a further 36 hours to allow for protein expression. 
 
2.2.3.5 Immunostaining 
48 hours post-transfection, COS7 cells were washed once in ice-cold PBS (Gibco, Life 
Technologies, Paisley, UK) and then fixed in 4% Paraformylaldehyde (PFA, Sigma-
Aldrich, Poole, UK) for 20 minutes on ice.  Following fixation, cells were washed twice 
in PBS to remove PFA.  Positive controls transfected with PAC- GFP Nuc were stored 
in PBS containing 0.2% sodium azide (Sigma-Aldrich, Poole, UK) at 4°C. 
 
In wells containing coverslips, cells were permeablised in 0.1% Triton X-100/PBS 
(Sigma-Aldrich, Poole, UK) for 5 minutes at room temperature, and then blocked in 5% 
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BSA, 4% Triton X-100/PBS  solution for 1 hour to prevent non-specific antibody 
binding.  Cells were incubated with mouse anti-APP695 antibody (Invitrogen, 1:500, 
diluted in 5% BSA, 1% Triton X-100/PBS) for 2 hours at room temperature to detect 
wtAPP695/ SweAPP695. After incubation with primary antibodies, cells were washed 
three times in 5% BSA, 0.2% Triton/PBS and then incubated with the secondary 
antibody, anti-mouse Fluorescein isothiocyanate (FITC) (Jackson Laboratories, Maine, 
USA, 1:500) in the absence of light for 2 hours at room temperature to visualise bound 
APP primary antibody. 
 
The coverslips were washed for a further three times in 5% BSA, 0.2% Triton/PBS to 
remove unbound excess antibody.  Excess washing solution was removed by dabbing 
edge of coverslip with tissue.  The coverslips were then mounted by inverting them 
onto glass slides with HardSet Mounting Medium containing 4', 6-diamidino-2- 
Phenylindole (DAPI) (VectaShield, Vector Laboratories, Peterborough, UK) to stain the 
nuclei.  The coverslips were left to dry overnight (protected from light) before 
examination by fluorescence microscopy (section 2.2.3.6). 
 
2.2.3.6 Fluorescence Microscopy 
Stained COS7 were examined using the Leica SP2 fluorescent microscope.  Cells 
were imaged with the 10x/63x dry/oil objectives.  Fluorescent images were taken using 
the green filter cubes (excitation λ of 495nm, emission λ of 519nm) for APP 
visualisation and blue filter cube (excitation λ of 345nm, emission λ of 455nm) for 
nuclear visualisation.  The exposure and intensity were altered accordingly for optimal 
image capture.  Microscope images were analysed using the LAS AF Lite software. 
2.2.3.7 Protein expression from transfected COS7 cells 
COS7 cells were lysed in 300μl of RIPA buffer and with replicate wells pooled together 
(see section 2.2.2.1) and the protein concentration of the lysate determined in 
accordance with section 2.2.2.2). 
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10μg of cell lysates were subjected to SDS PAGE analysis using a 10% resolving gel 
(see section 2.2.4) and then transferred onto nitrocellulose membranes (see section 
2.2.5) overnight at 30V, 90mA on ice.  Membranes were blocked in 5% powdered milk 
and probed with mouse anti-APP695 (Invitrogen, Camarillo, USA, 1:2000, diluted in 3% 
powdered milk) or mouse anti-Aβ (1-42) (6E10, Covance,1:2000, diluted in 3% 
powdered milk) antibodies to detect the wtAPP695/SweAPP695 and Aβ (1-42) 
respectively (see sections 2.2.3 to 2.2.5).  As a positive control, neuronal NT2.D1 
lysate (known to express APP) was included when APP blotting and synthetic Aβ1-42 
(AnaSpec, CA, USA, 20μM) made up in HEPES was used as a positive control for 
blotting Aβ.   
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2.3 Results 
2.3.1 Plasmid Construction 
To generate stable cell lines over expressing wtAPP695 or APP containing the 
Swedish mutation (SweAPP695), initially this required the DNA sequence encoding 
wtAPP695 as well as the sequence of APP bearing the Swedish mutation 
(K595N/M596L).  After identifying groups working with constructs containing APP or 
SweAPP plasmids, these constructs were requested in order to provide the base APP 
sequences for incorporation into new constructs.  A wild type donor APP construct 
(Plasmid IL695) was obtained as a kind gift from Dr Illiya Lefterov (Pittsburgh 
University, PA, USA) and the coding sequence of the APP bearing the Swedish 
mutation (FGSwe695) was obtained from Prof. Frank Gunn-Moore (St Andrews 
University, Fife, UK). 
 
Constructs were initially sequenced using primers reading outwards from the human 
wild type APP695 DNA sequence (full primer sequences for each construct are 
contained in appendix).  In order to do this, primers capable of checking the sequence 
integrity of the APP gene were designed.  These primers were then used in sequencing 
reactions (section 2.2.1.2) to obtain the sequence of the APP genes in each construct.  
The sequence data was compared against the sequence of human APP695 (obtained 
from the NCBI nucleotide database, accession no. NM_201414.2). 
 
Sequence alignments showed that both plasmids contained sequence anomalies when 
compared to APP695.  Full sequence alignments were carried out using Multialin 
(http://multalin.toulouse.inra.fr/multalin/).  The sequence alignment of FGSwe695 and 
the wtAPP695 sequence are shown in Figure 2.1.  The alignment shows that the 
sequence of the plasmid FG695 correctly aligned with the wild type sequence but did 
not contain the expected Swedish mutation (KM595/596NL).  The sequence contained 
an additional point mutation at position 1924 (position 2124 in Figure 2.1) of the APP 
DNA sequence.  This was identified as a rare Japanese mutation, which causes FAD.  
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This Japanese mutation corresponds to amino acid substitution V642F, valine to 
phenylalanine substitution at position 642 of primary sequence of APP695 (Hashimoto 
et al., 2000, Yamatsuji et al., 1996). 
Figure 2.1.  Alignment of the FGSwe695 plasmid and the wtAPP695 gene using the 
Multialin software.  The base change from G>T occurs at position 1924 of the APP 
gene sequence.  This was detected in the sequencing reaction containing the 
APP1004 and that containing the APP1545 primer, demonstrating that this apparent 
base change is genuine, and not the result of inaccurate sequencing. 
 
The sequence of the IL695 plasmid when aligned with the wild type sequence 
(NM_201414.2) using Multialin did not produce a correct alignment, suggesting either 
no sequence similarity or a large number of inserted/deleted bases.  The sequences 
were compared using the EMBOSS Matcher (EMBL-EBI) software 
(http://www.ebi.ac.uk/Tools/psa/emboss_matcher/nucleotide.html), which highlighted 
an insertion of a 168bp fragment (Figure 2.2) in the derived sequence when compared 
with wtAPP695.  The inserted sequence was identified as the region of DNA that 
encodes the KPI domain of APP using the Basic Local Alignment Search Tool (BLAST, 
NCBI, http://blast.ncbi.nlm.nih.gov/Blast.cgi) to compare the obtained sequence with all 
known sequences in the database.  This suggested that the donor construct in fact 
contained a larger isoform of APP (APP751), which was confirmed by direct alignment 
of the inserted sequence with the reference sequence of APP751 (data not shown).  
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Figure 2.2.  Sequence alignment (using the EMBOSS Matcher program) of the known 
wtAPP695 sequence (NM_201414.2) compared against the sequencing data obtained 
for the IL695 plasmid.  The highlighted area shows an extra length of sequence from 
the donor that is 168bp long located in the middle of APP.  
 
In summary the obtained constructs contained APP695 with an unwanted mutation 
(FGSwe695) or in the case of IL695 a larger wild type APP751.  For clarity, these 
plasmids were re-designated FG695 and IL751 respectively. 
 
2.3.2 Generation of APP695 
Sequencing of the donor constructs had demonstrated that neither of the obtained 
constructs contained the desired APP695 or SweAPP695 gene.  However, this 
analysis also demonstrated that different areas of each of the donor genes were 
completely homologous to the APP695 reference gene.  After careful analysis of the 
obtained sequences revealed that using the appropriate gene construction strategy, it 
was possible to ligate specific fragments of each construct together in order to create 
wild type APP695. 
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2.3.2.1 Donor APP gene transfer into pcDNA3.1 
2.3.2.1.1 Transfer of the donor APP cDNA into pcDNA3/pcDNA 3.1 
Prior to the construction of the APP695 gene, both donor APP genes were moved into 
the mammalian expression vector pcDNA3.1.  As only the APP gene sequence and 
150bp of sequence upstream and downstream of this gene had been confirmed in the 
original constructs, both donor genes were inserted into the well-characterised plasmid 
pcDNA3.1.  To do this, two unique restriction sites were selected from pcDNA3.1 and 
primers designed to incorporate these restriction sites at the 5’ end and 3’end of APP.  
The primers were designed and analysed using the NetPrimer software (Premier 
Biosoft, http://www.premierbiosoft.com/netprimer/) to minimize primer dimer formation 
and predict the primer melting temperature. 
 
These restriction sites were introduced by PCR (section 2.2.1.4) with the forward 
primer encoding the HindIII site recognition sequence (Figure 2.3) and the reverse 
primer encoding the recognition sequence for XbaI (Figure 2.4).  Primers were 
obtained from Eurofins, MWG Operon, (Ebersberg, Germany) (see appendix for 
sequences).  These sites were selected as they are present only once in the 
mammalian expression vector pcDNA3.1 allowing for directional ligation into these 
vectors.  The donor plasmids served as the template in the PCR reaction and the 
resulting APP amplicons were then doubly digested for ligation into 
pcDNA3/pcDNA3.1.  
5’ TCCCAAGCTTGCCACCATGCTGCCCGGTTTGGC 3’ 
 
Figure 2.3.  Diagram showing the forward primer (named ex alt For in appendix) with 
key sites identified.  Sequence (highlighted in yellow) is matching to the APP gene 
sequence beginning from the start codon; the underlined sequence is the Kozak 
sequence to facilitate initiation of translation of the APP protein. 
 
5’ AGCTTCTAGACTAGTTCTGCATCTGCTCAAA 3’ 
 
Figure 2.4.  Diagram showing the APPwt695 Rev (reverse) primer with key sites 
identified.  The highlighted sequence matches the end of the APP gene sequence.  
HindIII recognition site 
XbaI recognition site 
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Amplicons were visualised by agarose gel electrophoresis (see section 2.2.1.4).  
Products corresponding to the expected size for APP from FG695 (Figure 2.5) and 
APP751 from IL751 (Figure 2.6) were then gel purified (see section 2.2.1.10). 
Figure 2.5.  Agarose gel of PCR amplification of APP insert from FG695 plasmid using 
the primers ex alt APP695 and APP695rev (1% agarose gel).  PCR products (lanes 3, 
4, 5, 6, 7) were analysed alongside with Mass Ruler High (lane 1).  
 
Figure 2.6.  Agarose gel electrophoresis of PCR amplification of APP751 insert (lanes 
1 to 5) using the primers ex alt APP695 and APP695rev (1% agarose gel).  Lanes 7 
and 8 Mass Ruler Low Range and Mass Ruler High Range respectively. 
 
 
After quantifying the DNA concentrations, both APP amplicons were digested with 3 
Units of HindIII and 3 Units of Xbal (section 2.2.1.11).  The digested inserts was then 
subject to PCR purification (see section 2.2.1.12) to remove the small (<25bp) 
fragments and restriction enzymes.  pcDNA3.1 was also digested with these enzymes 
(section 2.2.1.11), and dephosphorylated (section 2.2.1.13) to reduce the possibility of 
self-ligations, and gel extracted (section 2.2.1.10).   
 
2000bp 
1         2        3       4         5        6        7
   
1       2        3        4        5       6        7         8           
2000bp 
90 
 
Both purified APP inserts were ligated into the digested vector (section 2.2.1.14).  
Ligations were then transformed (section 2.2.1.16) and the colonies screened (see 
section 2.2.1.17) for presence of the APP insert using the T7 forward and BGH Rev 
sequencing primers (see appendix for sequences).  Figures 2.7 and 2.8 show the 
results of the screening of colonies for FG695 and IL751 respectively.  Twelve 
JapAPP695 colonies and eleven IL751 colonies were chosen for screening. 
Figure 2.7.  Agarose gel of colony PCR of bacterial clones transformed with 
JapAPP695-pcDNA3.1 (1% agarose gel).  Lane 1, Mass Ruler High, lane 2, Mass 
Ruler Low Range, lane 3,negative control, lane 4,self-ligation reaction, lanes 5 to 7, 
bacterial clones designated EM1-3, lane 9, self-ligation reaction for size comparison, 
lanes 10 to 14, bacterial clones designated EM4 – 8, lane 15,negative control, lane 16, 
Mass Ruler Low Range, lane 17 Mass Ruler High Range.  Clones EM1, 2, 3, 4, 6, 7 
and 8 were confirmed positive for the presence of the 2000bp insert that corresponds 
to JapAPP695. 
Figure 2.8.  Agarose gel electrophoresis of colony PCR of bacterial clones transformed 
with APP751 pcDNA3.1 (1% agarose gel).  Lane 1, Mass Ruler High, lane 2, Gene 
Ruler 100bp, lane 3, negative control, lane 4, self-ligation, lanes 5 and 6 bacterial 
clones designated EP1 and EP2, lane 7, self-ligation, lanes 8 to 16, bacterial clones 
designated EP3 to EP11 lane 17 negative control. Clones EP3 and EP5 were 
confirmed positive for the presence of the 2168bp insert that corresponds to APP751. 
 
Analysis of the recovered colonies of cells transformed with JapAPP695-pcDNA3.1 
revealed that of the screened clones, seven (EM1, 2, 3, 4, 6, 7 and 8) contained an 
1      2       3       4      5      6     7       8      9     10    11    12    13    14    15    16    
1      2      3       4      5      6      7     8       9     10    11    12    13    14    15    16     17     
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insert of the expected size generating a 2000bp amplicon, with 1 colony expected to be 
a self-ligation of the parental plasmid.  Colonies designated EM3, EM4, EM7 were 
selected for small scale isolation (section 2.2.1.18) and prepared for sequencing 
(section 2.2.1.2).  Analysis of the colonies generated after transformation with APP751-
pcDNA3.1 showed that most of the colonies appeared to be the result of self-ligation of 
the parental vector.  Two colonies designated EP3 and EP5 were selected for small 
scale isolation (section 2.2.1.18) and prepared for sequencing (section 2.2.1.2).  
Sequencing results were compared with the designed sequence using Multalin 
software and revealed that all sequenced clones contained the correct sequence.  
Clone EM3 (JapAPP695-pcDNA3.1) and clone EP3 (APP751-pcDNA3.1) were 
selected for large scale plasmid isolation (section 2.2.1.19).  The sequencing results of 
this intermediate step are contained in Appendix 7. 
 
2.3.2.2 Construction of APP695 into pcDNA3/3.1 
Having obtained pcDNA3.1 constructs containing the FGJapAPP695 
sequence/APP751, a strategy was devised to correct the sequence back into that of 
wild type APP695 using fragments of the APP genes.  In both APP genes, an EcoRI 
site, is located upstream of the Japanese point mutation in FGJapAPP695 and also 
downstream of the KPI domain in APP751.  This was used along with the 3’XbaI 
restriction site which flanks both APP genes to produce the essential fragments needed 
to reconstruct wtAPP695 (see Figure 2.9).  The region of DNA following the EcoRI site 
of pcDNA3.1-APP751 is 294bp in size and is identical to the corresponding flanking 
region of wtAPP695, whilst the first ~1800bp of the FGJap695 gene is identical to the 
corresponding region of wtAPP695.  Therefore, the complete sequence of wtAPP695 is 
contained in both plasmids, and could be generated by the excision and re-ligation of 
purified fragments to reconstruct the full wtAPP695 gene within pcDNA3.1. 
 
Initially, the pcDNA3-JapAPP695 plasmid was digested with EcoRI HF and XbaI HF (3’ 
end of APP, which was what was originally used to clone the donor genes into 
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pcDNA3.1).  This produces two fragments; one that is approximately 7000bp in size 
which incorporates the first approximately 1800bp of wtAPP695, with the 5’ end of the 
APP gene attached to the backbone of the pcDNA3.1 vector, and a small 294bp 
fragment, representing the 3’ flanking region of APP695 containing the Japanese point 
mutation that was to be removed.  
 
 
 
 
 
 
 
Figure 2.9.  Diagram of the key fragments identified in pcDNA3-JapAPP695 which 
were used to construct the wtAPP695 gene. 
 
 
The pcDNA3-APP751 plasmid was digested with EcoRI-HF and XbaI-HF, producing 
two fragments; one is a large unwanted fragment of the APP gene attached to the 
backbone of the plasmid (carrying the KPI domain and a smaller fragment homologous 
to the 3’ region of wtAPP695 (see Figure 2.10 for restriction site location).  Directional 
ligation of the excised 7158bp fragment from JapAPP695-pcDNA3.1 with the 294bp 
terminal sequence from pcDNA3-APP751 was used to create a wild type APP695 
construct in a characterised mammalian expression vector. 
  
pcDNA3.1-
JapAPP695 
JapAPP695 
First 1800 bps of DNA 
sequence is identical to 
wtAPP695 
JapAPP695 point 
mutation found within 
this region of gene 
EcoRI 
restriction 
site 
 
 
 
 
5’ HindIII RE site 3’ XbaI RE site 
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Figure 2.10.  Diagram of the key fragments in APP751-pcDNA3.1 which were used to 
construct the wtAPP695 gene. 
 
 
APP751-pcDNA3 was digested (with EcoRI-HF and XbaI-HF) and the products 
separated by agarose gel electrophoresis.  Digestion APP751 led to the formation of 
two fragments; the large fragment (7158bp) represented the upstream region of the 
APP gene containing the unwanted KPI domain (found only in the larger APP isoforms) 
and the vector backbone and a small 294bp fragment which forms 3’ end of the APP 
gene.  The 294bp fragment was isolated from the gel in Figure 2.11.  The JapAPP695-
pcDNA3 plasmid was digested with XbaI-HF and EcoRI-HF) and the 7158bp fragment 
(Figure 2.11) consisting of the vector backbone and 5’ end of the APP gene was 
excised and purified to remove 294bp (containing the unwanted Japanese mutation) 
from the end of JapAPP695. 
  
pcDNA3.1-
APP751 
5’ HindIII RE site 3’ XbaI RE site 
Last 294 bp is identical to 
the flanking region of 
wtAPP695 
EcoRI 
RE site 
APP751 
KPI 
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Figure 2.11. Purification gel (1% Seaplaque gel) APP751–pcDNA3.1 (lane 1) and 
FGJap695-pcDNA3.1 (Lane 4) digested with EcoRI and XbaI. The 294bp fragment 
excised from APP751 is highlighted and the 7158bp large fragment from JapAPP695 
pcDNA 3.1 containing the first 1800bp of the wtAPP695 gene and the pcDNA3.1 
backbone. 
 
 
Ligation reactions (section 2.2.2.9) were performed to insert the purified 294bp 
fragment into the JapAPP695 pcDNA3.1 backbone.  After transformation into E.coli 
only six colonies were recovered.  All colonies were screened using colony PCR 
(section 2.2.1.17).  The gel in Figure 2.12 shows that of the six colonies, three 
produced an amplicon of the expected size (2092bp). 
Figure 2.12. Colony PCR analysis of bacterial clones transformed with wtAPP695 
pcDNA3.1 (1% agarose gel).  Lane 1, Mass Ruler High, lane 2 Mass Ruler Low Range 
ladder, lane 3, negative control lanes 4 to 9 represent PCR products derived from 
bacterial clones designated EW1 to EW6, lane 7, negative control. 
 
 
Plasmid DNA was recovered from the three positive clones designated EW3, EW5 and 
EW6 and sequenced (see section 2.2.1.2).  The sequences were compared with that of 
the wtAPP695 DNA sequence (accession number, NM_201414.2).  The clones EW3 
and EW5 contained the correct sequence.  The sequence alignment of clone EW3 is 
shown in Figure 2.13. 
1       2     3                       4 
 1 2 3        4       5      6        7        8       9 
2000bp 
294bp 
fragment 
7158bp 
fragment 
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Figure 2.13.  Sequencing of wtAPP695-pcDNA3.1. Sequence alignment of clone EW3 
with wtAPP695 gene confirmed the correct wildtype sequence had been generated 
(also confirmed by additional sequencing reactions).  A section of the chromatogram 
obtained after sequencing with the (PCDNA+70 rev) primer demonstrating the 
corrected G->T base change at position 1923 of the APP gene sequence (enclosed 
within the black box).   
 
2.3.3 Construction of the SweAPP695-pcDNA3.1 
Once the wtAPP695-pcDNA3.1 had been successfully constructed, it was used as a 
DNA template to introduce the Swedish mutation by primer-induced mutagenesis.  The 
Swedish mutation is a GA–TC mutation (Lysine–Methionine and Asparagine–Leucine 
(KM-NL) that lies just upstream of the unique EcoRI restriction site within the APP695 
cDNA sequence.  The mutagenic APPSwe Rev primer (Figure 2.14), was designed to 
be complementary to the wtAPP695 sequence except in the region where it encodes 
the TC mutation which is stabilised during the PCR by the 14 complementary base 
pairs upstream and 11 base pairs downstream of the point mutation.  The primer ends 
in an EcoRI recognition site (see appendix for sequence). 
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wtAPP695 sequence   5’-GAAGTGAATCTGGATGCAGAATTCCGA-3’ 
APPSweRev   3’-CTTCACTTAGACGTAGCTCTTAAGGCT-5’ 
Figure 2.14.  Sequence of the APPSwe Rev (reverse) primer used to introduce the TC 
mutation.  Complementary base pairing is shown upstream and downstream of the two 
point mutations.  The EcoRI recognition site is italicised for clarity. 
 
 
The forward primer, Ex APP alt For was used with the mutagenic primer, APPSwe Rev 
in a PCR reaction (section 2.2.1.4) to produce an 1800bp product with the introduced 
Swedish mutation flanked by a 5’ HindIII site and a 3’ EcoRI site.  This allowed the 
mutagenized fragment to be inserted into the wtAPP695-pcDNA3.1 construct by 
cassette mutagenesis. Initially a gradient PCR reaction (section 2.2.1.4) was performed 
to find the optimal annealing temperature. The resulting PCR products were analysed 
by agarose gel electrophoresis (section 2.2.1.9, Figure 2.15).   
Figure 2.15.  Agarose gel of gradient PCR (1% agarose gel).  Lane 1, MassRuler High 
Range, lane 2, MassRuler Low Range, lanes 3 and 4 are plasmids EW3 and EW5 
respectively, lanes 5 to 16, gradient PCR to determine optimal temperature for primer 
annealing in lanes 5 to 16.  Temperatures ranged from 51.6 to 68.3°C.   
 
The chosen temperature was 65°C, which is estimated to give a PCR product between 
lanes 13 and 14 (as indicated by the red arrow).  This temperature gives maximal PCR 
product with relatively little primer dimer interaction (as shown by weak lower banding).  
A large scale PCR (section 2.2.1.4) was set up using 3ng of wtAPP695-pcDNA3.1 as 
template DNA and the resulting APP amplicons analysed by agarose gel 
electrophoresis (section 2.2.1.9) (see Figure 2.16.). 
 
1      2      3     4     5     6     7      8     9    10   11    12    13   14   15   16  
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Figure 2.16.  Agarose gel of PCR amplification of the 1800bp APP695 amplicon 
carrying the Swedish mutation (1% agarose gel).  Lane 1, Mass Ruler High Range 
ladder, lane 2, Mass Ruler Low Range ladder, lanes 3 to 7 PCR products.   
 
 
As only a single amplicon was visible in the SweAPP PCR products, the APP amplicon 
was PCR purified (see section 2.2.1.12) to remove unwanted small fragments along 
with the Pfu taq polymerase.  The wtAPP695-pcDNA3.1 construct (10µg) and the 
purified APP amplicons (5µg) were digested with HindIII-XF and EcoRI-HF (4 hours at 
37°C).  After heat inactivation (80°C for 20 minutes), the digested plasmid was gel 
extracted (Figure 2.17, see section 2.2.1.10) and PCR purified (see section 2.2.1.12).  
Amplicons were PCR purified to remove unwanted small fragments removed in the 
digestion. 
Figure 2.17.  Agarose gel purification of the double digest (HindIII and EcoRI) of 
plasmid EW3 (1% Seaplaque gel).  The large band corresponds to the pcDNA3.1 
backbone attached to the 3’ end of APP695.  The lower target band of 1800bp 
(highlighted by the arrow) was excised and gel purified. 
 
 
The purified plasmid was dephosphorylated (section 2.2.1.13) and a ligation reaction 
was set up with a 3:1 molar ratio of insert to vector (section 2.2.1.14) to insert the 
purified 1800bp APP amplicon carrying the Swedish mutation into the digested vector.  
A self-ligation was also performed in the presence of dephosphorylated vector.  The 
ligation reactions were transformed into Mach1™T1R cells (section 2.2.1.16), and 
selected by plating on LB containing ampicillin (section 2.2.1.15).   
    1   2       3       4       5        6       7    
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Only two colonies were recovered from the transformation.  Both colonies were 
screened by colony PCR (section 2.2.1.17) for the presence of the full length APP 
gene.  Agarose gel electrophoresis of the colony PCR products (Figure 2.18) showed 
that only one of the two recovered clones contained the full length insert.  This clone 
was designated ES1 and small scale plasmid isolation performed (section 2.2.1.18) 
and the DNA prepared for sequencing (section 2.2.1.2). 
Figure 2.18.  Agarose gel analysis (1% agarose gel) of clones transformed with 
SweAPP695-pcDNA3.1.  Lane 1, Mass Ruler High Range ladder, lane 2, Mass Ruler 
Low Range ladder, lanes 3 and 6, negative controls, lane 4, clone ES1 and lane 5, 
clone ES2.  Only ES1 was positive for the APP insert. 
 
 
Sequence alignments between clone ES1 (Figure 2.19) and wtAPP695 in pCDNA3.1 
showed complete homology with the inserted sequence except in the mutagenized 
region.  One of the alignments obtained using the primer APP1004 is shown in Figure 
2.19 with the 1985-1986bp region in the figure corresponding to the Swedish mutation 
at 1784-1785 of the APP gene.  Alignments of multiple sequencing runs with differing 
forward and reverse primers spanning the entire construct confirmed the successful 
construction of SweAPP695-pcDNA3.1 (data not shown). 
  
1 2       3        4        5        6 
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Figure 2.19.  Alignment of APP gene sequence identified using the primer APP1004.  
The boxed area shows clearly the presence of the TC mutation, which when aligned 
with the wtAPP695 sequence in Multialin, shows its correct position at 1784-1785 of 
the APP gene.  This mutation was also identified using the APP1545 primer, 
demonstrating that this apparent base change is genuine, and not the result of 
inaccurate sequencing. 
 
2.3.4 Immunocytochemistry (ICC) of COS7 
To ensure correct expression of the APP protein, the newly generated mammalian 
constructs were tested by transient transfection into COS7 cells in order to perform 
immunocytochemistry and protein expression studies.  The African green monkey 
kidney fibroblast-like cell line, COS7 cell line was used to test expression of wtAPP695/ 
SweAPP695-pcDNA3.1 created from the two donor plasmids. 
 
To confirm expression of both wtAPP695 and SweAPP695, immunocytochemistry was 
employed, using antibodies directed against APP.  Immunostaining is useful as it can 
be used to identify proteins in their native conformation and allows visualisation of 
cellular localisation.  COS7 cells were transiently transfected (section 2.2.3.4) with the 
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SweAPP695 and wtAPP695 plasmids or the respective controls.  After 48 hours, the 
transfected cells were fixed and permeablised for ICC (section 2.2.3.5) using mouse 
anti-APP695 (Invitrogen, 1:500).  The fixed cells were mounted on microscope slides 
and imaged using a Leica SP2 microscope (section 2.2.3.6), using the capture settings 
listed in Table 2.3. 
Table 2.3.  Microscope settings used to view different fluorescent components of the 
cells. 
 
 
The control cells (transfected with GFP-NLS) expressed GFP which was localised to 
the nucleus (data not shown).  Negative controls (untransfected COS7 cells) did not 
express detectable APP that could be visualised via immunostaining (data not shown).  
This suggested any green fluorescence after staining of the APP transfected wells 
would be due to the presence of APP and not auto-fluorescence of the cells.  
 
Results from SweAPP695- pcDNA3.1 and wtAPP695-pcDNA3.1 transfected cells 
(Figure 2.20) confirm that the APP was expressed within transfected cells and in most 
cases was diffusely located throughout the cytoplasm.  APP expression which is 
normally found at the plasma membrane or within vesicles of the trans Golgi network 
was not confirmed by ICC.  This non-organelle specific expression could suggest some 
loss of normal processing due to massively high levels of APP expression under the 
strong CMV promoter.  In addition, the same primary antibody was able to recognise 
and bind to the SweAPP695 protein.   
  
Component 
to view 
Colour  Filter 
cube 
UV Excitation 
λ (nm) 
UV 
Emission 
λ (nm) 
Cells Greyscale Phase bright - - - 
FITC (APP) Green Fluorescence GFP  495 519 
GFP-NLS Green Fluorescence GFP 498 516 
Nuclei 
(DAPI) 
Blue Fluorescence A4 345 455/478 
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Figure 2.20.  Representative fluorescent images of transfected COS7 cells (43 x oil 
objective).  Mouse anti-APP695 antibody was to visualise APP and FITC secondary 
antibody used to visualise the primary antibody. Figure A) shows the wtAPP695 
transfection and Figure B) shows COS7 cells transfected with SweAPP695.  Nuclei 
were visualised using Hard Mounting Medium containing DAPI (blue).  Scale Bar 
25µm. 
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2.3.5 Western blot 
To further confirm the presence of APP, immunoblotting of the transfected COS7 cells 
was carried out.  Immunoblotting using anti-APP695 antibody was able to detect bands 
in lanes containing COS7 cell lysate (Figure 2.21).  The approximate molecular weight 
of APP695 is 115kDa and comparison to the molecular weight markers revealed 
protein bands detected between 100–130kDa in all 4 lanes.  Weak APP protein 
expression was observed in untransfected COS-7 cells and in NT2.D1-derived 
neuronal cell lysates, which are known to express APP, and were used as a positive 
control.  An increased level of APP expression was observed in wtAPP695 and 
SweAPP695 transfected cells, suggesting that the constructs were successfully 
overexpressing APP in these cells.  Membranes were also blotted using anti-Aβ 
antibodies, as a secondary conformation.  These blots showed similar protein bands 
(data not shown) with the additional amyloid positive control at approximately 4kDa.  It 
should be noted whilst increased APP expression seems apparent, it is unclear 
whether APP is processed accordingly. 
Figure 2.21. Western blot of APP695 expression in transfected cells. Lane 1,COS7 
control lysate, lane 2, wtAPP695 transfected COS7 lysate, lane 3, SweAPP695 
transfected COS7 lysate, lane 4, positive control of natural APP found within NT2 
lysate (provided kindly by Dr Marta Tarczyluk). 
 
2.3.6 Construction of pLenti6.4 Syn1 wtAPP695/ SweAPP695 lentiviral constructs  
Transient transfection of both APP expressing constructs in pcDNA3.1 led to increased 
levels of detectable APP695 in COS7 cells suggesting both constructs are expressed 
effectively.  The base plasmid pcDNA3.1 drives expression of these genes under the 
control of a cytomegalovirus enhancer (CMV) promoter.  The high level expression of 
genes driven by the CMV promoter is beneficial for transient transfection, as results 
can be gained quickly.  For the creation of a cell line, such high levels of expression 
 
  1           2            3        4 
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over long periods of time may however be detrimental to cell growth and metabolism.  
The CMV promoter is also active in all cell types, but in the brain, APP695 expression 
is predominantly limited to neurons.  Prior to the creation of the cell lines, the tested 
coding sequence of APP695 and SweAPP695 were moved into a lentiviral vector and 
the promoter replaced with a neuronal specific promoter which drives low to medium 
level expression in neuronal cells. 
 
Lentiviral vectors were used in the creation of the cell line as transduction with 
lentivirus results in stable integration of the cloned DNA into the host cell genome with 
better efficiency than spontaneous integration of plasmid DNA.  The use of lentiviral 
vectors has the added advantage of being able to transduce differentiated cells for 
future studies.  To construct the lentiviral vector, the ViraPower HiPerform 
Promoterless Gateway Expression System (Invitrogen Paisley UK) was used, as the 
included lentiviral destination vector already includes a blasticidin resistance marker, to 
enable the selection of transduced cells and thus create a cell line.  This system allows 
for a high level of expression using any promoter to express a transgene of interest in a 
choice of cell types.  The gateway system relies upon recombinase enzymes derived 
from bacteriophage Lambda, to catalyse the linking of separate strands of DNA 
contained in donor “entry” vectors into one continuous strand of DNA contained within 
the desired final expression construct.  An outline of the technology is shown in Figure 
2.22. 
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Figure 2.22.  Schematic of the gateway® recombination reaction.  During recombination 
attL and attR sites recombine to form an attB site (known as the LR reaction).  The 
diagram represents the steps in the creation of lentiviral constructs expressing APP 
under the control of the Synapsin I (SYN1) promoter.  The viral vector ccdB gene 
(essentially a “death gene”) is removed by the recombination allowing negative 
selection of non-recombined DNA.  Note, after recombination, the attB1 region which 
separates the promoter and transgene of interest is only 40-50bps in size. 
 
 
As can be seen from Figure 2.22, by taking advantage of the specific recombination of 
the unique attP and attB sites allows directional recombination of multiple DNA coding 
sequences into the final expression construct.  In the construction of the lentiviral viral 
vectors, the final expression plasmid was the lentiviral vector pLenti6.4/R4R2/V5-
DEST.  To produce these constructs the first step was the creation of donor “entry” 
vectors containing either the APP695 or SweAPP695 coding sequence, suitable for 
recombination into the final expression vector.  
 
2.3.6.1 Construction of pCR8-wtAPP/SweAPP  
An entry vector containing the correct attL1 and attL2 sites was selected for the cloning 
of human wtAPP695 and SweAPP695.  The pCR8/GW/TOPO TA vector was selected 
as it is one of the few plasmids bearing the correct attL1 and attL2 sites for directional 
recombination into pLenti6.4/R4R2/V5-DEST.  This plasmid forms part of a TA Cloning 
Kit (Invitrogen, Life Technologies, Paisley, UK).  TA cloning is a subcloning technique 
which utilises topoisomerase to link PCR products into a topoisomerase charged vector 
utilising the additional 3’Adenine bases added by Taq polymerase during PCR 
attB2 SYN1 attB1 APP attB4 
Entry vectors 
LR Clonase II Plus 
Final product 
attR2 attR4 ccdB cmR 
attL4 SYN1 attR1 
BlastR 
Destination vector 
attL1 APP attL2 
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amplification.  It is quicker than traditional subcloning but is non-directional.  Thus the 
first step in the creation of the APP entry vectors was the amplification of the coding 
sequences (ensuring they contained the necessary 3’A overhangs), for their cloning 
into pCR8/GW/TOPO TA vector, and the identification of those plasmids in which the 
inserts were cloned in the correct orientation.  
 
The wtAPP695/SweAPP695 genes were amplified with Phusion High-Fidelity DNA 
polymerase (NEB, New England, USA) in GC reaction buffer, using the wtAPP695/ 
SweAPP695 pcDNA3.1 plasmids (described in section 2.2.4 and 2.2.5) as a template 
DNA.  A gradient PCR was performed to determine the optimal annealing temperature 
for the primers; APP8 TOPO For G and APP FRAME STOP / APP P8 Rev 2STOP 
(sequences contained in appendix) using the cycling conditions in Table 2.3 for a total 
of 31 cycles. 
Step Task Temperature Duration 
1 Initial denaturation 98°C 50 seconds 
2 Primer annealing 60°C with gradient 
of20°C  
50 seconds 
3 Extension 72°C 42 seconds (20 seconds 
per 1kb of template) 
4 Final extension 72°C 10 minutes 
Table 2.4.  PCR amplification steps for Phusion amplification of template DNA. 
 
Agarose gel analysis (Figure 2.23) of the amplicons showed a single specific band at 
most temperatures.  An annealing temperature of 66°C was chosen for large scale 
amplification of the wtAPP695 and SweAPP695 genes. 
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Figure 2.23.  Agarose gel electrophoresis of gradient PCR with APP P8 TOPO and 
APP P8 2STOP primers (1% agarose gel).  Lane 1, MassRuler High Range, lane 2, 
MassRuler Low Range, lanes 2 to 14 correspond to APP amplicons amplified at 
different annealing temperatures. 
 
 
Both wtAPP695 and SweAPP695 were amplified in large scale PCR reactions using 
the primers and an annealing temperature of 66°C.  The resulting PCR products were 
gel purified (see Figure 2.24 for SweAPP695 and Figure 2.25 for wtAPP695 gel 
purification, section 2.2.1.10) to remove the Phusion DNA polymerase and PCR 
purified (section 2.2.1.12) to remove any impurities carried through from the gel 
extraction.   
Figure 2.24.  Purification gel for SweAPP695 amplicons (1% Low melting point agarose 
gel). 
Figure 2.25.  Purification of wtAPP695 amplicons DNA (1% low melting point agarose 
gel). 
 
 
As the DNA polymerase Phusion has 3’ to 5’ proof-reading activity, it is capable of 
removing any overhanging adenine bases from the 3’ end of amplified products.  Prior 
to cloning the wtAPP695 and SweAPP695 genes into the TOPO vector (which is 
linearized and tagged with an overhanging Thymine) the 3’A overhangs were added to 
the purified products using a tailing reaction (section .2.2.1.5).  The tailed products 
1     2     3    4     5     6     7     8     9    10   11   12    13   14 
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were cloned into the pCR8/GW/TOPO TA using a Topo cloning reaction (section 
2.2.1.6).  Topo reactions were transformed (section 2.2.17) into E.Coli Mach1TR cells 
and selected using LB agar containing spectinomycin.  The success of the Tailing/Topo 
reactions was confirmed by the recovery of large numbers of colonies (see Table 2.4). 
Plasmid transformed Volume of broth 
plated (µl) 
Number of 
colonies 
SweAPP695 FRAME 
pCR8 
80 25 
160 68 
SwAPP695 2STOP 
pCR8 
80 45 
160 90 
wtAPP695 FRAME 
pCR8 
80 2 
160 7 
wtAPP695 2STOP pCR8 80 4 
160 19 
LB only  Confluent 
Spectinomycin plate with 
TOPO vector only 
 0 
Table 2.4.  Colonies recovered after transformation with topoisomerase cloned PCR8-
APP695 and PCR8SweAPP695 vectors. 
 
 
No transformants were present as a result of transforming with the TOPO vector alone, 
but large numbers of colonies were recovered when insert was included which 
indicated high efficiency of ligation between the APP insert and pcR8 TOPO vector.  
There was a marked difference in colony recovery between vectors containing the 
SweAPP695 insert and the wtAPP695 insert with an approximately 7 fold greater total 
colony recovery in the SweAPP695.  This difference in recovery was unexpected, as 
no protein expression would be expected to occur from the vector used.  Furthermore, 
as the cloned DNA sequences were identical with the exception of the two base pairs 
encoding the Swedish mutation, it was considered unlikely that protein toxicity or 
changes in DNA structure of the insert would be the cause.  It was considered that the 
difference in recovery most likely reflected differences between the quantitated and 
actual amounts of each insert after gel purification (where DNA is at a low 
concentration and difficult to quantitate) and therefore differences in the actual amount 
of each insert added into the Topo reactions.  Twelve colonies expressing the 
SweAPP695/wtAPP695-pCR8 plasmid were picked for colony screening using colony 
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PCR (section 2.2.1.17).  The results of the preliminary colony screen are shown in 
Figure 2.26 and Figure 2.27. 
Figure 2.26.  Agarose gel electrophoresis of clones transformed with SweAPP695-
pCR8 (1% agarose gel); lane 1, MassRuler High Range, lane 2, MassRuler Low 
Range, lane 3 negative control, lanes 4 to 15 are clones designated SAP1 to SAP12.  
  
Figure 2.27.  Agarose gel electrophoresis of clones transformed with wtAPP695-pCR8 
(1% agarose gel); lane 1, MassRuler High Range, lane 2, MassRuler Low Range, lane 
3 negative control, lanes 4 to 15 are bacterial clones designated WAP1 to WAP12. 
 
 
The preliminary colony screen identified all the screened clones as containing an insert 
of approximately 2000bp, suggesting that topoisomerase mediated insertion of DNA 
occurred at high efficiency.  Small scale plasmid isolation (section 2.2.1.18) was carried 
out for each of the twelve clones for SweAPP695-pCR8 and wtAPP695-pCR8 for 
further screening.  As topoisomerase mediated cloning is non directional, a further 
screening strategy was devised to identify the clones in which the APP gene was 
contained in the correct forward orientation prior to sequence analysis.  Plasmid maps 
of the desired constructs with APP in both orientations were analysed for suitable 
unique restriction sites in the vector backbone/ insert that could be used to clearly 
identify insert orientation.  As shown in Figure 2.28, digestion with EcoRV (whose 
recognition sequence is in the plasmid backbone) and BamHI (approximately 1330bp 
into the clone APP gene), leads to the release of APP fragments of 891bp and 4028bp 
1      2     3      4      5     6      7      8     9     10    11    12    13    14    15 
1       2      3       4      5      6       7      8      9     10    11   12    13    14   15 
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if the insert is in the correct orientation, but fragment sizes of 1467bp and 3452bp if the 
insert is in the reverse orientation.   
 
 
 
 
1111 
Figure 2.28.  Diagrammatic representation of APP695 pCR8.  The backbone is the 
pCR8 vector containing the EcoRV recognition site.  If APP695 is in the correct 
orientation, the unique BamHI site lies at position 2019 of the vector (in the APP gene), 
but if APP695 is inserted in the reverse orientation, the BamHI site lies at position 
1443. 
 
 
Six to eight clones of wildtype APP695 / SweAPP695 were digested and the resulting 
fragments analysed by agarose gel electrophoresis (Figure 2.29, Figure 2.30).  
Figure 2.29.  Agarose gel electrophoresis of orientation analysis from fragments 
excised from SweAPP695 plasmids (1% agarose gel); lane 1, MassRuler High, lane 2, 
MassRuler Low Range. Lanes 3 to 6 are from clones SAP1 to 4, lane 7, uncut SAP4 
plasmid, lanes 9 to 13 clones SAP7, SAP 8, SAP10, SAP12, lane 14, uncut SAP8, lane 
16 ,MassRuler High Range and lane 17, MassRuler Ruler Low Range. 
  
1467bp 
(reverse) 
  1     2    3    4    5     6    7    8    9  10  11  12  13 14 15  16  17 
891bp 
(forward) 
Reverse APP attL1 attL2 Backbone Backbone 
BamHI site at 
position1443 
EcoRV site at 
position 2910 
BamHI site at 
position 2019 
EcoRV site at 
position 2910 
For APP attL1 Backbone attL2 Backbone 
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Figure 2.30.  Agarose gel electrophoresis of orientation analysis from fragments 
excised from wtAPP695 pCR8 plasmids (1% agarose gel); lane 1, MassRuler High 
Range, lane 2, MassRuler Low Range, lanes 3 to 5, WAP1, WAP4, WAP6, lane 6, 
uncut plasmid, lanes 9 to 11, clones WAP10, WAP11 and WAP12, lane 12 uncut 
WAP11 plasmid, lane 13, MassRuler Low Range, lane 14, MassRuler High Range.   
 
 
Clones SAP4, SAP10, WAP4 and WAP6 clones contained the 891bp and 4028bp 
fragment sizes confirming that the APP was in the correct orientation.  These clones 
were selected for sequencing (section 2.2.1.2).  Sequencing data was compared with 
the sequence of the designed APP constructs using MultiAlin software 
(http://multalin.toulouse.inra.fr/multalin/).  Of the four clones sequenced (2 Swedish and 
2 wildtype), all contained the correct SweAPP695/ wtAPP695 gene sequence inserted 
in the correct orientation, with the attL sites intact.  However, one clone (SAP10) 
contained a point mutation (A > G) at position 1661, possibly due to a PCR-induced 
error.  This clone was removed from further analysis.  As each clone required four 
reactions to cover the complete APP sequence, a summary of sequencing results is 
tabulated (Table 2.5) for the remaining clones.  
Sample  Primer Construct Comments 
1 M13 FOR SAP4 (start of attL1 site – 1545 (APP) 
2 APP613 SAP4 1363-2197 
3 APP1004 SAP4  1730 – 2716 
4 M13 REV SAP4  1920 – 2917 (into attL2) 
9 M13 FOR WAP4  575 – 1545 
10 APP 613 WAP4  1406 – 2268  
11 APP1004 WAP4  1802 – 2716 
12 M13 REV WAP4  1941 – 2916 (into attL2) 
13 M13 FOR WAP6  575 – 1579 
14 APP 613 WAP6  1363 – 2268 
15 APP1004 WAP6  1805 – 2670 
16 M13 REV WAP6  1915 – 2791 (end of APP) 
Table 2.5.  Sequencing results of successful clones confirming the correct sequence of 
APP and upstream and downstream of insert. 
 
1467bp 
(reverse) 
  1     2     3     4    5     6    7    8     9    10   11  12  13  14    
891bp 
(forward) 
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Once sequence analysis had confirmed that the SweAPP695/wtAPP695 gene 
sequence was correct, and that the attL recombination sites were intact, two clones 
SAP4 and WAP4 were taken forward for large scale plasmid isolation (see section 
2.2.13). 
 
2.3.6.2 Construction of the promoter entry vector 
Many studies of APP expression have been based upon the use of viral-based 
promoters to achieve high level protein expression in all cell types.  However, these 
levels may be considered abnormally high and in the case of neuronal expressed 
APP695, this approach is not appropriate.  Therefore, a neuronal specific promoter was 
selected ensuring APP695 expression would be expressed in neuronal cells as would 
occur naturally in the brain.  The chosen neuronal promoter for the viral construct was 
the Synapsin I promoter.  Synapsins are a group of neuronal phosphoproteins, which 
coat the cytoplasmic surface of synaptic vesicles and specifically SynI and SynII are 
only expressed in the nervous system, which established the synapsin genes as good 
candidates for an investigation of neuron-specific gene expression (Schoch et al., 
1996).  Originally, APP expression was to be studied in the NT2.D1 embryocarcinoma 
cell line which differentiates into neuronal and astrocytic co-cultures, therefore placing 
APP expression under Synapsin I control would ensure APP expression within only 
neuronal cells.  However, despite repeated attempts to create stable NT2.D1 cells 
expressing APP this line proved unsuitable for long term expression studies (data not 
shown).  The project was redirected to use another available neuronal cell line in the 
laboratory, the neuroblastoma derived SHSY5Y line.  SHSY5Y cells have been 
previously shown to express Syn1 (Goodall et al., 1997).  The SYN1 promoter was 
chosen for physiological levels of APP expression after preliminary qPCR studies (data 
not shown) suggested an approximate ratio of 2:1 of APP to SYN1 mRNA.  Therefore it 
was estimated (assuming that transcription from the incorporated SYN1 promoter is 
identical to that of the native promoter), that incorporation of a SYN1 driven APP 
112 
 
construct would result in an approximate 1.5 fold increase in APP in differentiated 
SHSY5Y cells. 
 
An entry vector containing the correct attL4 and attR1 sites was selected for the cloning 
of human Synapsin I.  The pENTR 5’-TOPO TA vector was selected as one of the few 
plasmids bearing the correct attL4 and attR1 site for directional recombination into 
pLenti6.4/R4R2/V5-DEST.  This plasmid forms as part of a TA Cloning Kit (Invitrogen, 
Life Technologies, Paisley, UK).  
 
The creation of the SYN1 entry vector followed a similar approach to that used to 
create the APP entry vectors.  The SYN1 promoter was amplified from an existing 
plasmid construct (PZS-SYN1-eGFP, kindly provided by Dr David Nagel).  This clone 
contains a truncated 495bp Syn1 promoter described in (Liu et al., 2008).  The 
amplified products were tailed to ensure they contained the necessary 3’A overhangs 
for cloning into the pENTR5’ TOPO TA vector, and then cloned using topoisomerase 
ligation before identifying those plasmids in which the SYN1 insert was cloned in the 
correct orientation. 
 
The SYN1 gene was amplified with Phusion High-Fidelity DNA polymerase (NEB, New 
England, USA) in GC reaction buffer using the PZS-SYN1-eGFP plasmid as template 
DNA.  A gradient PCR was performed to determine the optimal annealing temperature 
for the primers, SYN1 Pentr5 For G and Syn1 Pentr5 rev (complementary to the SYN1 
promoter sequence) (see appendix for primer sequence and section 2.2.1.3).  The 
cycling conditions are listed in Table 2.6.  A total of 31 cycles was performed. 
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Table 2.6.  PCR conditions set out to amplify the SYN1 gene. 
 
 
After amplification, PCR products were analysed on a 2% agarose gel (section 2.2.1.9) 
(see Figure 2.31), for the presence of 495bp amplicons.   
Figure 2.31.  Agarose gel analysis of products from the gradient PCR of the SYN1 
promoter using Syn 1 Pentr5 For g and Syn1 Pentr5 Rev primers (2% agarose gel).  
Lane 1, Mass Ruler High Range, lanes 2 to 13 correspond to products formed at 
increasing annealing temperatures, lane 14, Gene Ruler 100bp Plus.  
 
 
The SYN1 promoter was subsequently amplified in large scale PCR reactions (section 
2.2.1.4) using the primers Syn 1 Pentr5 For g and Syn1 Pentr5 Rev with an annealing 
temperature of 64.5°C.  The resulting PCR products (Figure 2.32) showed 
predominantly a single band with minimal additional banding. 
Figure 2.32.  Agarose gel analysis of large scale PCR amplification of the SYN1 gene 
(1.75% agarose gel).  Lane 1, Gene Ruler 100bp Plus, lanes 2 to 6, SYN1 amplicons of 
495bp.   
 
 
The amplicons were gel purified (section 2.2.1.10) and then PCR purified (section 
2.2.1.12).  Purified amplicons were tailed (section 2.2.1.5) and cloned into the pENTR5’ 
Step Task Temperature Duration 
1 Initial denaturation 98°C 50 seconds 
2 Primer annealing 60°C with 
gradient of 20°C  
50 seconds 
3 Extension 72°C 15 seconds (20 seconds 
per 1kb of template) 
4 Final extension 72°C 10 minutes 
1       2      3        4        5        6     
1     2    3     4     5    6     7    8    9   10   11  12  13   14 
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TOPO vector (section 2.2.1.6).  Topo reactions were transformed (section 2.2.1.7) into 
E.Coli Mach1TR cells and selected using LB agar containing kanamycin.  The success 
of the Tailing/Topo reactions was confirmed by the recovery of large numbers of 
colonies (data not shown, due high numbers of colonies recovered, estimated 
>2000/plate).  Twelve colonies were picked and screened using M13 For and M13 Rev 
primers (section 2.2.1.17) and analysed on a 1.75% agarose gel (see Figure 2.33). 
Figure 2.33.  Agarose gel analysis of colony screening of the pENTR5 SYN1 TOPO 
clones (1.75% agarose gel).  Lane 1, Gene Ruler 100bp Plus, lanes 2 to 13, G1 to G12 
bacterial clones and lane 14, GeneRuler 100bp Plus.  
 
The presence of the SYN1 gene and the two attL sites, which together produce 
amplicons approximately 800bp in size, was confirmed in all but clone G9.  Small scale 
plasmid isolation (section 2.2.1.18) was carried out using the eight clones positive for 
the 495bp insert for analysis of insert orientation. 
 
To identify the clones in which the SYN1 gene was contained in the correct forward 
orientation prior to sequence analysis, plasmid maps of the desired constructs with the 
SYN1 gene in both orientations were analysed for suitable unique restriction sites in 
the vector backbone and insert that could be used to clearly identify insert orientation 
(Figure 2.34).  As shown in Figure 2.34, digestion with a single enzyme PST1 (whose 
recognition sequence is in both the plasmid backbone and cloned SYN1 gene), leads 
to the release of fragments of 668bp and 2477bp if the insert is in the correct 
orientation, but fragment sizes of 1211bp and 2934bp if the insert is in the reverse 
orientation. 
1      2      3      4      5      6     7      8     9     10   11    12   13    14 
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Figure 2.34.  Diagrammatic representation of the PST1 sites in SYN1 pENTR5’.  One 
site lies within the SYN1 promoter, whilst the other in the pENTR5’ (backbone) vector.  
If SYN1 promoter is in the correct orientation, both PST1 sites are 668bp away from 
one another, but if SYN1 is in the reverse orientation, the PST1 sites lie closer to each 
other (209bp). 
 
 
Eight bacterial clones of SYN1 were digested with Pst1 and the resulting fragments 
analysed by agarose gel electrophoresis (Figure 2.35). 
Figure 2.35.  Agarose gel analysis of SYN1 pENTR5’ clones digested with Pst 1 to 
determine SYN1 gene orientation (2% agarose gel).  Lane 1,GeneRuler 100bp Plus, 
lane 2, uncut clone (G1), lanes 3 to 10, clones G1, G2, G6, G7, G8, G10, G11 and 
G12.   
 
 
From the digest, clones G2 (lane 4), G6 (lane 5) and G12 (lane 10) were confirmed to 
carry SYN1 in the correct orientation.  These were prepared for sequencing (section 
2.2.1.2) using M13 For and M13 Rev primers.  Sequencing data was analysed against 
the construct map of SYN1-pENTR5’ created using the promoter sequence described 
in (Liu et al., 2008) using MultiAlin.  Clone S12 for which the alignment is shown in 
Figure 2.36 contained the correct SYN1 promoter sequence and was chosen for large 
scale plasmid isolation to prepare for the final step of lentiviral plasmid construction. 
 
 Forward SYN1 attR1 attL4  backbone backbone 
Pst I at 717 Pst I at 1385 
Reverse SYN1 attR1 attL4 backbone backbone 
Pst I at 1385 Pst I at 1174 
1      2       3      4       5       6      7       8     9      10   
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Figure 2.36.  Alignment of pENTR’5 SYN1 (clone S12) using M13 For and Rev primers 
aligned with the SYN1 gene sequence show complete alignment of the whole gene. 
 
 
2.3.6.3 Construction of the pLenti6.4 SYN1- wtAPP695/ SweAPP695 V5 DEST 
The final step in the construction of the lentiviral vectors was recombination of the Syn1 
promoter and either the wtAPP695 or SweAPP695 coding sequence with the lentiviral 
destination vector.  To recombine pCR8-wtAPP695 or pCR8-SweAPP695 with the 
pENTR5’ Syn1 TOPO vector into the final destination vector (pLenti6.4 R4 R2 V5 
Dest), a recombination reaction (section 2.2.1.8) was prepared according to the 
manufacturer’s instructions.  The reactions were immediately transformed into Stbl3 
E.coli and the recovery of colonies assessed (Table 2.7).  Maps of the final vectors 
were constructed in Clone Manager 5 to approximate the insert size expected for 
sequencing. 
 Volume of inoculated 
broth plated (µl) 
Colonies 
pLenti Syn1- 
SweAPP695 
200 102 
300 152 
pLenti Syn1-wtAPP695 200 76 
300 106 
Negative control 200 1 
300 1 
Table 2.7.  Bacterial transformants recovered after transformation with pLenti6.4 SYN1-
SweAPP695 or pLenti6.4 SYN-1-wtAPP695.  The high number of transformants 
reflects the high efficiency of the LR reaction. 
 
 
Eight wtAPP695 and eight SweAPP695 clones were selected for colony screening 
using pLenti6.4 Forseq and WPRE Seq Rev seq primers (which read from beyond the 
attP sites and into the recombined region).  Results of the colony screening were 
analysed by agarose gel electrophoresis (see Figures 2.37 and 2.38). 
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Figure 2.37.  Agarose gel electrophoresis showing the colony PCR for pLenti6.4-
SweAPP695 clones (1% agarose gel).  Lane 1, negative control, lanes 2 to 5, clones 
WLR1 to WLR4, lane 6, MassRuler High Range, lane 7, MassRuler Low Range, lanes 
8 to 11, clones WLR5 to WLR8, 12, negative control.  
Figure 2.38.  Agarose gel electrophoresis showing the colony PCR of pLenti6.4-
wtAPP695 clones (1% agarose gel).  Lane 1, negative control, lanes 2 to 5, clones 
SLR1 to SLR4, lane 6, MassRuler High Range, lane 7, MassRuler Low Range, lanes 8 
to 11, clones SLR5 to SLR 8. 
 
Of the clones screened, all appeared to produce the expected insert size of 
approximately 3000bp.  This shows the 100% efficiency of recovery using this 
recombination technique.  Only colonies containing the recombined vector would grow 
under ampicillin selection.  Clones WLR 5, WLR7, SLR2 and SLR3 were prepared for 
sequencing (see appendix for list of primers).  Sequencing data was analysed against 
pLenti-SYN1-wtAPP695/ SweAPP695 gene sequences (constructed using Clone 
Manager 5) using Multialin software.  The complete sequence alignment of clone 
WLR7 (Figure 2.39) showed complete homology with the designed Syn1-wtAPP695 
sequence.  The alignment of clone SLR3 with the designed Syn1-SweAPP695 
construct (Figure 2.40) again demonstrated complete homology and confirmed that, 
clones SLR3 and WLR7 represented the correct Syn1-SweAPP695 and Syn1-
wtAPP695 promoter/gene constructs in plenti6.4 R4 R2 V5.  These plasmids were re-
transformed into Stbl3 E.coli for large scale isolation (section 2.2.1.19) to be kept as 
stocks to be used in lentiviral production. 
 1     2       3       4      5       6       7      8       9     10  11    12 
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Figure 2.39.  Final sequence alignment of the WLR7 (PLenti6.4 SYN1-wtAPP695) using 
the primers; pLenti6.4for seq, APP748 Rev, APP613 For, APP1004 For and WPRE Rev.  
Note SYN1 gene sequence begins at position 140 in Mulitalin.  The end of the sequence 
finishes beyond the APP gene sequence and into the plasmid encoded WPRE 
(mismatching bases at the end of the sequence are in very close proximity to the 3’ end of 
the WPRE Rev primer binding site and in a non-manipulated area of the plasmid
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Figure 2.40.  Complete sequence alignment of SLR3 (pLenti6.4 SYN1- SweAPP695) 
using the same primers (primer sequences can be found in appendix).  Note the start 
of SYN1 gene is at position 140 in Multialin.  The end of the sequence signifies the end 
of the V5 epitope, which lies beyond the APP695 gene sequence. 
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2.4 Discussion 
The aim of the work described in this chapter was to construct lentiviral vectors to 
enable the long term expression of either wtAPP695 or SweAPP695.  Sequencing of 
the donor plasmids revealed abnormalities in the gene sequence and therefore the aim 
of the initial molecular cloning described was to correct these abnormalities by excision 
and ligation of desired APP gene fragments to create the correct wtAPP695 gene 
sequence.  Testing of the reconstructed wtAPP695 and SweAPP695 genes by 
expressing in the COS7 cell line demonstrated that APP695could be expressed in a 
non-neuronal cell line, and that APP protein expression was recognised by antibodies. 
 
Wildtype APP695 is the predominant isoform of APP expressed within the CNS.  In AD, 
wtAPP695 is abnormally processed to form fragments, one of which is the Aβ1-42 
peptide.  Increased production of this peptide is associated with neuronal cell death 
seen within both AD patient brains and animal models.  In particular, overexpression of 
wtAPP695 can lead to AD pathology as observed in many Down syndrome patients by 
the fourth decade of life (Lott and Head, 2001).  In fact, there are many APP duplication 
mutations that lead to AD (as shown in Table 1).  This was the basis of the decision to 
study overexpression of wtAPP695.   
 
In addition to the wtAPP695 gene construction, an overexpression system containing a 
known familial mutation of APP695 was constructed using molecular cloning 
techniques.  Familial mutations in the APP gene have long been associated with 
EOAD, by influencing APP processing towards the amyloidogenic pathway.  The 
Swedish mutation is one of a number of APP695 mutations identified to cause FAD by 
increasing BACE cleavage of APP, thereby increasing Aβ1-42 production.  This 
mutation was selected as it is used to create many AD transgenic mice models, most 
notably the Tg2576 mouse model, which exhibit age-dependent plaque formation, 
reflecting human brain pathology as well as showing signs of oxidative stress which is 
121 
 
one aspect considered important in affecting neuronal health.  In addition, the 
expression of SweAPP695 within H4 cells was studied in terms of global gene 
expression,  where as a result of SweAPP695 expression, 283 genes were found to be 
down-regulated and 384 genes were up-regulated (Shin et al., 2010). 
 
Both the wtAPP695 and SweAPP695 genes were placed under the control of the 
Synapsin I promoter in a lentiviral construct.  Previous studies have utilised viral 
promoters such as CMV which promote abnormally high expression of protein, in a 
non-cell specific manner that can also be transient (Moriyoshi et al., 1996).  This may 
be due to the fact that viral CMV promoters may be more prone to being silenced in 
host cells than eukaryotic promoters (Akaaboune et al., 2000b, Choi et al., 2005).  
Expression of high levels of protein may also prove toxic to host cells.  As APP695 
expression is highest in neurons where AD pathology is found, the APP gene construct 
was designed for expression under the control of the neuronal Synapsin I promoter.   
 
The original objective of this PhD project was based on expression of APP in which 
Synapsin I is expressed in neurons but not in the astrocytes derived from the NT2.D1 
cell line (NT2 differentiation leads to development of neuronal-astrocytic co-cultures).  
However, preliminary studies performed in our laboratory found that infection of NT2 
cells failed to give stable long term expression when using neuronal specific or even 
ubiquitous promoters.  Therefore, the most suitable alternative neuronal cell line 
available was the SHSY5Y cell line.  Lentiviral constructs were utilised as the method 
to generate stable cell lines, as they can transduce both actively proliferating and non-
dividing cells, integrating genetic material into host cells for stable, long term transgene 
expression.  In the future, this system could be used to transduce alternative cell lines 
for the study of AD. 
 
Generation of cell lines expressing either wtAPP695/SweAPP695 will allow for the 
study of APP expression/ Aβ production on the effects of cellular metabolism.  AD 
122 
 
brains show metabolic changes, which include reductions in glucose consumption, 
correlating strongly with cognitive deterioration.  Key changes are observed before the 
onset of AD.  In fact, PET scans of people who carry familial AD mutations or those 
exhibiting MCI, which often develops into AD, found severe reductions in glucose 
consumption (Berti et al., 2010, Mosconi, 2005).  These observations also extend to 
cognitively normal older persons (Mosconi et al., 2012) whose AD progression has 
been followed through MCI and then to AD, as well as middle-aged individuals carrying 
the ApoE4 genotype (Mosconi et al., 2004).  The latter is particularly interesting, 
considering that the ApoE4 allele is a strong genetic risk factor for LOAD. 
 
Furthermore, signs of oxidative stress are evident as observed by increased oxidation 
of proteins (Butterfield and Lauderback, 2002) and mitochondrial dysfunction in AD 
brains (Moreira et al., 2010).  Mitochondrial dysfunction is widely associated with Aβ, 
which can lead to the disruption of normal energy homeostasis.  Mitochondrial 
aberrations involve reductions of enzymes, pyruvate dehydrogenase and ketoglutarate 
dehydrogenase (Gibson et al., 1998)  This has been observed in the 3xTg AD model, 
shown by decreased mitochondrial respiration and pyruvate dehydrogenase, as early 
as 3 months.  At this age, there is little brain Aβ deposition, suggesting that 
mitochondrial abnormalities may occur before AD pathology sets in (Yao et al., 2009a).  
Mitochondrial dysfunction is discussed in further detail in section 3.1.  With these early 
changes in metabolism which precede symptomatic AD, the generation of cell lines 
expressing wtAPP695/ SweAPP695 constructed in this chapter allow for the effects of 
APP expression and consequent early changes in metabolism to be monitored.  This 
work is discussed further in chapter 3. 
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Chapter 3: Creation and Characterisation of APP-expressing SHYSY5Y 
cell lines 
3.1 Introduction to AD modelling 
Numerous models have been developed to investigate the pathogenesis of AD.  
Expression of familial AD mutations within cell lines is a common method used to 
simulate AD at the cellular level.  In addition, overexpression of APP in vitro has been 
shown to lead to development of AD pathology.  This is reflected in patients with Down 
syndrome, who carry three copies of chromosome 21 (where the APP gene is located) 
(Lott and Head, 2001).  However, not all individuals with DS develop dementia, which 
highlights the complexity of this disease and therefore warrants the further investigation 
of the role of APP in AD.  In vivo models which express mutated APP/overexpression 
of wild type APP, have consistently been shown to secreted increased levels of Aβ.  
This leads to behavioural changes, similar to those associated with cognitive decline 
found in humans (Elder et al., 2010), further justifying use of the APP gene for studying 
AD pathology.   
 
3.1.1 APP and mitochondrial function 
As AD is increasingly considered to be a metabolic disorder with clear changes in 
glucose uptake and mitochondrial dysfunction associated with the disease, the study of 
energy homeostasis within the human brain in relation to neurodegenerative disorders 
is an important area of study.  To understand how APP is involved in mitochondrial 
function, it is necessary to first understand the complex metabolic pathway oxidative 
phosphorylation, performed by most cells to release energy efficiently. 
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Figure 3.1.  Diagram of oxidative phosphorylation within the mitochondrion.  Oxidative 
phosphorylation involves five complexes embedded in the inner mitochondrial 
membrane which all have distinct but vital functions. Image attributed to Wikimedia 
Commons https://commons.wikimedia.org/wiki/File:ETC.svg,  
 
 
Mitochondria are key organelles, with key roles in calcium homeostasis and ATP 
production (Brookes et al., 2004).  The process by which ATP is generated is known as 
oxidative phosphorylation, as outlined in Figure 3.1.  It involves the transfer of electrons 
along several complexes embedded in the inner mitochondrial membrane.  The first 
protein complex, Complex I known as NADH (nicotinamide adenine dinucleotide) 
dehydrogenase acts to dehydrogenate/oxidise NADH to form NAD+; this provides the 
protons that are actively pumped into the outer mitochondrial membrane to establish an 
electrochemical gradient, whilst providing free electrons to Complex II.  NADH is an 
energy-rich molecule which carries electrons that are fed into the system from the citric 
acid cycle and fatty acid oxidation.  This first reaction is catalysed by coenzyme Q10 
(CoQ)/ubiquinone (represented by Q in the equation below), a quinone found within the 
mitochondrial membrane: 
NADH + Q + 5H+ matrix NAD+ + QH2 + 4H+  intermembrane 
 
In the second reaction, Complex II (known as succinate-Q oxidoreductase) acts to 
oxidise succinate to fumarate, in the process transferring electrons to Coenzyme Q 
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(CoQ).  The transfer of electrons to CoQ effectively reduces CoQ, which then acts to 
carries these electrons to Complex III.  Complex II contains a bound flavin adenine 
dinucleotide (FAD) cofactor which facilitates conversion of succinate to fumarate 
reaction, by becoming hydrogenated itself.  The reaction below summarises the key 
reaction: 
 
Succinate + Q  Fumarate + QH2 
No protons are produced in this reaction, and therefore no protons are transported 
across the mitochondrial membrane, and thus this reaction contributes less energy the 
overall reaction. 
 
The transfer of electrons from CoQ to Complex III (known as Q-cytochrome c 
oxidoreductase) allows for the oxidation of one molecule of ubiquinol (the reduced form 
of Q in the reaction below) and the reduction of two molecules of cytochrome c (Cyt c).  
Cyt c is a water soluble heme protein, found within the intermembrane space, and is 
limited to carrying a single electron (as opposed to the two electrons carried by CoQ), 
which it transfers onto Complex IV.  This limiting step causes the reaction mechanism 
within Complex III to take place in two steps, known as the Q cycle.  The reaction is 
summarised as follows: 
QH2+ 2Cyt c oxidised + 2H+ matrix Q + 2Cyt c reduced + 4H+ intermembrane 
The protons released from the reaction are passed into the intermembrane space, 
further contributing to the electrochemical gradient.  
 
The next complex in the pathway is Complex IV, known as Cytochrome c oxidase.  It 
receives the electrons from Cyt c to mediate the reaction between protons and 
molecular oxygen to produce water.  The oxygen is known as the terminal electron 
acceptor.  Simultaneously, this complex pumps protons across the membrane, 
maximising the proton gradient.  The reaction is summarised below: 
 
4Cyt c reduced + O2 + 8H+ matrix   4 Cyt c oxidised + 2H2O + 4H+  intermembrane 
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The transport of electrons between the complexes within the mitochondria is known as 
the electron transport chain and it is these electrons that provide the energy required to 
actively transport protons across the mitochondrial membrane.  This electrochemical 
gradient is utilised by the final complex V, ATP synthase, where the protons pass from 
the outer mitochondrial membrane, through the ATP synthase (via a proton channel) 
providing the energy needed to drive the synthesis of ATP from the reaction of ADP 
and phosphate (Pi). 
 
3.1.2 Mitochondria and oxidative stress 
Oxidative stress plays a role in early AD pathogenesis in which mitochondrial 
dysfunction plays a central role.  AD patients exhibit a significant decrease in energy 
metabolism, correlated with an increase in oxidative damage and reduced activity of 
mitochondrial enzymes; cytochrome C oxidase, pyruvate dehydrogenase, and α-
ketoglurate dehydrogenase (Readnower et al., 2011).  ATP production in mitochondria 
is a source of electron leakage (Orrenius et al., 2007).  These negatively charged ions 
can reduce oxygen to form toxic reactive oxygen species (ROS) predominantly from 
the activity of Complex I, Complex II and Complex III.  ROS can react with hydrogen 
ions to form toxic hydrogen peroxide.  Cells possess defence systems against these 
reactive molecules, such as the release of glutathione (GSH) and superoxide 
dismutase activity to reduce ROS exposure.  However, if there is a disturbance in the 
ROS-antioxidant balance that favours oxidation, oxidative damage occurs.  Damage to 
mitochondria is detrimental to cell survival as mitochondria are key regulators of 
cellular metabolism and apoptosis. 
 
Further evidence of mitochondrial involvement in AD is the presence of a mitochondrial 
targeting signal within APP.  APP can be imported into this organelle by binding to the 
transporter outer membrane 40 (TOM40) and transporter inner membrane (TIM23) 
mitochondrial import proteins.  However, complete transport is impeded by the acidic 
C-terminal sequence.  Interestingly, previous studies have demonstrated the 
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localisation of γ-secretase to the mitochondria, where this enzyme can cleave APP to 
form Aβ peptides (Hansson et al., 2004).   
 
Aβ can accumulate in mitochondria in AD patients.  Indeed, intracellular and 
mitochondrial accumulation of Aβ is likely to precede extracellular amyloid deposition.  
Aβ was found to accumulate as early as 4 months in transgenic mice especially within 
synaptic mitochondria.  Specifically, synaptic mitochondria contain a substantial 
amount of cyclophilin D (Cyp D), which functions to initiate opening of the mitochondrial 
permeability transition pore (mPTP).  Mitochondrial Aβ has been found to interact with 
CypD.  In fact, a deficiency in CypD ameliorates Aβ-induced mitochondrial stress and 
cognitive impairment in an AD mouse model (Guo et al., 2013).  This key observation 
of the interaction between CypD and amyloid suggests a role of CypD in AD 
pathogenesis.  
 
Opening of the mPTP allows the transport of calcium ions across the mitochondrial 
membrane, which dissipates the mitochondrial membrane potential and causes the 
release of pro-apopotic molecules such as cytochrome C, Smac/Diablo and apoptosis-
inducing factor (Martinou and Green, 2001, Zimmermann and Green, 2001).  Collapse 
of the mitochondrial membrane potential not only leads to reduced mitochondrial 
calcium retention capacity, but also increases ROS production and ultimately cell 
death.  Mitochondria within synapses regulate calcium homeostasis and therefore 
changes in calcium can perturb synaptic function (Du et al., 2012).  As synaptic 
dysfunction is a prevalent feature of AD, this may be one possible effect of amyloid on 
neuronal cells. 
 
Mitochondrial kinetics appears to be significantly affected in AD patients when 
compared to controls, with mitochondrial fission occurring more frequently than fusion 
in AD (Santos et al., 2010, Wang et al., 2009b).  Mitochondrial fission is whereby 
mitochondrial can divide by binary fission whereas fusion occurs when two 
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mitochondria fuse together.  The balance between fission and fusion is required to 
maintain functional mitochondria.  The overexpression of APP, which influences 
increased Aβ production, can increase fission-related protein levels such as dynamin-
related protein 1 (Drp1) and Fis1 and inhibit levels of proteins that are associated with 
fusion, for example mitofusins 1 and 2 (Wang et al., 2009a).  Increase of mitochondrial 
fission may occur during apoptosis or when mitochondrial lose their mitochondrial 
potential (van der Bliek et al., 2013), therefore changes in mitochondrial dynamics may 
be a cellular response to alleviate mitochondrial stress before resorting to initiating cell 
death.  
 
These cellular observations have also been reflected into animal AD models.  The 
3xTg AD mouse model display impaired mitochondrial function, observed by decreases 
in state 3 and 4 respiration, lower COX IV activity and increased oxidative stress.  
Furthermore, it was reported that APP and Aβ could be localised to the mitochondria, 
in which they have been shown to bind to HSP60, a molecular chaperone (Yao et al., 
2009b, Walls et al., 2012a).  This latter finding suggests a contribution of amyloid to the 
mitochondrial unfolded protein response (UPR).  The UPR is a stress response 
pathway operating in higher eukaryotes, following the disruption of protein folding 
(Pellegrino et al., 2013).  The Molecular chaperones likes HSP60 are important in 
transport and refolding of proteins from the cytoplasm into the mitochondrial matrix, 
therefore maintaining homeostasis and protecting against adverse effects of protein 
folding and aggregation (Haynes and Ron, 2010).   
 
More interestingly, neural cells stably expressing the Swedish APP mutation or 
wildtype APP695, where APP exhibit a strong association with HSP60, demonstrated 
mitochondrial dysfunction (Walls et al., 2012a).  Researchers in this study observed a 
decrease in ATP production with increased levels of oxidative stress.  When comparing 
energy metabolism between the two cell lines, both were able to utilise oxidative 
phosphorylation and glycolysis equally.  Surprisingly, maximal respiration (which is 
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defined as the maximal rate that oxygen is consumed to generate high levels of ATP in 
conditions of high energy demand) was higher in the Swedish APP-expressing cells.  
The authors suggested that this was a compensatory response to depleted ATP levels.  
Another key observation was that Swedish APP-expressing cells were more 
susceptible to secondary oxidative insults such as Aβ oligomers.   
 
One of the earliest signs of AD is the reduction in glucose uptake, which is a major 
energy substrate.  Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) 
scans have shown that AD brains exhibit reduced uptake of radiolabelled glucose, 
leading to some researchers to believe that AD is a hypometabolic disorder.  This is 
also reflected in animal models, which express mutated genes (APP, PS1, Tau) to 
increase amyloid deposition and/ development of tau tangles.  In these animals, 
researchers have found regional differences in cerebral glucose uptake (Nicholson et 
al., 2010).  These mouse models include the PDAPP, PSAPP, TG2756 and the triple 
transgenic mice.  Reductions in glucose uptake occur in an age dependent manner in 
areas of the brain that are responsible for the behavioural deficits.  Epidemiological 
evidence has indicated that type 2 diabetes is a risk factor for AD.  Insulin signalling is 
essential to brain glucose metabolism as insulin is able to cross the blood brain barrier 
and the neurons involved in cognitive function express insulin responsive glucose type 
4 (GLUT4) and GLUT8 transporters receptors (Bingham et al., 2002, Blázquez et al., 
2014, Membrez et al., 2006, El Messari et al., 1998, Apelt et al., 1999). 
 
Oxidative stress in AD leads to the presence of advanced glycation end products, 
nitration, lipid peroxidation adduction products, carbonyl-modified neurofilaments and 
free carbonyls.  These effects are observed in vulnerable neurons in AD with spatio-
temporal distribution of different types of damage seen in the brain.  The brain is 
particularly vulnerable to ROS, as it has a high metabolic demand, consuming 20% of 
the oxygen in the human body (Jain et al., 2010).  This potentially generates high levels 
of ROS during oxidative phosphorylation.  Furthermore, some brain areas contain high 
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levels of Fe, which can be used to catalyse the generation of ROS (Dixon and 
Stockwell, 2014).  The brain is also enriched in lipids with unsaturated fatty acids, 
which are potential targets for lipid peroxidation (Bourre, 2010).  Furthermore, the brain 
does not have substantial antioxidant defence systems, compared to other organs such 
as the liver and kidney, containing only moderate levels of superoxide dismutase 
(SOD), catalase and glutathione peroxidase.   
 
3.1.3 Antioxidant defences in the brain 
The most significant molecule used to defend against ROS in the brain is glutathione 
(GSH).  GSH is a tripeptide, generated from glutamine, cysteine and glycine.  Its 
synthesis requires ATP and occurs in two steps.  Firstly, γGluCys synthetase utilises 
glutamate and cysteine to generate γGluCys.  This forms the substrate for the enzyme 
glutathione synthetase that combines γGluCys with glycine to generate GSH.  The 
recycling of GSH is balanced by feedback inhibition of γGluSys synthetase by GSH. 
Figure 3.2. Diagram showing the synthesis of GSH. 
 
 
GSH homeostasis in the brain is maintained by the recycling of GSH precursors.  The 
synthesis of GSH is limited by cysteine, which can be provided to neurons by 
neighbouring astrocytes.  Astrocytes also produce GSH, as they express both of the 
enzymes required for GSH synthesis.  In response to oxidative stress, GSH is oxidised 
to GSSG (oxidised glutathione), which can be converted back to GSH by GSH 
reductase, and requires the cofactor NADPH (Pocernich and Butterfield, 2012). 
Figure 3.2 Diagram showing the synthesis of GSH. 
 
Levels of GSH in the brain decrease with age (Saharan and Mandal, 2014).  In AD, the 
level of GSH in peripheral lymphocytes is decreased whilst levels of GSSG are 
increased, in a manner that is consistent with an oxidative stress phenotype (Calabrese 
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et al., 2006).  The ratio between GSSG and GSH is a marker of redox thiol status and 
oxidative stress, found to be significantly increased in AD (Owen and Butterfield, 2010).  
There is a correlation between increased GSSG levels and decreased cognitive 
function in AD patients (Lloret et al., 2009).  Furthermore, individuals with MCI exhibit 
signs of oxidative stress, with the hippocampus showing decreased activity of SOD and 
glutathione S transferase (GST) (Sultana et al., 2008). 
 
3.1.4 Methods of probing mitochondrial function 
Evaluating mitochondrial functions and the influence of reactive species on this vital 
organelle is an important area of study.  Such studies can be performed by measuring 
the oxygen consumption of intact isolated mitochondrion or by measuring the activity of 
mitochondrial enzymes.  However, both methods do not measure mitochondrial 
function in vitro and therefore provide only a limited insight into organelle function in 
relation to its cellular environment. 
 
3.1.4.1 Clark Electrodes 
Clark electrodes have typically been used with cells suspended in stirred, buffered 
solutions in order to measure oxygen consumption (Chance and Williams, 1955).  
These electrodes are predominantly used to determine organelle function in isolated 
samples for clinical or animal studies.  Taking oxygen consumption measurements 
from cultured cells requires the removal of cells from growth substrate and placing 
them in a stirred solution.  However, this causes stress on many cells leading to cell 
death, especially in anchorage-dependent cells, accompanied by increased ROS 
production and mitochondrial damage (Li et al., 1999).  In addition, stirring of the 
electrode causes non-laminar shear increasing oxidative stress (De Keulenaer et al., 
1998).   
 
3.1.4.2 Fluorometric systems for cultured cells 
Recently, numerous studies across different fields of research have emphasized the 
application of the Seahorse XF24 flux analyser as an alternative to Clark Electrodes.  
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Results obtained using this instrument were found to be comparable to data obtained 
using electrodes and can be used to study both non-adherent and adherent cells in 
culture.   
 
The Seahorse XF24 instrument utilises fluorometric technology to measure oxygen 
consumption and proton release, enabling the study of mitochondrial respiration and 
glycolysis respectively.  Two sensors measuring either the oxygen consumption rate 
(OCR) or extracellular acidification rate (ECAR) are lowered into wells containing 
adherent cells and can be used to take multiple readings. 
 
Figure 3.3.  Schematic showing the side view of the layout of each well of a culture 
plate.  A single tube containing two sensors is lowered in the pool of media to taking 
regular measurements.  Compounds are stored in the ports over hanging the wells 
which the analyzer can be instructed to be inject into the well to elicit a metabolic 
response. 
 
 
 
This system allows for highly sensitive and specific measurements of mitochondrial and 
glycolytic function with a greater output than that which can be achieved with traditional 
electrode-based systems.  Compounds can be injected into the wells to stimulate a 
response in the cells, allowing the user to assess the ability of cells to response under 
stress, whilst cells are maintained at 37°C.  Experimental procedures can be tailored to 
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suit the needs of the user, allowing flexibility and even the potential study of novel 
therapeutic drugs targeting energy metabolism.   
 
Figure 3.4.  Diagram showing the typical metabolic profile of cells when studying 
mitochondrial function using the Seahorse analyser (taken from Seahorse Biosciences 
MitoStress Test manual). 
 
By monitoring OCR, measurements of mitochondrial function can be performed.  The 
analyser takes key readings to calculate mitochondrial parameters (Figure 3.4) after 
the injection of different mitochondrial inhibitors.  The first measure is basal respiration 
defined as the cellular oxygen consumption whilst at rest.  A decreased basal rate in 
treated or diseased cells versus controls can indicate a defect in the respiratory 
complexes.  The first compound injected, Oligomycin (ATP coupler) blocks ATPase 
activity.  This reduces OCR with the remaining respiration reflecting the natural proton 
leak of the mitochondria i.e the flow of protons across the inner mitochondrial 
membrane (which does not generate ATP).  Injection of the ETC accelerator carbonyl 
cyanide 4-(trifluromethoxy)phenylhydrazone (FCCP) dissipates the electrochemical 
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gradient, forcing the cells to increase the flow of electrons and oxygen consumption in 
an attempt to maintain the membrane potential leading to maximal respiration.  The 
spare respiratory capacity gives an indication of the cell’s ability to respond to 
increased ATP demand.  It is considered that cells with reduced respiratory capacity 
are more vulnerable to changes in energy demand.  Finally mitochondrial inhibitors, 
such as Rotenone and Antimycin A are added in the final injection to completely inhibit 
mitochondrial respiration.  As shown in Figure 3.4, non-mitochondrial respiration may 
occur, whereby certain cell types consume oxygen for cellular processes.  Examples 
include the activity of NADPH oxidases in macrophages during the respiratory burst, 
activated during an inflammatory response (Brand and Nicholls, 2011).  Most cells 
have low non-mitochondrial oxygen consumption, due to the activity of desaturase/ 
detoxification enzymes.  
 
The Seahorse XF analyser offers great insight into both mitochondrial and glycolytic 
functions of any cell type.  The ability to study a cell’s mitochondrial response to toxic 
insults is particularly relevant to AD, with its close association with mitochondrial 
dysfunction.  In this study, the Seahorse analyser was used to probe the mitochondrial 
responses of SHSY5Y cells expressing wtAPP695 and SweAPP695 in comparison to 
control cells. 
 
3.1.5 The SHSY5Y cell line 
Cytotoxicity studies on neuronal cell types have been performed extensively in the 
SHSY5Y cell line because of the relative ease of culture and cost effectiveness of 
reagents.  The neuroblastoma SHSY5Y cell line is a thrice cloned sub line of the 
neuroepithelioma cell line, SK-N-SH (Ross et al., 1983).  The parental cell line was 
derived from a bone marrow biopsy in 1970 from a young girl with metastatic 
neuroblastoma, which when cultured, produces two distinct cell types  (Ross et al., 
1983).  One is neuroblastic (known as N-type) in nature, whilst the other is substrate 
adherent (known as S-type) (Biedler et al., 1978).  It is the former cell type from which 
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clones were selected and eventually gave rise to the following cell lines; SH-SY5, SH-
SY5Y, MC-IIE and MC-IXC.   
 
The SHSY5Y cell line possesses a neuroblast-like morphology (Biedler et al., 1978).  
This cell line has many advantages in the field of studying neuronal cultures.  In 
addition to having a human neuronal lineage, the SHSY5Y cell line has a similar 
karyotype to that of human cells (with an extra copy of a fragment from 1q leading to a 
modal number of 47 chromosomes) (Yusuf et al., 2013).  They can be rapidly cultured 
and express several neuronal markers most notably neuronal specific enolase (NSE) 
(Odelstad et al., 1981). 
 
In vitro culture of SHSY5Y cells invariably leads to the growth of two cell types, one is 
adherent whilst the other are floating.  The adherent population of cells has been the 
main subject of study  (Kovalevich and Langford, 2013).  The N-type cells are of 
particular interest as they can be differentiated into a more neuronal phenotype.  Many 
methods are employed to differentiate these cells, with the use of retinoic acid (RA) 
being most common (Påhlman et al., 1984, Simpson et al., 2001, Sarkanen et al., 
2007).  
 
3.1.5.1 SHSY5Y differentiation 
SHSY5Y cultures are commonly differentiated in the presence of the vitamin A 
derivative RA, which leads to differentiation into a more neuronal phenotype (Pahlman 
et al., 1984).  Originally, the effect of RA was studied as a differentiation inducer in 
neuroblastoma therapy.  Currently, RA is used to induce neuronal morphology in 
neuroblastomas as in vitro neuronal models for human diseases and neuroblastoma 
therapy.  Therefore, studies into differential responses of proliferating and differentiated 
SHSY5Y cells to toxins have been extensively carried out (Hartley et al., 1996, Hong et 
al., 2003, Seoposengwe et al., 2013). 
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Treatment of RA on SHSY5Y cells leads to rapid withdrawal from the cell cycle, where 
cells arrest in G1-phase accompanied by DNA inhibition and gradual reduction in 
cellular proliferation detected within 48 hours (Melino et al., 1997).  Morphologically, 
cells begin to extend neuritic processes.  RA treatment was found to inhibit growth in 
the first 8-10 days of treatment (Encinas et al., 2000).  The resulting neuronal 
phenotype exhibits increased expression of NSE, synaptophysin, synaptic associated 
protein-97 (Cheung et al., 2009), dopamine beta hydroxylase (Oyarce and Fleming, 
1991) and tyrosine hydroxylase (Presgraves et al., 2003),. This has attracted 
researchers in the field of Parkinson’s disease who have used this cellular model 
(Lopes et al., 2010, Xie et al., 2010).  In addition, this cell line has applications in AD 
research, for example, it has been used in the study of tau phosphorylation and 
potential screening of glycogen synthase kinase 3 β inhibitors (Jamsa et al., 2004). 
 
Following RA treatment, researchers have used growth factors, which promote the 
survival of neuronal subtypes.  In particular, the neurotrophic factors which include 
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 
and neurotrophin 4/5.  Targeted knock down of the genes encoding neurotrophins or 
their specific tyrosine kinase receptors (TrkR) led to apoptosis of neuronal cell 
populations (Nguyen et al., 2010).  Culture of neurons in the presence of growth factors 
is vital to ensure survival and protection from apoptosis following differentiation 
(Kristiansen and Ham, 2014, Misko et al., 1987).  This dependence of neurons on 
neurotrophins has been also been demonstrated in the rat pheochromocytoma PC12 
cell line (Takebayashi et al., 2002).  The presence of NGF causes neurites to project 
from the cell bodies, forming neural networks.  Neurite extension requires microtubule 
assembly (Drubin et al., 1985), which is driven by expression of microtubule-associated 
proteins (MAPs) that are up-regulated following NGF treatment.  
 
Studies have shown that RA induces the expression of TrkB, allowing SHSY5Y cells to 
become responsive to BDNF (Kaplan et al., 1993) with BDNF enhancing the 
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differentiating effects of RA (Arcangeli et al., 1999).  Neuronal basal medium 
supplemented with B27 and dibutyryl-cyclic AMP, potassium chloride (KCl), and l-
glutamine has also been utilised to enhance differentiation.  B-27 consists of a cocktail 
of growth factors, antioxidants, hormones and other chemicals known to improve cell 
survival and development (Brewer et al., 1993).  Differentiation of SHSY5Y with 5 days 
of RA treatment followed by 5 days of BDNF treatment gives rise to a more 
morphologically neuronal phenotype (Gimenez-Cassina et al., 2006).  Neuronal 
proteins such as MAP1B and neurofilament (NF) protein, MAP2 (Sanchez Martin et al., 
1998), tau (Jamsa et al., 2004) and β-tubullin III are detectable within these cultures.  
Cultures also show decreased expression of cyclin-dependent kinase-1 (cdc2/ cdk1), 
evidence of withdrawal from the cell cycle. 
 
3.1.6 Generation of stable cell lines 
Numerous studies have utilised transient transfection to study the effects of APP 
expression.  Using this method, the transgene of interest is inserted in a plasmid that is 
introduced into the host cell, typically complexed with lipid reagents to mediate efficient 
delivery into cell’s nucleus.  Generally, transiently expressed transgenes can be 
detectable for up to seven days; however, transfected cells are usually harvested within 
24 to 96 hours post-transfection.  The transgene is not integrated into the genome, and 
following mitotic division is not passed from one generation to the next.  Therefore over 
time with each mitotic division, the levels of protein expression decrease.  In addition, 
transfection efficiencies can vary, meaning repeated experiments may be performed 
with cells expressing at different levels.  This poses a problem when studying the 
effects of APP expression with relation to AD, a developmental ageing disorder.  As 
such, in this project it was desirable to investigate methods to generate stably 
transfected SHSY5Y cell lines to study the chronic effects of APP expression. 
 
Generating stable cell lines has major advantages over transient transfection as it 
permits long term protein expression studies without loss of transgene expression.  
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Typically, stable cell lines have a transgene of interest permanently incorporated into 
their cellular genome under a specified promoter as desired by the researcher.  Stably 
transfected cells are selectable from a heterogeneous population as they also 
incorporate antibiotic resistance permanently into their genome.  With antibiotics added 
into the culture media at the minimal concentration, non-transfected cells are 
eradicated from the culture, thus retaining a reduced number of stable cells which carry 
the transgene and antibiotic resistance marker.  As the cultures grow, colonies arising 
from single cells develop which can be isolated and cultured as separate clones.  
Clones derived from a single cell, improve the consistency of protein expression over 
time, as all cells in the population have the same transgene, inserted in the same area 
of the chromosome.  Several methods to achieve long term gene expression are 
available, but in this project lentiviruses were chosen of the preferred method of choice.  
The rationale for this method will be discussed in the following section. 
 
3.1.6.1 The lentiviral age 
Over the last twenty years, a number of viral delivery systems have been developed 
which include adenovirus, adeno-associated virus, retrovirus and lentivirus.  
Lentiviruses in particular, are known to infect a broad range of cell types (Kim et al., 
2004), maintain chronic, sustainable transgene expression and have the major 
advantage of being able to stably integrate into quiescent, non-dividing cells (e.g. 
neurons) as well as actively dividing cells (Dissen et al., 2009).  In addition, up to 100% 
transduction efficiency has been reported in some cell types (Li et al., 2004).  Their use 
has also been extended to in vivo, where it is hoped they could form vehicles to deliver 
genes into the brain to treat neurodegenerative disorders (Bensadoun et al., 2000, de 
Almeida et al., 2001, Baekelandt et al., 2003).  Traditionally, neuronal cultures have 
been extremely difficult to manipulate and stably express genes of interest.  Since the 
sequencing of the HIV-1 retrovirus, significant advances in lentiviral technology have 
improved efficacy of infecting neuronal cultures to achieve stable and long term gene 
expression.  Viral infection is generally a more efficient method of introducing genes 
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into cells than standard in vitro transfection and has also been used in vivo for gene 
therapy applications.   
 
Lentiviral vectors are based upon HIV-1, which excel in host cell attachment, receptor 
mediated entry, viral mediated reverse transcription and genome integration (Zufferey 
et al., 1997).  They can be manipulated to deliver complex expression elements 
including introns or large stretches of genomic DNA whilst exhibiting low toxicity and 
inducing minimal immune response in the host (Dissen et al., 2009).  Lentiviral delivery 
systems have been modified, in that the pathogenic HIV genes have been removed 
and the remaining essential genes are spread over multiple plasmids.  Another feature 
is that the viral particles can be pseudotyped with other envelope proteins, whilst the 
structural and enzymatic components of the virion are derived from HIV-1, the 
envelope glycoprotein used for this project originates from vesicular stomatitis virus 
(VSV) (Naldini et al., 1996).  This was chosen due to its high stability and the broad 
tropism of its G protein (Zimmermann et al. 2011), which affords a vastly increased 
host cell range when compared to the natural limitations of the native HIV-1 trimeric 
envelope glycoprotein. 
 
The sequencing of the lentivirus genome has allowed researchers to manipulate the 
genetic structure in order to produce different vector systems with which to infect host 
cells.  There are three well established lentiviral systems; ‘first generation’, ‘second 
generation’ and ‘third generation’.  The main difference between these systems is the 
increase in biosafety due to the introduction of deletions in key genes and by 
partitioning genes involved in viral packaging onto separate vectors.  In this project, the 
second generation lentiviral system was utilised due to its ability to package large 
inserts and also its relative simplicity in comparison to the third generation system, 
whilst still providing improved safety over the first generation systems.  
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Second generation vectors consist of the transfer vector, the packaging plasmid and 
the envelope plasmid.  This split packaging system distributes key genes over several 
plasmids, as shown in Figure 3.5 and is one of several biosafety features. 
Figure 3.5.  Diagram showing the three plasmids with the key genes. 
 
The transfer vector has several lentiviral accessory genes deleted (vif, vpr, vpu and 
nef) as they are not essential for in vitro replication and are involved, to varying 
degrees, in HIV pathogenicity (Dull et al. 1998).  This plasmid carries the cis-acting 
genetic sequences essential for the vector to infect the target cell, as well as the 
transgene of interest.  Endonuclease restriction sites are also present to facilitate the 
insertion of transgenes of interest.  A key feature of this vector is the presence of the 
PSI (Ψ) packaging sequence, which ensures that only the transfer vector is packaged 
into infection competent virus.  Expression of DNA from the transfer vector is limited to 
sites of infection in HIV-1 negative cells.  Furthermore, the presence of promoter 
disabling mutations engineered into the U3 region of the 3’ long terminal repeat (3’LTR) 
renders the virus self-inactivating (SIN), thereby reducing the risk of the virus 
generating full-length vector RNA after viral integration (Logan et al., 2002).  Normally, 
when retroviral mRNA is reverse transcribed, the 3’LTR is copied to form the 5’LTR, 
acting as a promoter to direct expression of viral mRNA to be packaged into a new 
virus.  Therefore, SIN vectors carrying deletions in the 3’LTR are transcriptionally 
inactive after transduction and cannot be converted into full length RNA and therefore 
do not replicate, ensuring no infectious virus is produced.   
Promoter ENV 
cDNA 
TAT LTR LTR GAG POL 
LTR LTR Promoter 
REV 
Envelope plasmid 
Transfer plasmid 
Packaging plasmid 
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The packaging plasmid forms the backbone of the virus system, carrying the Gag, Pol, 
Rev, and Tat genes, which are essential for producing viral particles.  The Gag gene 
encodes the capsid and matrix proteins which make up the structural elements of the 
virus, while the Pol gene encodes for the reverse transcriptase (reverse transcribes 
RNA to cDNA) and integrase (integrates double stranded cDNA into host genome), 
which is required to generate new viral particles (Amado and Chen, 1999).  The Rev 
gene facilitates nuclear export of mRNA into the cytoplasm for translation of viral 
structural proteins.  In third generation systems, the Rev gene is located on a separate 
packaging plasmid to maximise biosafety.  Finally, the Tat gene encodes for a protein 
that significantly enhances viral transcription efficiency.  This gene is completely 
omitted in the third generation system as a further biosafety feature (Logan et al., 
2002).  The second generation packaging vector used for this project was psPAX2, 
produced by the Trono laboratory (Prof Didier Trono Lab Packaging and Envelope 
Plasmids (http://tronolab.epfl.ch/). 
 
The envelope plasmid carries the viral envelope gene, which in this case encodes the 
VSV surface glycoprotein.  This gene originates from a heterologous virus, which 
allows for pseudotyping of viral particles and the infection of a broad range of different 
cell types.  The glycoprotein plasmid used for this this project was PMD2G (from the 
Trono Laboratory).  
 
As previously stated, lentiviral based delivery systems have been shown to consistently 
infect non-dividing cells, such as neurons, with a high transduction efficiency (Klages et 
al., 2000).  It was decided that lentivial delivery of APP would most likely be the most 
appropriate method for successfully generating APP-expressing neuronal cell lines.  
The generation of these lines would provide consistently expressing wtAPP and 
SweAPP cell lines, allowing the investigation of the effect of APP expression on cellular 
metabolism. 
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3.1.7 Aims and objectives  
The aim of this study was to create wtAPP695/ SweAPP695 expressing SHSY5Y cell 
lines using lentiviral transduction.  The cell lines generated were characterised by 
immunoblotting before and after differentiation.  The levels of Aβ release were 
assessed by determining concentrations of amyloid in the media taken from cell lines 
after 24hours/48hours after differentiation using ELISA.  Differences in cell proliferation 
and glucose uptake were determined in transfected cells.  Finally mitochondrial 
function was studied in comparison to untransfected SHSY5Y cells using the Seahorse 
analyser. 
 
The hypothesis was that APP overexpression would cause metabolic dysfunction in 
cell lines and render cells more sensitive to oxidative stress.  Experiments were 
performed in order to determine whether overexpression of mutant APP and wildtype 
APP could drive changes in energy metabolism.  Identification of the relationship 
between APP overexpression or APP misprocessing and altered neuronal metabolism 
could yield important insights into the earliest stages of neuronal dysfunction in AD. 
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3.2 Methods and Materials 
3.2.1 Lentiviral packaging of the pLenti6.4 wtAPP/SweAPP695 constructs.   
The constructs, pLenti6.4 Syn1-wtAPP695/ SweAPP695 previously described (section 
2.3.6.3), were packaged into active Lentivirus using the HEK293FT cell line (section 
3.2.1.1).  Another lentiviral construct (provided kindly by Dr John O’Neil), pGIPz (a CMV-
driven GFP expression vector) was also packaged to test packaging and viral 
transduction into in the SHSY5Y cells.   
 
3.2.1.1 HEK 293FT cell culture 
The human embryonal kidney (HEK) 293FT cell line (Invitrogen, Paisley UK) was used 
as a host for lentiviral production.  This cell line is fast-growing; easily transfectable and 
can generate high viral titers.  It differs from HEK293 cells in that it carries the SV40 
large antigen, which allows very high levels of protein to be expressed from vectors 
containing the SV40 origin of replication.  All cell culture reagents were obtained from 
Gibco, Life Technologies, Paisley, UK, unless otherwise specified. 
 
All sub-culturing was carried out according to the manufacturer’s instructions (see 
appendix).  Cells were cultured in DMEM High Glucose containing 6mM glutamine, 
100U/ml Penicillin and 100μg/ml Streptomycin (PAA), 10% Foetal Bovine  Serum, 
0.1mM MEM Non-essential Amino Acids (NEAA) and 500µg/ml Geneticin.  
 
Initially, cells frozen in 10% DMSO; 90% complete medium were resurrected in medium 
without Geneticin to allow recovery.  After recovery and for all subsequent culturing, 
Geneticin was supplemented into the media.  When cells reached 80-90% confluence, 
they were passaged 1:5 -1:10 using trypsin/EDTA with the media refreshed every 
alternate day.  
 
3.2.1.2 Viral packaging 
The manufacturer recommends passaging of HEK293FT cells two to three times before 
preparing for packaging.  To prepare for packaging, HEK293FT cells were washed in 
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PBS and then detached with trypsin.  Cells were pelleted (200g, for 5 minutes) and the 
pellet re-suspended in fresh medium.  Live cells were counted using Trypan Blue 
exclusion dye on a haemocytometer (section 2.2.3.2).  Cells were seeded at 1.5x 105 
/flask into ten T25cm2 flasks (Corning, MA, USA) and returned to the incubator.  
 
After 24 hours, when the cells reached approximately 90% confluence, cells were 
refreshed with 5mls of fresh media without antibiotics and then returned to the incubator 
for 1 hour.  After this period, cells were transfected using Lipofectamine 2000 
(Invitrogen, Fisher Scientific, UK) according the manufacturer’s instructions with either 
the wtAPP695 or SweAPP695 pLenti6.4 transfer vector together with the packaging 
plasmids psPAX2 and pMD2.G (purchased from Addgene, MA, USA)  at a ratio (W/W) 
of 1:1:1 and returned to the incubator for 16 hours.   
 
On the next day, medium was replaced with 5mls packaging media (DMEM High 
Glucose containing 6mM glutamine, 10% Heat inactivated Foetal Bovine Serum, 0.1mM 
MEM Non-essential Amino Acids) and the cells were returned to the incubator.  After 72 
hours, all media was removed from flasks and clarified by centrifugation at 2000g for 10 
minutes.  The resulting supernatant was then passed through a 0.4µM cellulose acetate 
or polyethersulfone (PES);(low protein binding) syringe filter to remove any remaining 
cellular debris.  To test for the presence of p24 viral particles, which are indicative of 
active viral production, the clarified media was tested using the rapid Lenti GoStix 
(Clontech, Saint-Germain-en-Laye, France) (section 3.2.1.3). 
 
All tubes, pipette tips, medium, flasks etc that came into contact with the virus were 
decontaminated in 1% high level laboratory disinfectant (Virkon) for at least 20 minutes 
in the tissue culture hood before autoclaving.  Any equipment that was not in direct 
contact but opened in the tissue safety cabinet was decontaminated for 5 minutes with 
1% Trigene (Fisher Scientific, UK).  Surfaces were cleansed in 1% Trigene and the 
microbiological cabinet sterilised for 1 hour under UV illumination.  
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3.2.1.3 Lenti-X GoStix protocol  
To rapidly test for the presence of Lentiviral particles prior to purification, Lenti-X GoStix 
(Clontech, Saint-Germain-en-Laye, France) were used (for protocol see appendix).  
After lentiviral production was confirmed, the remaining viral supernatant was 
concentrated by sucrose cushion.  
 
3.2.1.4 Viral concentration  
To concentrate viral particles sucrose cushion centrifugation was employed, based on a  
method, described by (al Yacoub et al., 2007).  Briefly, a 20% sucrose (Sigma-Aldrich, 
Poole, UK) cushion was prepared in 15mls of TNE buffer (50mM Tris, 100mM NaCl, 
0.5M EDTA) and 5ml added to a 50ml centrifuge tube, to which 20mls of virus was 
overlaid.  The solution was centrifuged (6400g for two hours), with minimal acceleration.  
The viral pellet was then re-suspended in culture media and the lentiviral concentration 
determined (section 3.2.1.5).  All lentivirus was aliquoted for single use aliquots into 
microcentrifuge tubes, frozen in crushed dry ice and stored in double ziplocked bags at -
80°C to preserve viability. 
 
3.2.1.5 Determining Lentiviral Concentration 
Concentrated lentivirus aliquots were titered using the QuickTiter™ Lentivirus Titer Kit 
(Lentivirus-Associated HIV p24)(CellBioLabs, Cambridge Bioscience Ltd, Cambridge, 
UK) (see appendix for protocol).  Briefly, a series of lentiviral dilutions were prepared to 
ensure absorbance readings would fit within to the linear region of a p24 standard curve.  
Test samples and p24 standards were incubated in the anti-p24 antibody coated 96-well 
microplate overnight at 4°C.  On the following day, the wells were washed in wash buffer 
to remove unbound sample and samples incubated sequentially in diluted FITC-
Conjugated anti-p24 Monoclonal antibody and then diluted HRP-Conjugated Anti-FITC 
Monoclonal antibody for 1 hour at room temperature.  When all wells reached a visible 
blue hue, stop solution was added to all wells and the absorbance at 450nm was 
measured on a spectrophotometer (Ascent MultiSkan, Thermo Scientific, UK).   
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3.2.2 Testing the Syn1 wtAPP695/ SweAPP695 Lentiviruses 
Once the viral titers of both viruses were determined, the next step was to test infectivity 
rates in the human neuroblastoma cell line. 
 
3.2.2.1 SH-SY5Y  
Human neuroblastoma SH-SY5Y cells were cultured in RPMI-1640 medium containing 
100U/ml Penicillin and 100μg/ml Streptomycin), 10% Foetal Bovine Serum, 1% NEAA 
and 2mM L-Glutamine at 37°C, 5% CO2.  During the initial resurrection procedure, cells 
were defrosted slowly at 37°C, before transferred into media for pelleting (200g for 5 
minutes).  The resulting pellet was re-suspended in fresh media and seeded into a T25 
flask (Corning, MA, USA) for eventual expansion into T75 flasks.  Cells were passaged 
in 0.05% Trypsin-EDTA and split 1:5/1:3 2-3 times a week when reaching 80% 
confluence. 
 
3.2.2.2 Viral infection of GFP-expressing virus in the neuroblastoma cell line 
For viral transfection studies, the cells were seeded at a density of 5x103 cells in a 96-
well plate (Corning, MA, USA).  The numbers of cells were determined using a 
haemocytometer (section 2.2.3.2).   
 
To determine the optimal viral transduction into this cell line, SHSY5Y cells were 
transduced with CMV-driven GFP virus (pGIPz) (provided kindly by Dr John O’Neil) at 
varying multiplies of transfection (MOI).  Multiplities of infection refer to the number of 
virion particles infecting host cells.  This can be approximately quantified by determining 
the active viral concentration (using the p24-associated ELISA).  Different MOI’s were 
tested to determine the effects of sub-lethal viral concentrations in the presence of a 
cationic polymer, polybrene (Sigma-Aldrich, Poole, UK) which acts to increase the 
efficiency of infection. 
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MOI’s of 0, 5, 10, 25 and 50 were tested whereby 75µls of culture media were added 
to each well.  The cells were incubated overnight and then the media refreshed 
before returning the cells to the incubator.  After 3 changes of media, cultures were 
tested for the presence of p24 antigen to ensure that the safe removal of viral 
particles.  Upon obtaining a negative result, cells were considered non-infectious to 
be imaged for GFP using the fluorescence microscopy (see section 2.2.3.6). 
 
3.2.2.3 Testing of the APP lentivirus 
Once optimisation of viral transduction of SHSY5Y cells had been established, 
lentivirus carrying either SweAPP695 or wtAPP695 was transduced into SHSY5Y cells 
at an MOI of 5 and 10.   
 
SHSY5Y cells were plated at a density of 8 x 104 cells per well into a 12-wellplate 
(Corning, MA, USA) to achieve 50% confluence on the next day.  The cells were then 
differentiated in RPMI media containing 1 x10 -5 M RA for five days.  To prepare the 
cells f or infection, specific volumes of concentrated virus, which equated to an 
MOI of 5 or 10 were prepared in media.  900µls of virus containing media was pipetted 
into wells in triplicate and the cells were incubated overnight to allow for viral 
transduction to take place.  As a positive control, SHSY5Y cells were also infected 
with a virus expressing cherry red fluorescent protein under the control of the EIF1α 
promoter.  Non-transduced cells were used as a negative control.  After three changes 
of media, the positive control samples were visualised by fluorescence microscopy to 
determine the success of infection. 
 
Three days post-infection, total cell lysates were obtained using RIPA buffer and 
pooling three wells (section 2.2.2.1).  These were quantified (section 2.2.2.2) and 
assessed for APP expression by Western Blotting (section 2.2.2.3 to 2.2.2.5).  Pure 
Aβ1-42 was also run on the SDS gel to confirm primary antibody binding.  Mouse anti-
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Aβ (6E10, Covance, 1:1000) primary antibody was used to detect both full-length 
APP695 and Aβ oligomers/monomers. 
 
3.2.2.4 Blastocidin kill curve 
SHSY5Y cells were seeded at 4 x 104 cells per well of a 12-well plates and allowed to 
incubate overnight.  On the following day, Blastocidin S HCl, (Life Technologies, 
Paisley, UK) was diluted in media from 0 to 10µg/ml.  Cells were then grown in the 
presence of blastocidin with the media refreshed every alternate day for two weeks.  
The minimal concentration of Blastocidin that caused 100% of cell death was chosen 
for clone selection. 
 
3.2.3 Production of stable APP-expressing SH-SY5Y cell lines 
3.2.3.1 Lentiviral transduction 
SHSYSY cells were seeded into three T25 flasks to achieve approximately 90% 
confluence after 24 hours; cells were counted (section 2.2.3.2) in order to calculate 
multiplicities of infection (MOI).  An MOI of 1 was used to infect one flask with either the 
wtAPP695 orSweAPP695 virus in 4.5ml of culture media.  The flasks were then placed 
back into the incubator overnight.   
 
On the following day, the cells were plated at a density of 1 x 104 / 5 x 103 cells per well 
of 6-well plates (Corning, MA, USA) in media and allowed to settle overnight.  On the 
next day, media was replaced with media containing 2µg/ml of blastocidin to select for 
stably transduced cells.  The blastocidin concentration was gradually increased to 
3µg/ml which was determined to be the minimal concentration required to kill 
untransduced SHSY5Y cells. 
 
3.2.3.2 Clone selection and expansion 
Stable clones that formed colonies which grew to a sufficient size were washed with 
PBS and then isolated using glass cloning cylinders (Sigma-Aldrich, Poole, UK).  Cells 
were detached with trypsin-EDTA, centrifuged (200g for 5 minutes) and re-plated into 
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12-wellplates (Corning, MA, USA).  Upon reaching 90% confluence, clones were 
expanded into 6 well plates and then up scaled into T25 and subsequently T75 flasks.  
Once a sufficient number of cells were obtained, cells were frozen in FBS with 10% 
DMSO (Hybri-Max, Sigma-Aldrich, Poole UK) at -80C and then stored in liquid 
nitrogen. 
 
3.2.3.3 Characterisation of clones 
Stable lines were characterised for increased APP expression and/or increased Aβ 
production using Western blotting and Aβ ELISA.  Protein was extracted from APP-
expressing cells at the proliferative stage and following differentiation with RA for 7 
days.  Clones were also assessed for their ability to differentiate in to a neuronal 
phenotype.  
 
3.2.3.3.1 Protein expression 
Total cell lysate was extracted using RIPA buffer (see section 2.2.2.1) and the protein 
concentration determined (section 2.2.2.2).  To detect increases in APP expression in 
the stably selected cell lines, the protocol for SDS-PAGE (see section 2.2.2.3) was 
altered to maximise protein detection of APP in the lysates taken from the APP-
expressing SHSY5Y cell lines.  Resolving gels (12% polyacrylamide) were used for 
separation of 6.4µg of protein and the gels were electrophoresed for 40 minutes at 
200V.  20µM of Aβ1-42 made up in HEPES (Sigma-Aldrich, Poole, UK) served as a 
positive control with the PageRuler Prestained Protein Ladder (Thermo Scientific, 
Northumberland, UK) used to determine protein band sizes.   
 
The Western blotting procedure (section 2.2.2.4 and 2.2.2.5) was carried out but with 
several alterations.  Transfer of protein from the polyacrylamide gel onto nitrocellulose 
membranes was performed for 2 hours at 80V in transfer buffer containing SDS 
(0.0005%).  The membranes were then blocked overnight at 4°C in 5% powdered milk.  
On the following day, the nitrocellulose membranes were incubated overnight in mouse 
anti-human Aβ (1-42) antibody (W0-2, Millipore, 1:1000) at 4°C.  Secondary antibody 
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binding and developing of membranes using X-ray film was carried out as previously 
described. 
 
For loading controls, membranes were stripped of all bound antibodies.  The 
membranes were washed in stripping buffer (2% SDS, 100mM β-mercaptoethanol, 
62.5mM Tris) for 30 minutes at 50°C with gentle agitation.  Blots were then washed 
thoroughly in TBST six times (5 minutes each) before being blocked with 5% powdered 
milk for 2 hours.  Membranes were then incubated using rabbit anti-β-actin antibody 
(A5060, 1:1000, Sigma-Aldrich, Poole, UK) in 3% powdered milk at room temperature 
for 1 hour.  Membranes were washed thoroughly in TBST six times (5 minutes each) 
and then incubated in goat anti-rabbit HRP secondary antibody (1:5000, Dako, 
Cambridgeshire, UK) for 1 hour.  Membranes to be developed were processed as 
previously described (section 2.2.2.5).   
 
Polyacrylamide gels were retained  to be stained in Coomassie gel stain (1% 
Coomassie R250, 50% methanol, 10% glacial acetic acid) for 1 hour before being 
washed three times for 20 minutes in destaining solution (50% methanol, 10% glacial 
acetic acid) on a rocker.  Gels were stained to confirm that protein had successfully 
transferred onto the membranes. 
 
Protein bands were analysed using the GeneTools software (Syngene, Cambridge, 
UK), after initially capturing images of the X-ray films in the G:Box.  Manual band 
quantification was performed by manually defining the protein bands, using automatic 
background correction.  The raw volumes were corrected against β-actin protein bands, 
and then expressed as percentage of proliferating/7 day RA-differentiated SHSY5Y 
protein bands. 
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3.2.3.3.2 Amyloid ELISA 
The amount of Aβ1-42 secreted into media was quantified using the Human Aβ1-42 
ELISA kit (Invitrogen, Life Technologies, Paisley, UK). 
 
For cell preparation, control SHSY5Y cells and clones expressing 
wtAPP695/SweAPP695 were seeded at 2 x 105 cell per well of a six-wellplate.  On the 
following day, the media was refreshed with RPMI media containing RA (1x10-5 M).  
Cells were differentiated for 7 days in RA, with a final media change on the seventh 
day.  After 24 and 48 hours, conditioned media was retained and clarified (10,000rpm 
for 3 minutes).  Cells from which media was obtained were lysed for protein 
determination.  Media samples were then treated with 4-(2-Aminoethyl)benzenesulfonyl 
fluoride hydrochloride (AEBSF) protease inhibitor (200mM, Melford, USA) and the 
media concentrated by vacuum evaporation to one fifth of the original volume.   
 
The ELISA was performed in accordance with the manufacturer’s instructions (see 
appendix).  Briefly, media samples were incubated overnight in the coated ELISA plate 
at 4°C in human Aβ42 detection antibody.  Aβ standards were prepared in RPMI 
media.  On the following day, the contents of each well was carefully aspirated and the 
well washed in wash buffer (4 times).  100µls of anti-rabbit IgG HRP working solution 
was added to each well and the plate incubated at RT for 30 minutes with shaking at 
200rpm.  Wells were then washed again (4 times) and 100µl of stabilised chromogen 
added to the wells.  The plate was incubated for 30 minutes in the dark with shaking at 
200rpm.  To stop the reaction, 100µls stop solution was added to each well and the 
Abs450 read on a spectrophotometer (MultiSkan, Ascent, Thermo Scientific, UK).  
Amyloid concentrations were determined by plotting the Aβ standard against 
absorbance readings and performing linear regression analysis.  Concentrations were 
then corrected to the number of cells by normalising against the total protein 
concentration from cellular lysates. 
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3.2.3.3 SHSY5Y differentiation and immunostaining 
Clones were seeded into 6-well plates at density of 8 x 104 and then differentiated with 
7 days of RA in RPMI, which was then followed by 11 days of BDNF (10ng/ml, 
Peprotech, UK) treatment in neuronal basal media (Gibco, Life Technologies, Paisley, 
UK), containing B27 supplement (Gibco, Life Technologies, Paisley, UK), l-glutamine 
(2mM) and Pen/Strep (100x, Gibco, Life Technologies, UK).  To detect neuronal 
markers, immunostaining was carried out according to section 2.2.3.5.  Cells were 
incubated in rabbit anti-Tubulin III (1: 500, Abcam, UK) for 1 hour and then to detect 
bound antibody, visualised with goat anti-rabbit FITC (1:200, Jackson 
Immunoresearch, Europe).  Fluorescent images were taken using red filter cubes using 
fluorescence microscopy.   
 
3.2.4 Determining changes in metabolism between the cell lines 
3.2.4.1 Cell proliferation/ cellular growth assay 
Cell proliferation/growth was measured using the Cell Titer-Blue Cell Viability Assay 
(Promega, Southampton, UK) which provides a homogenous method to monitor cell 
viability.  The assay assesses the ability of viable cells to metabolise a redox dye, 
resazurin to resorufin.  The rate of this reaction is directly proportional to the number of 
viable cells, and can be measured as a change in absorbance/ fluorescence.  The 
absorbance maximum of resazurin is 605nm and that of resorufin is 573nm.  The end 
product, resorufin also emits a fluorescence at 590nm giving the user flexibility in using 
reading absorbance or fluorescence.  An additional advantage is that the cells remain 
viable after the removal of the assay reagent.   
 
3.2.4.1.1 Sample preparation 
To determine cellular growth rates, wtAPP695/ SweAPP695 expressing cell lines and 
control SHSY5Y cells (i.e untransfected cells) were plated at 1.5 x 104 per well into 96-
wellplates (Corning, MA, USA) in a triplicate.  After 24 and 48 hours of seeding, culture 
media was aspirated from the wells.  CellTiter-Blue reagent was diluted 1:6 in phenol-
free DMEM (Gibco, Life Technologies, Paisley, UK) and then 100µls of this solution 
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was added to each well.  The well plate was then returned to the incubator for 3 hours, 
after which time, the absorbance readings were taken at 590nm with background 
absorbance readings taken at 690nm.   
 
To calculate percentage cell viability, reference readings (A690) were subtracted from 
the A590, and reciprocals of the averages were taken (to calculate the proportion of 
resazurin metabolised).  All values were expressed as a percentage of the control 
(untransfected SHSY5Y cells). 
 
3.2.4.2 Glucose HK Assay 
The amount of total glucose levels remaining in conditioned media was detected using 
the Glucose HK assay (Sigma-Aldrich, Poole, UK).  This assay relies on the 
phosphorylation of glucose by hexokinase to glucose-6-phosphate in the presence of 
ATP.  The next step involving oxidation of glucose-6-phosphate to gluconate-6-
phosphate by glucose-6-phosphate dehydrogenase, results in an equimolar amount of 
NAD+ being reduced to NADH.   
Glucose + ATP  Glucose-6-phosphate + ADP 
G6P + NAD  6-Phosphogluconate + NADH 
The amount of NADH generated results in an increase in absorbance at 340nm which 
can be detected by a spectrophotometer, and is directly proportional to glucose 
concentration.   
 
3.2.4.2.1 Sample preparation 
Glucose uptake was measured in both proliferating SHSY5Y cells and seven day RA-
differentiated SHSY5Y cells.  Cell lines and control SHSY5Y cells were seeded at 2 x 
105 cells into six wells of a 6-wellplate (Corning, MA, USA).  After 24 and 48 hours of 
incubation, media was removed from three wells and the cells washed three times in 
cold PBS.  Total cell lysate was obtained using 1ml of RIPA buffer to lyse three wells, 
which were pooled.  Total protein was quantified (see section 2.2.2.2).  Meanwhile, 
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pooled media was clarified at 10,000rpm for 5 minutes to remove cellular debris and 
aliquoted into microcentrifuge tubes for storage at -20°C. 
 
Differentiated cells were plated as described above but on the following day, the media 
was replaced with media containing 1x10-5 M RA (Sigma-Aldrich, Poole, UK).  The 
media was then refreshed every alternate day for 7 days.  On the seventh day, media 
was refreshed and the cultures incubated for 24 and 48 hours, after which time they 
were harvested as described above.  
 
The assay was adapted to a 96-well microplate format.  Media samples were diluted 
1:10 in deionized water and glucose standards (1.0mg/ml Sigma-Aldrich, Poole, UK) 
were serially diluted 1:2 in deionised water with concentrations ranging from 500µg/ml 
to 15.6µg/ml, with water serving as a glucose-free control.  40µls of diluted media or 
standard were loaded into the microplate in duplicate and then 200µls of glucose HK 
reagent was added to each well.  The reaction was incubated at RT (15 minutes) and 
then the absorbance read at 340nm on a spectrophotometer (Ascent Multiscan, 
Thermo Scientific, UK).  The total glucose was then normalised to cellular protein 
levels, as determined using the BCA assay (see section 2.2.2.2).  
 
3.2.4.3 Analysis of mitochondrial function 
Mitochondrial function was assessed using the Seahorse XF Analyzer (Seahorse 
Biosciences, Massachusetts, USA).  To optimise conditions for each cell line, a series 
of optimization experiments were performed to achieve the best OCR readings (in 
accordance with the Seahorse MitoStress Test Manual).  XF assay media and calibrant 
was purchased from Seahorse Biosciences. 
 
3.2.4.3.1 Cell titration 
Human SHSY5Y cells were plated at different cell densities into a Seahorse XF24 
microplate in triplicate using the manufacturer’s recommended seeding protocol and 
incubated overnight at 37°C, 5% CO2 for 23 hours.  The Seahorse XF analyser was 
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warmed to 37°C overnight.  Assay cartridges were soaked in 1ml of XF Calibrant/well 
overnight (minimum of 16 hours) in a CO2-free incubator at 37°C.  Four wells were 
randomly selected as negative controls for the analyser to account for background 
correction.  After approximately 23 hours, XF assay media was prepared by 
supplementing with glucose (10mM, Sigma-Aldrich, Poole, UK) and sodium pyruvate 
(2mM, Gibco, Life Technologies, Paisley, UK).  The pH of the media was adjusted to 
7.4 with sodium hydroxide.  One hour prior to the experiment, the cells were rinsed in 
1ml XF assay media and then incubated in 1ml of fresh XF assay media in a CO2 free 
incubator.  Cell-free (negative control) wells were treated in a similar manner.  Using 
the Seahorse software, a protocol was set up as instructed in Table 3.1.  Following the 
protocol, OCR and ECAR readings were taken for each well and recorded.  
 
 
 
 
 
 
 
 
Table 3.1.  Table of experimental set up on the Seahorse software to record basal 
OCR readings.  
 
 
3.2.4.3.2 Protein normalisation 
OCR readings were normalised against protein.  To do this, cells were washed in PBS 
and then lysed in 30µl of RIPA buffer (Millipore, UK) for 30 minutes for 4°C.  The 
protein concentration was determined for each well (see section 2.2.2.2), using 10µl of 
lysate/BSA standard loaded in duplicate. 
3.2.4.3.3 Compound optimization 
The day before the assay, SHSY5Y cells were plated as at the optimal cell density (as 
determined in section 3.2.4.3.1).  Background (cell-free) wells were assigned to wells 
A1, B4, C3 and D5.  The cartridge was also soaked in Seahorse XF calibrant overnight.    
 
On the following day, cells were washed in XF Assay Media and the wells incubated in 
675µls of XF Assay media.  The four compounds Oligomycin, FCCP, Rotenone and 
Step  Instruction Duration 
1 Calibration ~30 minutes 
2 Equilibrate See below 
Loop steps 2-4 six times  
2 Mix 4 minutes 
3 Wait 4 minutes 
4 Measure  4 minutes 
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Antimycin A (all obtained from Sigma-Aldrich, Poole, UK) were prepared as a stock in 
DMSO (Sigma-Aldrich, Poole, UK) and stored as single use aliquots at -20C.  To 
perform the optimization experiments, each compound was diluted in XF Assay Media 
and 75µls of the compound was added to port A of the cartridge.  For background 
wells, 75µls of media was added to those relevant ports.  On the Seahorse XF 
software, the Mito Stress Test was selected and then optimization plate chosen from 
the list.  The protocol corresponding to each compound for optimization was chosen.  
Key information such as seeding density, basal OCR levels and the test concentrations 
were specified. 
 
After the experimental run was complete, the protein concentration for each was 
determined (see section 3.2.4.3.2).  For analysis of data, the subsequent excel file, 
which accompanies each XF Seahorse file calculated the average OCR reading for 
each concentration of compound test.  This is plotted as an OCR vs concentration 
curve, with values normalised to protein concentration. 
 
3.2.4.3.3.1 Oligomycin optimization 
Oligomycin is the first compound injected into the microplate wells to induce a rapid 
OCR response.  Oligomycin is an ATP coupler that inhibits ATP synthesis by blocking 
the proton channel of the Fc protein ATP synthase.  The software looks for the minimal 
concentration required to achieve the lowest OCR response.   
 
3.2.4.3.3.2 FCCP compound optimization 
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) is the second 
compound required for optimization.  This compound is a protonophore, which acts as 
an uncoupler of oxidative phosphorylation by preferentially transporting protons across 
the mitochondrial membrane instead of through the ATP synthase complex, leading to 
a rapid consumption of energy and oxygen without the generation of ATP.  OCR 
increases as a result of uncoupling and the ECAR will also increase as the cells revert 
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to glycolysis to generate ATP.  The software looks for the maximal OCR response at 
the lowest FCCP concentration.  
 
According to the literature (Schneider et al., 2011a, Xun et al., 2012), 7 day RA-
differentiated SHSY5Y cells exhibit an increase in maximal OCR response compared 
to proliferating cells.  Therefore, FCCP was also titrated across the plate containing 7 
day RA-differentiated SHSY5Y cells. 
 
3.2.4.3.3.3 Rotenone and Antimycin concentration optimization 
The third compound titrated across the XF microplate was rotenone.  Rotenone is a 
complex I inhibitor, inhibiting electron transfer from the iron-sulphur centre in complex I 
to ubquinone.  Inhibition of complex I prevents the potential energy in NADH from being 
converted to usable energy in the form of ATP.  The fourth inhibitor optimized was 
antimycin A (which is a specific complex II inhibitor.  This binds to the Qi site of 
cytochrome reductase to inhibit the oxidation of ubquinol in the electron transport chain 
of oxidative phosphorylation.  Inhibition of this reaction disrupts the formation of the 
proton gradient across the inner membrane, subsequently inhibiting ATP production.  
The software assesses the minimal concentration required to achieve the lowest OCR 
readings for both compounds. 
3.2.4.3.4 Performing the MitoStress test 
Once the optimization experiments were complete, the next step was to proceed to 
perform the MitoStress test to study mitochondrial responses.  This assay measures 
OCR in response to the mitochondrial inhibitors to produce a unique metabolic profile.   
 
To prepare the plate, three replicates of three SweAPP695-expressing cells, three 
wtAPP695-expressing cells and control uninfected SHSY5Y cells were plated at 8 x 
104 cells per well.  The assay cartridge was soaked in XF Calibrant overnight.  Control 
SHSY5Y and wtAPP695/SweAPP695 expressing cell lines were also tested after 
seven days of RA treatment.  Initially, 2 x105 cells were seeded into three wells of a 6-
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wellplate (Corning, MA, USA).  On the following day media was replaced with RA (1 x 
10-5 M) and the media was refreshed every other day.  On the seventh day, cells were 
washed in PBS and detached using Accutase (Gibco, UK).  The cells were pelleted 
(200g for 5 minutes), re-suspended in media containing RA and counted (section 
2.2.3.2).  8 x 104 cells were seeded into the XF24 microplate in three replicate wells.   
 
On the following day, the experiment was performed according to the manufacturer’s 
instructions (XF Cell Mito Stress test kit manual).  Briefly, Seahorse Assay media was 
supplemented with 10mM D-glucose (Sigma-Aldrich, Poole, UK) and 2mM sodium 
pyruvate (Gibco, Life Technologies, Paisley, UK).  Compounds were diluted to 
previously determined optimal concentrations in XF Assay media.  Cells were washed 
in 1ml of XF Assay media and then incubated in 500µls of fresh assay media 1 hour 
prior to the experiment in a CO2-free incubator at 37°C.  After the experiment was run, 
protein concentration from each well was determined (see section 3.2.4.3.2).  
 
3.2.4.3.4.1 Seahorse Analysis 
The data file was analysed using the Seahorse Wave 2.0 software, which allows for 
normalization of OCR values against protein (or other means) and the removal of 
outlying values (determined by the standard deviation).  The analysed data was then 
saved as a new Excel file.  This file was then opened up in MitoStress Report 
Generator which automatically uses the raw values to calculate key measurements.  
Subsequent values were then analysed using two-way ANOVA using Graph Pad Prism 
6.0. 
 
3.2.4.4 Oxidative stress response 
wtAPP695 and SweAPP695 expressing cells were treated with hydrogen peroxide 
(H2O2)  to determine the stress response of cells.   
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3.2.4.4.1 Optimization of seeding density and H2O2 concentration 
The optimal seeding of SHSY5Y cells and the IC50 of hydrogen peroxide was 
determined.  The IC50 for a given compound/ drug refers to the concentration at which 
the induced response is halfway between the baseline and maximum after a specified 
exposure period.  In this case, the concentration of hydrogen peroxide required to kill 
50% of the cells was determined.  SHSY5Y cells were plated at 30 x 105 cells per well 
in duplicate and serially diluted 1:2 to 3.75 x 103 cells across the 96-wellplate in a total 
volume of 200µls per well.  After 24 hours of incubation, the cells were treated with 
various concentrations of hydrogen peroxide to determine the minimum inhibitory 
concentration required to achieve 50% cell death.  APP-expressing cell lines were also 
seeded in a similar manner to determine their responses to increasing hydrogen 
peroxide concentrations. 
 
For cell treatments, fresh hydrogen peroxide (Sigma-Aldrich, Poole, UK) was diluted in 
phenol-free red media supplemented with 2mM l-glutamine to 6400µM.  The stock was 
then serially diluted 1:2 to a final concentration of 25µM.  Media was then removed 
from each well and replaced with 100µls of hydrogen peroxide solution in duplicate.  
Cells were incubated for 1 hour at 37°C after which time the hydrogen peroxide was 
replaced with 200µl of complete media to allow the cells to recover for 18 hours at 
37°C.  After 18 hours of recovery, cell toxicity was assessed by MTT assay (see 
section 3.2.4.4.2). 
 
3.2.4.4.2 MTT assay 
Cell viability was measured using the 3-[4,5-Dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide (MTT) assay.  In this assay, the tetrazolium salt MTT, is 
reduced by dehydrogenase enzymes within metabolically active cells into insoluble 
formazan crystals.  These intracellular crystals can then be solubilised and the 
absorbance determined as a direct measure of cell viability.   
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MTT (Sigma-Aldrich, Poole, UK) was dissolved in PBS to 2.5mg/ml and then filter 
sterilised using a 0.2µM filter.  Stocks were stored in aliquots and protected from light 
at -20°C.  To perform the assay, MTT stock was diluted 1:5 in phenol red-free DMEM 
and 100µl of the diluted stock was added to the wells.  The microplate was incubated 
at 37°C for 3 hours.  After incubation, all MTT solution was removed and 50µls of 
DMSO was added to each well to solubilise the formazan crystals.  The microplate was 
mixed on a shaker (500rpm for 30 seconds) and then incubated at 37°C for a further 10 
minutes to ensure complete crystal solubilisation.  Finally, the absorbance at 570nm 
and reference absorbance at 690nm was read using a spectrophotometer (Ascent 
MultiScan FX, Thermo Scientific, Loughborough, UK).  Cell viability was determined by 
subtracting the reference readings from the absorbencies from each hydrogen peroxide 
concentration tested.  Results were expressed as a percentage of the untreated control 
(of that cell line).   
 
3.2.4.4.3 Statistical analysis  
When making comparisons between the control SHSY5Y cell lines and the APP-
expressing cell lines at different time points, two way ANOVA was performed with 
Dunnetts multiple comparisons/student’s T test as appropriate in Graph Pad Prism 6.0.  
A dose response curve was plotted for each cell line with increasing concentrations of 
hydrogen peroxide to determine the IC50.   
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3.3 Results 
3.3.1 Optimization of transduction into SHSY5Y cell line 
Prior to infecting SHSY5Ycells with the APP lentiviruses, it was first important to 
establish a transduction protocol, with which lentiviral infection would be effective and 
cause minimal toxicity.  To do this, a lentivirus expressing GFP, driven by the viral 
promoter CMV, pGIPz was packaged into active virus using psPAX2 and PMD2.G.  
SHSY5Y cells were seeded and differentiated with RA over five days.  Different 
multiplicities of infection of pGIPz were determined by using the appropriate amount of 
virus (titre determined by p24 ELISA) to infected the cells.  The efficiency of retrovirus-
mediated gene transfer can be enhanced, most commonly with the use of cationic 
polymers, such as polybrene and protamine sulfate.  Therefore, viral infection was 
tested in the presence or absence of Polybrene.  48-hours post infection, cells were 
visualised using fluorescence microscopy (section 2.2.3.6).  Figure 3.6 shows GFP 
fluorescence detectable after 48 hours at all MOI’s.   As the MOI increases, the level of 
GFP fluorescence increases, as more cells have been infected and these cells may 
contain multiple viral copies.  This effect was further enhanced in the presence of 
Polybrene. 
 
Cells were also viewed 10 days post-infection (Figure 3.7).  GFP fluorescence was still 
detectable at increased levels at lower MOI’s in comparison with 48 hours imaging.  
Increasing the MOI resulted in fewer cells which were still expressing GFP expected to 
be due to toxicity.  In the presence of Polybrene, there was significantly less GFP 
fluorescence due to cell death.  Lower MOI’s and infection without the use of Polybrene 
lead to potentially long term viable cells with stable protein expression.  It should also 
be noted that the CMV promoter was utilised to maximise GFP expression for testing 
transduction efficiency.  This promoter is noted to be prone to silencing and has 
associated toxic effects due to the high levels of protein expression.   
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Without Polybrene        With Polybrene 
 
 
 
 
Figure 3.6.  Fluorescent images of Lentiviral-GFP infected cells 48 hours following 
transduction. A1, MOI 5 without polybrene, A2, MOI 5 with polybrene, B1, MOI 10 
without polybrene, B2, MOI 10 with polybrene, C1, MOI 25 without polybrene, C2, MOI 
25 with polybrene, D1, MOI 50 without polybrene, D2, MOI 50 with polybrene.  Scale 
Bar 100μm. 
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163 
 
Without Polybrene    With Polybrene 
 
 
 
 
Figure 3.7.  Fluorescent images of Lentiviral-GFP infected cells 10 days following 
transduction. E1, MOI 5 without polybrene, E2, MOI 5 with polybrene, F1, MOI 10 
without polybrene, F2, MOI 10 with polybrene, G1, MOI 25 without polybrene, G2, MOI 
25 with polybrene, H1, MOI 50 without polybrene, H2, MOI 50 with polybrene.  Scale 
Bar 100μm. 
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3.3.2 Testing of the lentiviral constructs 
The pLenti6.4 Syn1-wtAPP695/ SweAPP695 constructs were successfully packaged 
into lentivirus using the HEK293FT cell line.  Packaging of p24-associated lentivirus 
was first confirmed using the Lenti GoStix (data not shown), and then the lentivirus was 
collected and concentrated using the sucrose gradient method (section 3.2.1.4).  Both 
Lentiviruses were then diluted 1:500 / 1:1000 to obtain absorbance values within the 
p24-assocated ELISA standard curve.  The APP lentiviruses were tested at different 
MOI’s.  Using the results of the ELISA, the multiplicities of infection of 5 and 10 were 
determined from the viral titre of each virus.  Five days post-RA differentiation, 
SHSY5Y cells were transduced with EIFa driven lentivirus expressing cherry red 
fluorescent protein (as a positive control) and with pLenti6.4SweAPP695 / wtAPP695 
both at an MOI of 5 and 10.  After three changes of media, the cells were viewed under 
the microscope to assess for RFP fluorescence (in the case of the positive control) and 
to assess for cell viability post infection (see Figure 3.8). 
 A      B 
Figure 3.8.  Fluorescence (A) and phase contrast image (B) of positive control for viral 
transduction testing with eIF1a-cherry red fluorescent protein. 
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A      B 
Figure 3.9.  Phase contrast image of SHSY5Y cells infected with pLenti6.4 SYN-1 
SweAPP695 lentivirus at MOI of 5 (A) and at MOI of 10 (B) 48 hours post-transduction. 
 
 
A      B 
Figure 3.10.  Phase contrast image of SHSY5Y cells infected with pLenti6.4 SYN-1 
wtAPP695 lentivirus at MOI of 5 (A) and at MOI of 10 (B) 48 hours post-transduction. 
 
 
Cell lysates from transduced wells were also collected and assessed for APP protein 
expression by Western blotting using anti-APP695 antibody (Figure 3.11).  Results 
show a protein band that corresponds to 100-130kDa in size, which is the approximate 
size of APP695.  Protein expression in the untransduced (control) SHY5Y cell line is 
comparatively weak compared to cells transduced with either SweAPP695 / wtAPP695.  
The results also show that anti-APP695 antibody can detect both forms of APP.  
Furthermore, the increase in MOI from 5 to 10 did not substantially increase APP 
protein expression.       
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Figure 3.11.  Western blot analysis of cell lysates from SHSY5Y cells transduced with 
SweAPP695 lentivirus.  Lane 1, control cell lysate, lane M, Prestained Protein Ladder, 
lanes 2 and 3, cell lysates from SHSY5Y cells transduced with lentivirus at MOI of 5 
and 10 respectively. 
 
 
Figure 3.12.  Western blot analysis of cell lysates from SHSY5Y cells transduced with 
wtAPP695 lentivirus.  Lane M Protein Prestained Ladder, lane 1, control cell lysate, 
lanes 2 and 3, SHSY5Y cells lysates transduced at MOI of 5 and 10 respectively. 
 
 
3.3.3 Generation of cell lines 
SHSY5Y cell were seeded into flasks and transduced the next day with either pLenti6.4 
wtAPP695 or SweAPP695 at an MOI of 1.  Following transduction, cells were then re-
plated into 6-wellplates and transduced cells were selected with Blastocidin-containing 
media (3µg/ml).  Over next few weeks, well plates were assessed daily to detect the 
presence of clones derived from single cells.  The clones were viewed under a light 
microscope (x10 objective), and when considered large enough, they were carefully 
isolated with a cloning cylinder from remainder of the well.  Clones were then grown in 
separate wells of a 6-wellplate to be expanded into larger flasks.  Clones were named 
in order of selection, with some clones unable to survive the isolation and re-plating 
step.  This eventually led to the selection of potential clones (Table 3.2). 
  
130kDa 
100kDa 
70kDa 
55kDa 
1         M        2                   3 
130kDa 
100kDa 
70kDa 
M     1    2         3  
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wtAPP695 
expressing cell lines 
SweAPP695 
expressing cell lines 
W1 S2 
W2 S3 
W3 S4 
W4 S6 
W5 S7 
W7 S9 
W9 S10 
W11 S11 
W13 S14 
W14 S15 
W17 S17 
W18  
Table 3.2.  Table of final clones isolated and expanded successfully.  
 
 
After picking the clones that survived, the morphology and general growth rate of each 
clone was assessed by light microscopy.  The ability of clones to differentiate into a 
more neuronal phenotype was assessed after RA and BDNF treatment.  Clones were 
also immunostained for Tubulin, a marker of neurons (Figure 3.13).  Clones were 
picked based on their ability to differentiate into neurons in comparison to differentiation 
of control SHSY5Y cells.  After BDNF treatment, chosen clones (W17, W18, S7, S10) 
showed extensive neurite extension from small cell bodies.  Over time the 
differentiation period, the number of cells decreases, influencing the density and 
distance between cells.  In all cases, differentiated cells stained positively for the 
neuronal marker, tubulin, in particular highlighting the extensive neurite networks 
formed between cells.  The level of differentiation between these different cell lines 
may be affected by the level of expressed APP695, as it is known that APP fragments 
are involved in cellular growth and neuronal differentiation. Therefore, levels of the APP 
fragments may differ between each cell line, due to different levels of BACE1. 
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 A      B         
   
 
C      D          
  
E 
 
Figure 3.13.  Fluorescence/ bright-field images of SHSY5Y clones post-BDNF 
treatment, immunostained for β-tubulin III (x10 objective). A, clone W17, B, clone W18, 
C, clone S7, D, clone S10, E, Bright-field image of differentiated of control SHSY5Y 
cells after RA and BDNF treatment (x10 objective, scale 100µM). 
 
 
3.3.4 Metabolic studies of wtAPP695/SweAPP695 expressing SHSY5Y cell lines 
 
3.3.4.1 Cell proliferation 
Chosen clones were assessed for their ability to proliferate over 24 and 48 hours 
following initial seeding using the Cell Titer Blue assay.  Proliferation rates are 
presented as a percentage of the control SHSY5Y (untransfected) cell line (Figure 
3.14).  After 24 hours of growth, all cell lines exhibit slow growth, with none of the 
clones showing any significant changes in proliferation at 24 hours in comparison to the 
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control cell line.  After 48 hours of incubation, proliferation increased slowly, clone S7 
showed a significant increase in growth over the control of 107.7 ± 2.0 % (p value = 
0.0283).  Proliferation was important to consider as any differences in growth/ 
metabolic activity between clones could be due to differential processing of APP, 
leading to the production of different APP fragments.  Furthermore, proliferation rate is 
important as experiments on the Seahorse analyzer a sufficient amount of cells to 
seed. 
Figure 3.14.  Cell proliferation rates of wtAPP695 and SweAPP695 clones using Cell 
Titer Blue.  Results are expressed as a percentage of control SHSY5Y ± SEM, n=3, p 
<0.05. 
 
 
3.3.4.2 APP protein expression 
Cell lines were assessed for altered APP protein expression.  Total cell lysate was 
taken from proliferative SHSY5Y cells and 7 day RA-differentiated cells and the lysates 
assessed for APP protein expression by Western blotting using antibodies directed 
against Aβ (6E10, Covance).  Blots show that both SweAPP695/ wtAPP695 protein 
was detected by this antibody.  β-actin was blotted as a reference control.  Figure 3.15 
shows one Western blot.  Using manual band quantification in Gene Sys Tools, the 
pixels of each protein band were determined, corrected using automatic background.  
APP protein expression was normalized against βactin protein band for each cell lysate 
sample blotted.   
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Figure 3.15.  Representative Western blot analysis of total cell lysates taken from 
control SHSY5Y lines, wtAPP and SwedishAPP expressing cell lines.   
 
 
Figure 3.16 shows the relative pixel density for APP protein detected from lysate from 
each cell line, normalized to β-actin.  Results are presented as a percentage of APP 
expression from the control (untransduced) cell line.  APP protein levels vary widely 
across all cell lines analysed.  Lysate taken from proliferating wtAPP695 expressing 
cell lines generally contained more APP than the control, but levels appear to decrease 
after seven days of RA differentiation.  By contrast, the SweAPP695 expressing cell 
lines appeared to contain less APP during the proliferative stages and after RA 
differentiation, with the exception of clone S7. 
Figure 3.16.  Percentage pixel density of APP protein detected in cell lysates.  Results 
are presented as a percentage of the control SHSY5Y (proliferative/7 day RA 
differentiated) ± SEM n=2. 
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3.3.4.3 Amyloid production in 7 day RA-differentiated cell lines 
Amounts of Aβ1-42 secreted into the media were assessed after differentiation of the 
cell lines, at 24 and 48hours of incubation following the seventh day of changing the 
media.  SHSY5Y cells are reported to secrete amyloid from the cells (Zheng et al., 
2013), in small amounts (Prasanthi et al., 2009).  Media samples were vacuum 
evaporated five times the original volume and the concentration of Aβ1-42 was 
determined using the ELISA method.  Figure 3.17 shows variable amounts of amyloid 
across the cell lines.  After 24 hours, there was little amyloid or no amyloid detected, 
but after 48 hours, there was considerably more amyloid detected in the media.  Clone 
S10 showed a significant increase in the amount of Aβ1-42 secreted when compared 
to control.  After 24 hours, 0.008pg/ml/ mg of protein ± 0.002 SD was detected in 
conditioned media of clone S10 while the control media contained 0.00009 ± 0.00002 
pg/ml/ mg of protein (p value <0.0001).  After 48 hours, S10 media contained 0.014 ± 
0.000152  pg/ml of amyloid compared to the control media, which contained 0.00104 ± 
0.00023 pg/ml (p value <0.0001).  At 24 hours, the Aβ ELISA detected more Aβ in the 
conditioned media from the wtAPP-expressing cells compared to the control media, but 
this was not significant.   
Figure 3.17.  Graph showing concentration of Aβ1-42 secreted into media of 7 day RA-
differentiated cell lines.  Results are expressed as pg/ml, normalized to total cellular 
protein, n=2, p< 0.0001 (****).  
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3.3.4.4 Glucose uptake 
 
3.3.4.4.1 Glucose uptake in the proliferating cell lines 
Glucose uptake was measured by quantifying the concentration of glucose remaining 
in conditioned media taken from undifferentiated cell lines incubated after 24 and 48 
hours.  This was performed using the Glucose HK assay (Figure 3.18).  The amount of 
glucose remaining in the media is expressed as a percentage of the control SHSY5Y 
cell line, after normalisation to total protein.  At both incubation times, there is a general 
trend that there was more glucose remaining in the conditioned media compared to the 
control cell line, suggesting decreased glucose uptake by the proliferating cells.  
However, this was not found to be statistically significant most likely due to variations in 
glucose readings between replicate experiments.  There was significant difference 
when comparing between the control cell line and the undifferentiated S10 clone, with 
the S10 clone showing an average of a 268.5 increase ± 68% over the control (p value 
= 0.03335).  
Figure 3.18.  Graph the amount of glucose remaining in conditioned media after 24 and 
48 hours of incubation of undifferentiated cell lines using the Glucose HK assay.  
Results are expressed as a percentage of the control ± SEM, n=3 (p<0.05 (*). 
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3.3.4.4.2 Glucose uptake in 7 day RA-differentiated cell lines 
Cell lines were also differentiated with RA for seven days, and on the seventh day, 
media was refreshed.  Glucose remaining in the media was measured after 24 and 48 
hours, and normalised to total protein (Figure 3.19).  At both incubation times, there 
was a general trend that both wtAPP695 and SweAPP695 expressing cell lines 
demonstrated more glucose in the media, and hence decreased glucose uptake.  
However, this was only statistically significant in a number of the cell lines tested.  At 
the 24 hours incubation time, differentiated W17 clones showed an average of a 247.0 
± 12.3 % increase in remaining glucose over the differentiated control cell line (p value 
= 0.011).  The differentiated W18 clone showed a significant increase in remaining 
glucose of 286.3 ± 72.8% over the control (p value = 0.0014).  None of the 
differentiated SweAPP-expressing clones showed any significant differences.  At the 
48 hour time point, clone W17 showed a significant increase of 221.7 ± 46.0% SEM 
over the control (p value = 0.0386), whilst the W18 clone showed a significant increase 
of 332.3 ±11.0 SEM over the control (p value = 0.0001).  These results between 
proliferative and the RA-differentiated SHSY5Y cell lines highlight differences in 
glucose uptake at both time points.  
Figure 3.19.  Graph of glucose remaining in conditioned media after 24 and 48 hours of 
incubation taken from 7 day RA-differentiated cell lines.  Results are expressed as a 
percentage of the control ± SEM, n=3 p<0.05 (*), p< 0.01 (**), p< 0.001, p<0.0001. 
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3.3.4.5 Seahorse experiments 
3.3.4.5.1 Optimization of seeding cell density  
For optimisation of conditions to establish a metabolic profile of mitochondrial function 
(see Figure 3.4 for a typical profile with the parameters obtained from such a profile) in 
SHSY5Y cells using the Seahorse analyser, cells were seeded between 20000 to 
100000 cells per well in triplicate with six readings taken over a number of time points 
(Figure 3.20).  80000 cells was chosen as the optimal seeding density with an average 
basal OCR of 421pMoles/min.  Basal OCR refers the oxygen consumed by cells at 
rest.  Readings were consistent throughout and this in agreement with other studies 
using this cell line on the Seahorse analyser.   
Figure 3.20.  Representative graph of OCR readings over time of cells over a range of 
seeding densities. 
 
 
3.3.4.5.2 Optimization of mitochondrial inhibitor concentrations 
Optimization of mitochondrial inhibitors was performed according to the Seahorse 
software.  Subsequent OCR data is averaged by the software, and a graph is plotted of 
compound concentration against the average OCR reading.  The last three 
measurements immediately following injection of each inhibitor into the well were 
measured and normalized against protein determined for each well.  Replicate wells 
which produced outlying OCR values were excluded (determined by the large standard 
deviation), with the remaining replicate wells for each concentration tested averaged.  
The corrected values were plotted by the Seahorse Software into an Excel 
spreadsheet.  Optimal concentrations determined are tabulated below (Table 3.3).  
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Additionally, FCCP titration was performed with SHSY5Y cells differentiated with RA for 
seven days.  Past studies have suggest that the metabolic profiles between 
proliferative and differentiated SHSY5Y cells differ in that the spare respiratory capacity 
increases with differentiation (Schneider et al., 2011a).  Therefore, it was necessary to 
perform FCCP titration on differentiated SHSY5Y cells.  The effects of increasing 
glucose concentration and sodium pyruvate concentration were determined in order to 
maximise the OCR response to FCCP treatment (data not shown).  Glucose 
concentrations of 2mM, 5mM, 10mM and 25mM and sodium pyruvate concentrations 
of 0.5mM, 1mM, 2mM and 4mMM were tested.  It was found that 10mM glucose and 
2mM sodium pyruvate gave the maximal OCR response to FCCP. 
 
 
 
  
 
 
 
Table 3.3.  Table of optimal concentrations determined after protein normalization. 
 
3.3.4.5.3 Mitochondrial function of proliferative cell lines 
The MitoStress test was then performed on cell lines at the proliferative cells.  Results 
are presented as graphs detailing two measurements.   
Figure 3.21.  Percentage of basal OCR against time plotted for each cell line.  Data 
shown is representative of one experiment. 
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Figure 3.21 shows raw data of OCR readings obtained over time for one experiment.  
The raw data was then analysed using the Seahorse MitoStress Report generator to 
calculate different parameters of mitochondrial function.  When looking at the basal 
OCR readings for the proliferative cell lines (Figure 3.22), there was a statistical 
difference between the control which had an average basal OCR of 0.315 ± 
0.053pMoles/min/mg protein and the proliferating clone S7, which an average basal 
OCR of 0.125 ± 0.030pMoles/min/mg protein (p value = 0.0046).  There was also a 
difference between the control and clone S10, which had an average OCR of 0.125 ± 
0.030pMoles/min/mg protein (p value = 0.0046). 
Figure 3.22.  Graph of basal OCR and proton leak measurements for proliferating cell 
lines.  Results presented as average OCR ± SEM, n=3. P< 0.005 (**). 
 
 
When comparing maximal respiration and the spare respiratory capacity between the 
proliferating different cell lines (Figure 3.23), there were no significant differences. 
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Figure 3.23.  Graph of maximal respiration and spare respiratory capacity of 
proliferating SHSY5Y cell lines.  Results are presented as average OCR ± SEM, n=3. 
 
There were no differences in non-mitochondrial respiration across any of the 
proliferating cell lines (Figure 3.24). ATP production did show some differences.  There 
was a difference between the control, which had an average OCR of 0.221 ± 
0.042pMoles/min/mg protein and the proliferating clone S7, which had an average 
OCR of 0.096 ± 0.013pMoles/min/mg protein (p value = 0.0377).  
Figure 3.24.  Graph showing measurements of non-mitochondrial respiration and ATP 
production in proliferating SHSY5Y cell lines.  Results presented as OCR ± SEM, n=3, 
p< 0.05 (*). 
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3.3.4.5.2 Mitochondrial function in RA-differentiated cell lines 
Mitochondrial function was also assessed for RA-differentiated cell lines.  Figure 3.25 
shows the OCR data plotted against time for one experiment.   
Figure 3.25.  Percentage of basal OCR plotted against time for each RA-differentiated 
cell line. Data shown is representative of one experiment. 
 
 
RA-differentiated cell lines showed no significant differences between the wtAPP695-
expressing cell lines in terms of the resting (basal) OCR (Figure 3.26).  However, there 
was a difference between the control, which had an average OCR of 0.445 ± 0.030 
pMoles/min/mg protein, and the S7 clone, which had an average OCR of 0.254 ± 0.102 
pMoles/min/mg protein (p=0.0337).  No differences in proton leak between the cell 
lines were observed.  
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Figure 3.26.  OCR measurements of basal respiration and proton leak of RA-
differentiated cell lines, presented as average OCR ± SEM, n=3.  p<0.05 (*). 
 
 
Maximal respiration was measured in these cell lines (Figure 3.27) but no significant 
differences were found between the control cell line and the APP-expressing cell lines.  
No differences in spare respiratory capacity were found between cell lines.  
Figure 3.27.  Graph of maximal respiration and spare respiratory capacity of RA- 
differentiated control, wtAPP695 and SweAPP695 expressing cell lines, presented as 
averaged OCR ± SEM, n=3. 
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Non-mitochondrial respiration and ATP production was also studied in the differentiated 
cell lines (Figure 3.28).  There were not differences between any of the cell lines.  ATP 
production was found to vary in the S7 clone, which produced less ATP but there were 
no significant differences between this clone and the control cell line. 
Figure 3.28.  OCR readings for 7 day RA differentiated cell lines, showing non-
mitochondrial respiration and ATP production, presented as averaged OCR ± SEM, 
n=3. 
 
 
3.3.4.6 Oxidative stress studies  
As oxidative stress is strongly associated with AD, APP-expressing cell lines treated 
with, hydrogen peroxide to determine their ability to withstand stress.   
 
3.3.4.6.1 Optimization of seeding density and hydrogen peroxide concentration 
The optimal seeding density of proliferating SHSY5Y cells was found to be 15000 per 
well.  The maximum concentration of hydrogen peroxide that killed 100% of cells was 
3200µM whilst concentration of 25µM did not cause significant cell death.  Therefore 
cells were treated with a range of concentrations from 3200µM to 25µM.  
 
3.3.4.6.2 Hydrogen peroxide treatment 
Undifferentiated APP-expressing cell lines were seeded and treated with decreasing 
concentrations of hydrogen peroxide.  Cell viability was assessed on the following day 
using the MTT assay.  Results shows that all cell lines demonstrate susceptibility to 
hydrogen peroxide.  A non-linear regression curve fit was plotted to produce a dose 
response curve for each cell line plotted against the control cell line (Figure 3.29 and 
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3.30) and IC50 values were calculated using Graph Pad prism.  An unpaired Student’s 
test was performed to determine significant differences between IC50 values for each 
cell line (Table 3.4 and 3.5).  Results demonstrate that there were no significant 
differences between any of the SweAPP-expressing cell lines tested. 
Figure 3.29.  Dose response curve of SweAPP695-expressing cells to hydrogen 
peroxide using the MTT assay.  Results expressed as a percentage of untreated ± 
SEM, n=3. 
 
 
Cell type Average 
IC50 (M) 
T test analysis compared 
against control SHSY5Y 
P value 
Control SHSY5Y 55.3 ± 2.977 - - 
S7 70.2 ± 5.22 NS 0.0847 
S10 40 ± 5.76 NS 0.1031 
 
Table 3.4.  Table of the calculated IC50 calculated for each cell line.  An unpaired 
Student’s test (with Welch’s correction) was performed between the IC50’s of the control 
SHSY5Y versus each of the SweAPP695-expressing cell lines. 
 
 
When comparing the dose response curves of the wtAPP695-expressing cell lines 
(Figure 3.30), Student’s T test revealed that there no significant differences between 
the lines and the control cell line in the IC50 values (Table 3.5). 
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Figure 3.30.  Dose response curve of wtAPP695-expressing cell lines using the MTT 
assay.  Results are presented as a percentage of cell viability compared to untreated 
cell line ± SEM, n=3. 
 
Cell type Average 
IC50 (M) 
Student T test analysis compared 
against Control SHSY5Y 
P value 
Control SHSY5Y 55.3 ± 2.977 - - 
W17 51.3 ± 2.98 NS 0.6209 
W18 59.8 ± 2.56 NS 0.6224 
Table 3.5. Students T test analysis (unpaired, two tailed with Welch’s correction) of IC50 
for each cell line compared to control cell line.  Results are expressed as molar 
concentration ± SEM. 
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3.4 Discussion 
3.4.1 Lentiviral infection of SHSY5Y cells 
Viral transduction of the SHSY5Y cells with CMV GFP demonstrated they could be 
readily transduced with lentivirus and maintain stable integration and expression of 
GFP over 10 days post-infection without the need for cationic polymers such as 
Polybrene to enhance lentiviral efficiency.  High MOIs and the use of Polybrene elicited 
potential toxicity informing future transduction approaches using the SHSY5Y line.  
Using the lentiviral system to generate stable cells has many advantages, as the 
transgene is readily inserted into the host cell genome by viral integrases.  In addition 
unlike plasmid transfection where integration is random, lentivirus tends to integrate in 
areas of active chromatin (Gierman et al 2007) which provides more comparable 
expression in clones formed from different insertions, than when using plasmid 
mediated techniques.  The use of a lentiviral system also provides the opportunity to 
infect post-mitotic, non-dividing cells such as neurons which expands the potential 
future uses of these constructs.   
 
The Swedish/wtAPP695 lentiviruses were tested in the SHSY5Y cell line at relatively 
high MOI’s to ensure that expression of excess APP protein would not be toxic.  The 
cells were initially differentiated for five days in RA to increase expression from the 
Synapsin I promoter that should drive APP expression within transduced cells.  Whilst 
small amounts of toxicity were observed at MOI’s of 10, most cells survived.  Western 
blotting for APP protein expression however showed that increasing the MOI from 5 to 
10 did not appear to lead to an observable increase in APP expression suggesting that 
the amount of expression was limited by the availability of the transcriptional machinery 
of the cells capable of interacting with the SYN1 promoter and not the copy number of 
the inserted transgene.  
 
Many cellular models of AD have utilised a lentiviral mediated approach to generate 
cell lines.  For example, expression of the amyloid precursor protein has been a 
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common avenue for studying the effects of APP expression on cellular activity.  Indeed, 
an extra copy of the APP gene is sufficient to cause FAD in DS patients, therefore 
there is premise to overexpress the APP gene to study cellular effects.  Furthermore 
the discovery of familial mutations such as the Swedish mutation of APP695 has 
allowed the effect of altered amyloid processing on cellular metabolism to be studied in 
vitro in terms of a human relevant model. 
 
In this study, the effects of overexpression of both wildtype and APP695 containing the 
Swedish mutation were studied after stable transduction of the SHSY5Y cell line.  Both 
APP genes are of great importance in relation to AD, as both have been demonstrated 
to cause AD pathology in human and AD models.  The results of some of these studies 
should be taken with caution due to the use of viral promoters to drive APP expression. 
The CMV promoter has been used to drive high level expression of APP in many 
studies.  However the level of APP driven by this promoter is not reflective of levels 
expected in the human brain.  With relevance to AD, the purpose of this study was to 
determine the utility of using a neuronal-based promoter to drive APP expression within 
neuronal cells.  Use of the Synapsin I promoter to simulate ‘’physiological’’ levels of 
APP might lead to more physiologically relevant downstream effects similar to those 
observed in the human AD brain.  Increases in APP695 expression were also achieved 
by differentiating the SHSY5Y cell line to become more neuronal in phenotype.  As 
SHSY5Y cells possess a functional wtAPP695 gene, the inclusion of APP695 under 
the Syn1 promoter was expected to lead to overexpression of wtAPP695 which could 
be compared to cells expressing the Swedish APP695.  wtAPP695 expression was 
expected to increase APP protein expression while, SweAPP695 expression was 
expected to increase APP cleavage via the amyloidogenic pathway, produce more 
amyloid 1-42.   
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3.4.2 Characterisation of APP-expressing cell lines 
The clones were characterised by their ability to differentiate into a more neuronal cell 
type with RA and BDNF treatment.  The clones tested produced extensive neurite 
networks at the end of BDNF treatment, with cultures staining positively for β-tubulin (a 
marker of neuronal differentiation).  When differentiating cells with BDNF in the 
absence of serum, cell death often occurred, leading to differing densities of neuronal 
networks in these cultures.  To overcome this problem further studies of these cell lines 
were carried out in RA differentiated cells to ensure similar cell numbers at the time of 
testing, which was especially important for the Seahorse studies. 
 
APP protein expression was assessed before and after seven days of RA treatment.  It 
was expected that RA treatment would increase APP expression by increasing 
expression from the Synapsin I promoter.  Interestingly, Western blot analysis showed 
a trend toward larger amounts of APP in the proliferating wtAPP695-expressing SHY5Y 
cells compared to that of RA treated cells.  All cells showed greater levels of APP than 
control.  By contrast, after RA differentiation, SweAPP695-expressing cells contained 
more APP within differentiated cell than in proliferative cells, with a general trend 
toward these cells containing similar or lower levels of APP than the control cell line.  
This may have been due to increased cleavage of APP to the Aβ peptide, which could 
be secreted out of the cell and into the media.   
 
The conditioned media was assessed for Aβ1-42.  ELISA results showed varying 
amounts of amyloid secreted from cell lines.  The significant result was from clone S10 
which showed less APP protein expression within the cell but the most amyloid 
secreted into the media.  The variations in APP695 protein expression and Aβ 
secretion may have been due to several reasons.  Firstly, the manner in which the 
stable cell lines were made using lentiviral transduction.  Lentivirus stably integrate the 
transgene of interest into the host genome in ‘’hotspot’’ regions, however the number of 
insertions cannot be predicted, therefore multiple copies of the wtAPP695/ 
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SweAPP695 gene may have integrated into the SHSY5Y cell line.  Furthermore, the 
location in the genome where the transgene is integrated into the host genome may 
affect gene expression of native genes adjacent to the integration site.  This could be 
addressed in future studies by determining how many copies of the APP gene may 
have integrated by Southern blotting, and characterising the integration sites by 
sequencing. 
 
The production of cells that overexpress APP is an important step in the determination 
of this proteins function within cells.  The results obtained in this chapter demonstrate 
that lentiviral transduction can be used to generate stable cells lines that over express 
both wild-type and APP carrying the Swedish mutation under the control of a neuronal 
promoter.  Interestingly, overexpression of wtAPP695 increases the level of APP in 
proliferative cells whereas the overexpression of SweAPP695 results in lower levels of 
APP present in cell lysates.  This could be a result of an increase in APP processing 
leading to the release of APP fragments including Aβ in cells carrying the Swedish APP 
mutation, which influence BACE cleavage of APP to produce amyloid, leading to 
decreased amounts of APP detectable by Western blotting.  Furthermore, production of 
sAPPα or sAPPβ into media cannot be ruled out.  Results of the Aβ ELISA agree with 
this interpretation with clones demonstrating a general increase in the secretion of Aβ 
1-42.  Results between clones were variable which may reflect differences in APP 
expression or APP processing.  A more detailed analysis should be performed in order 
to determine the levels of multiple APP fragments including soluble APP (sAPPα), as 
well as the ratio of Aβ1-42/40.  
 
3.4.3 Changes in metabolism between cell lines 
In vivo studies of AD patient brains show consistent reductions in glucose utilisation in 
areas of the brain known to be affected by amyloid (Chen and Zhong, 2013, Mosconi, 
2005).  Further analysis of the glucose utilisation of proliferating clones in this study 
suggested a general trend for increased glucose levels in the media suggesting a 
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reduction in glucose uptake.  However, only 1 clone expressing Swedish APP 
demonstrated any significance.  Interestingly this clone (S10) was also the only clone 
to demonstrate a significant increase in Aβ1-42 production.  Analysis of differentiated 
clones revealed a significant reduction in glucose uptake in all of wild type clones, with 
a similar but insignificant profile in SweAPP expressing clones.  These results could 
suggest a difference in the metabolism of differentiated cells, which potentially renders 
them more sensitive to increased APP or Aβ production.  Production of sAPPα in these 
cells is important to consider as it is known to have potent neuroprotective effects 
against amyloid-induced oxidative injury (Goodman and Mattson, 1994) and glucose 
deprivation (Mattson et al., 1999, Barger and Mattson, 1995), the latter of which 
showed the ability of   sAPPα to increase glucose transport through activation of 
guanylate cyclase.   
 
Previous studies have demonstrated a difference in the metabolism of proliferating and 
differentiated SY5Y cells (Swerdlow et al 2013, (Schneider et al., 2011 ).  Specifically, 
glucose uptake studies show a general trend that the APP-expressing cell lines utilise 
less glucose than the control cell line once differentiated.  The differences in glucose 
uptake between proliferative and RA-differentiated SHSY5Y cells may also reflect the 
change in metabolism from glycolysis to oxidative phosphorylation.  Cancerous cell 
lines such as SHSY5Y cell lines typically utilise glycolysis to sustain their energy needs 
(Swerdlow et al 2013), whereas RA-differentiated SHSY5Y cells predominantly rely on 
oxidative phosphorylation (Schneider et al., 2011b).  
 
Schneider et al. (2011) demonstrated that SHSY5Y cells differentiated with RA exhibit 
increased mitochondrial membrane potential compared to proliferating cells.  They also 
noted greater stimulation of mitochondrial respiration and increased bioenergetic 
energetic capacity.  This trend was reflected in the RA-differentiated cell lines tested in 
this chapter.  Comparison of the responses between the wtAPP695 and the 
SweAPP695 lines demonstrated a significant increase in basal oxygen consumption 
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compared to the control, yet only clone S10 showed significantly higher amount of Aβ1-
42 secreted into the media. Interestingly, wtAPP695 expressing cells exhibited 
increased maximal respiration, which could be explained by increased number of 
mitochondria or an altered substrate supply.   
 
There were no other correlations between SweAPP695, wtAPP695 and controls for 
any of the other Seahorse analyses carried out.  There was no clear changes in ATP 
turnover or maximal respiration/ spare respiratory as either proliferative or RA-
differentiated cell lines which suggests that the electron transport chain may be 
unaffected.  This may reflect effects of differential APP processing between the cell 
lines leading to different responses in the MitoStress test.   
 
Interestingly, previous studies have shown  that wtAPP695 and SweAPp695 
expressing cells were able to utilise both oxidative phosphorylation and glycolysis 
equally, and that these cells were healthy (Yang et al., 2009).  In other studies stable 
transduction of pre-mitotic C17.2 cells with SweAPP695 found that these cells were 
more vulnerable to secondary insults such as Aβ oligomers.  This suggests that whilst 
the expression of APP/SweAPP695 in the cell lines may have had some effect on 
metabolism, the cells may have been able to compensate for this.  Future work could 
employ a secondary insult such as the introduction of Aβ oligomers to help identify the 
metabolic impact on the overexpressing cell lines. 
 
A study performed in embryonic neurons derived from 3-x-Tg-AD mice demonstrated 
decreased mitochondrial respiration and an increase in glycolysis (Yao et al., 2009b).  
However in this study, there were no significant changes in maximal respiration which 
suggest that to observe any changes between the cell lines, further studies using the 
glycolysis stress test may be appropriate.  The glycolysis stress test allows for the 
measure of basal glycolysis, that being the conversion of glucose to pyruvate, which 
produces ATP.  Pyruvate may either be converted to lactate in the cytoplasm or to 
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carbon and water in the mitochondria.   In the test, glycolysis is measured by the rate of 
protons released into the media after the addition of glucose.  The second compound 
injection is oligomycin, which acts to inhibit oxidative phosphorylation and thereby 
forcing cells to rely on glycolysis to maintain ATP production.  Elevated rates of 
glycolysis is known as the glycolytic capacity of the cell.  It is also important to note the 
mutant genes expressed in the triple transgenic mouse model are the under the control 
of the mouse Thy1.2 regulatory element, whereas the cell lines studied in this chapter 
are under the control of the Synapsin I promoter.  Therefore APP/Aβ expression within 
the SHSY5Y cell lines may be insufficient to observe any change in mitochondrial 
function.   
 
Results suggest that RA-differentiated cell lines, which increase APP expression due to 
up-regulation of SYN1 may lead to decreased glucose uptake, with respect to the 
wtAPP-expressing cell lines. There were generally no significant differences between 
the proliferative cell lines and the control in terms of glucose uptake, with the exception 
of the S10 clone which produced the most Aβ.  A decrease in glucose uptake could be 
explained by negative feedback of glucose-6-phosphate accumulation within the cell, 
which leads decrease in flow of glucose through the hexokinase pathway.  However 
further studies are needed to be able to draw any meaningful conclusions.  Such 
studies will investigate the use of tritiated glucose to determine the efficiency of glucose 
uptake, as well assessing the effects of glycolysis in these cultures. 
 
Mitochondrial function in AD is clearly perturbed and has been considered as an 
underlying mechanism in the early stage of AD, as deficits in energy metabolism are a 
fundamental characteristic of the AD brain.  The fact that both full length APP and Aβ 
are found to accumulate within mitochondria in the brains of AD patients strengthens 
this hypothesis.  Mitochondrial enzyme activity is decreased in AD brains and animals, 
in particular PDH and α-ketoglutarate activity.  Decreased activity of these enzymes 
was found to correlate with the cholinergic deficits associated with AD.   
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These observations are also reflected in animal models, where mitochondria of 
presymptomatic Tg2576 mice were shown to be defective, particularly in  mitochondria 
taken from areas of the brain important in cognition (Varghese et al., 2011).  However, 
the authors could not fully ascertain whether the increased production of Aβ1-42 and 
not other fragments was responsible for these abnormalities.  In another study, 
mitochondria taken from platelets of MCI and sporadic AD patients were transferred 
into mitochondria-depleted SHSY5Y cells (Silva et al., 2013).  Analysis of mitochondrial 
function and glucose utilisation of these cells revealed changes in OCR, respiratory 
capacity and glucose utilisation.  In particular, less ATP and increased NADH levels 
were observed in the diseased cybrids compared to controls.  However, the patients 
from which the platelets were taken from were assessed by cognitive testing with no 
measurements in Aβ levels in platelets made. Therefore whilst mitochondrial deficits 
did occur, it could not be conclusively attributed to amyloid, as other APP cleavage 
products are present in AD derived platelets (see Chapter 4). 
 
Past studies have investigated the therapeutic of compounds including lipoic acid, 
nicotinamide mononucleotide (NMN) and hydroxybutyrate, which may help to improve 
mitochondrial function and could be tested in cell lines developed in this project in the 
future.  Lipoic acid supplemented to AD mice increased brain glucose uptake and 
reversed impairments in synaptic function (Sancheti et al., 2013).  Furthermore, lipoic 
acid improved memory and cognition in SAMP8 mice, Tg2576 transgenic mice and 
aged NMRI mice (Quinn et al., 2007, Farr et al., 2003, Stoll et al., 1993).  Lipoic acid is 
a cofactor for acyltransferase activity PDH and α-ketoglutarate dehydrogenase, acting 
to boost enzyme activity for both (Walgren et al., 2004, Tretter and Adam-Vizi, 2005).  
This leads to increased substrate delivery to the electron transport chain, ultimately 
driving glucose uptake.  NMN is a NAD precursor which is shown to ameliorate 
mitochondrial dysfunction in mice (Long et al., 2015).  Repletion of NAD is essential as 
it is a cofactor in metabolic reactions such as the conversion of pyruvate to acetyl CoA, 
which forms the first substrate in the Kreb’s cycle, as well as being involved in other 
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steps of the Krebs cycle.  Hydroxybutyrate is a ketone body, which provides an 
alternative energy source for the brain, by being converted to acetyl CoA, effectively 
bypassing the requirement of glucose.  Increased levels of ketones were demonstrated 
to rescue mitochondrial enzyme activity, the mitochondrial membrane potential and 
improved memory in mice (Zhang et al., 2013). 
 
Oxidative stress plays an important role in AD and other diseases.  Previous models of 
AD show signs of oxidative stress (Morley et al., 2012, Butterfield et al., 1999, Oikawa 
et al., 2012), which provides an intriguing premise to study oxidative stress responses 
in these manipulated cell lines.   All proliferating cell lines tested were susceptible to 
hydrogen peroxide, but there were no significant differences between wtAPP or 
SweAPP-expressing cell lines and the control SHSY5Y cell line.  This may be due to 
the fact that as proliferative cells, APP expression was not upregulated (as it is driven 
by a neuronal promoter, whose expression is low in proliferative SHSY5Y cell lines).  
Further work should assess the stress responses of these cell lines in a differentiated 
state, where they are more neuronal in nature and may be more susceptible to 
hydrogen peroxide with increased APP expression/ Aβ production.   
 
There are potential issues with the methodology employed in this project, which may 
have resulted in inconsistent or insignificant results.  The lack of control over levels of 
expression between clones is a potential issue.  The mitochondrial deficits and glucose 
changes observed in other models may be due to the use of stronger promoters than 
the Synapsin I promoter utilised in this project.  Therefore the level of expression of 
APP695 may be insufficient to observe any short term negative effects on cell 
metabolism.  More importantly, the lack of significance in many of the studies 
conducted could be attributed to the use of RA to differentiate the SHSY5Y cell lines.  
Retinoic acid was found to down-regulate BACE1 expression in the brains of Tg2576 
mice (Wang et al., 2015b), via NFκB, thereby providing an anti-inflammatory effect 
(Koryakina et al., 2009).  Down-regulation of BACE1 would prevent the production of 
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Aβ1-42.  Further work should assess for the levels of BACE1 protein expression before 
and after RA-induced differentiation of SHSY5Y cell lines to address this issue. 
 
An alternative method of expressing APP at controllable levels would be to use a TET-
based system (as described in Long et al., 2015).  In this system, cells grown in the 
presence of different concentrations of Doxycycline would produce varying amounts of 
APP and therefore Aβ.  It should also be noted that many in vivo studies use powerful 
promoters to drive expression of APP/ PSEN1 protein expression.  Animal models such 
as the TG2576 mice (which express the SweAPP595 mutation) express 8 times the 
normal level of amyloid (compared to the brain) and do not experience all of the 
symptoms of AD such as cell death.  As such the results from these systems should be 
considered carefully, if they are overexpressing these proteins at abnormally high 
levels to observe cellular deficits. 
 
The use of the Glucose HK assay to study glucose uptake has a drawback that it will 
also incorporate glucose oxidation/ usage in addition to glucose uptake, therefore may 
not be the ideal method to analyse glucose uptake.  Alternative methods could be to 
utilise 3H 2deoxyglucose or 2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-
Deoxyglucose).  Both forms of glucose are readily taken up by cells but cannot be 
metabolised and therefore accumulate within the cell.  In terms of the Seahorse 
studies, cells are supplemented with 10mM D-glucose, which is relatively high 
compared with physiological concentrations of 2.5mM in the human brain.  
Supplementation of high levels of glucose may hamper the ability to observe any small 
differences in mitochondrial function due to the different clones. 
 
The benefits of using SHSY5Y are that they are cheap and provide a high throughput 
model.  However, as they are derived from cancer cells they have an abnormal 
karyotype and their metabolism does not model that of neuronal cells unless they are 
differentiated. Once differentiated cells demonstrate an enhanced sensitivity to APP 
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therefore highlighting the need to carefully consider the metabolic state of the cell used.  
However, differentiated cultures of SHSY5Y have a limited lifespan which precludes 
their use for long term studies. 
 
In conclusion, issues with the phenotype of this cell line and the difficulties associated 
with overexpressing exogenous proteins complicate the analysis of the metabolic 
pathways perturbed in AD.  Ideally, large subsets of clones should be analysed 
individually and then grouped according to levels of either APP or Aβ expression in 
order to determine any significant differences.  Additionally, each clone should be 
characterised to determine how APP is processed, as the variation in the OCR 
readings from the Seahorse experiments may reflect differential APP processing into 
other APP fragments, some of which are known to be neuroprotective (sAPPα).  
Expression of these soluble APP fragments could help to explain the lack of metabolic 
dysfunction in some of the cell lines as APP processing can still occur via the non-
amyloidogenic pathway in these cells.  It would also help to address any potential 
changes in cell proliferation between the different clones.   
 
A better model of AD would naturally develop AD in culture and produce natural levels 
of APP/amyloid and therefore avoid insertion related effects on other genes.  Also, 
such models would not overstress cellular systems produced abnormal levels of protein 
or sequester cellular factors due to the use of viral promoters.  The results presented 
here do not provide a conclusive argument as to the effects of APP overexpression on 
cellular metabolism that have been reported elsewhere.  Perhaps a viral promoter 
would have produced much larger amount of APP and therefore more Aβ1-42 and 
provide more significant results.  As models that produce natural levels of APP may 
provide much clearer results, AD patient derived fibroblasts were used in order to 
determine the effects of APP misprocessing in an unmodified cellular system.  The 
results will be discussed in Chapter 4. 
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Chapter 4: Characterization of FAD patient–derived fibroblasts 
Alzheimer’s disease has long been considered a disease that is limited to the brain.  
However, a number of studies have described differences in the phenotypes of 
numerous cell types around the body in FAD patients.  These differences may be due 
to the genetic mutations that are associated with AD (especially in FAD cases) and 
therefore suggest that AD pathology is not merely limited to the human brain, and that 
pathways perturbed in the brain may also be disrupted in peripheral tissues.  As such, 
studies into the pathways perturbed in these cells that may provide an insight into the 
earliest stages of AD.  In this chapter FAD patient fibroblasts were studied.  The 
metabolic profile of these cells was measured using the Seahorse analyser.  In 
addition, glucose uptake and responses to oxidative stress were studied in these lines 
along with the effect of the addition of the AD associated peptide Aβ 1-42 to fibroblasts. 
 
4.1 Introduction to familial mutations 
Whilst familial forms of AD constitute a small fraction of AD cases, cells taken from 
these patients provide a useful model of AD.  As discussed in Chapter 3, duplications 
of the APP gene (Rovelet-Lecrux et al., 2006), mutations in the APP coding sequence 
and presenilin genes are the major genetic mutations associated with FAD, with the 
latter being more predominant.  At least 10 pathogenic APP mutations have been 
discovered, all of which cluster near the proteolytic cleavage sites of APP (Figure 1.3 in 
Chapter 1) (De Jonghe et al., 2001), leading to increased Aβ production (Feng et al., 
2006).  In this study, patient derived fibroblasts carrying the London V717I mutation in 
APP as well as the presenilin mutations M146I and Intron 4 were studied. 
 
The London mutation was the first FAD mutation to be recognised (Goate et al., 1991) 
and is the most frequent APP mutation observed (Cruts et al., 2012).  This mutation 
has been reported in several families suffering from FAD and causes a missense 
mutation at position 717, resulting in the transition from a Valine to Isoleucine base 
195 
 
substitution.  This region of the APP gene appears to be a hotspot for mutation with 
several allelic variants identified to be pathogenic (Chartier-Harlin et al., 1991).  
Approximately 30 families identified from different countries were found to carry this 
mutation, affecting both Caucasian and Asian populations.  
 
Variations of sequence at this position may increase amyloid deposition due to 
changes in APP processing, or that there may be increased APP mRNA translation 
(Tanzi and Hyman, 1991).  Mouse models carrying this mutation display increases in 
Aβ42/ Aβ40 ratio, due to increased levels of Aβ42 production (Herl et al., 2009, Theuns 
et al., 2006, Moechars et al., 1999).  More recently, studies using iPSC-derived 
neurons carrying the APPV717I mutation demonstrated increased BACE1 cleavage of 
APP, altered the initial cleavage site of γ-secretase, leading to increased amyloid 
peptide 1-42 and 1-38 production.  Increased levels of total tau and phosphorylated tau 
were also observed (Muratore et al., 2014). 
 
PS1 and PS2 proteins are encoded by the PSEN1 and PSEN2 genes, which are 
localized to chromosome 14q24.3 (Sherrington et al., 1995) and 1q42.1 (Rogaev et al., 
1995, Takano et al., 1997) respectively.  Both genes are similar in structure and consist 
of 13 exons, where 10 exons make up the coding sequences (Hutton and Hardy, 
1997).  The PS1 gene consists of 13 exons, of which exons 3-12 code for a protein, 
467 amino acids in length (Prihar et al., 1996, Clark et al., 1995).  Alternative splicing of 
a 12bp sequence in exon 3 and exon 8 (Sherrington et al., 1995) has been reported to 
give rise to different transcripts (Rogaev et al., 1997, Clark et al., 1995), with these 
transcripts leading to mutations associated with FAD.  There are at least 180 mutations 
in the PS1 gene, which may account for up to 25-30% of early-onset AD, making this 
the most common genetic aberration to cause FAD.  Interestingly de novo PS1 
mutations have been reported in clinically sporadic, EOAD cases (Dumanchin et al., 
1998, Levy-Lahad et al., 1995).  Many of these mutations lie with the transmembrane 
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domains or adjacent to predicted loop domains, with most PS mutations reported to be 
missense mutations (Singleton et al., 2000).   
 
4.1.1 Presenilins structure  
PS1 and PS2 are homologous intracellular aspartyl proteases (Li et al., 2013).  They 
are a transmembrane spanning protein (see Figure 4.1), having six to eight 
transmembrane domains with the N terminus, the large sixth hydrophilic loop (HL-VI) 
and the C-terminal hydrophobic regions associated with the cytosolic face (Price and 
Sisodia, 1998).  Two putative catalytic residues, Asp162 and Asp220 are found on 
loops six and seven.  During protein maturation, they are endoproteolytically processed 
within the HL-VI region, producing a 30kDa N-terminal fragment and a 20kDa C-
terminal fragment (Thinakaran et al., 1996).  The production of both products is tightly 
regulated ensuring equal amounts of both fragments are produced.   
 
The function of PS1/PS2 was discovered through studies of the C.elegans homologue 
Sel-12, that functions to mediate LIN-12/ Notch signalling during cellular development 
(Wong et al., 1997).  Wildtype PS1 can rescue mutant SEL-12 induced phenotypes in 
C.elegans but PS1 containing FAD-associated mutations only led to partial recovery 
(Qian et al., 1998).  Both presenilins have some sequence similarity to SPE-4, found 
within C.elegans spermatocytes (L'Hernault and Arduengo, 1992).  It is now 
understood that PS1 is involved in APP processing, as demonstrated by gain-of-
function phenotype in PSEN1 mutations.  PSEN1 mutations result in an increase in the 
production of Aβ42 in plasma and fibroblasts of mutation carriers (Scheuner et al., 
1996b), in media of transfected cells (Citron et al., 1997) and in the brains of transgenic 
mice (Duff et al., 1996).  PSEN1 knockout mice are embryonic lethal, exhibiting axial 
skeleton malformation and CNS defects.(Qian et al., 1998, Shen et al., 1997).  
However, PSEN2 null nice do not show these defects (Parent and Thinakaran, 2010). 
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Figure 4.1. Diagram showing the structure of presenilins embed within the cell 
membrane. 
 
 
PS1 and PS2 exhibit significant structural differences in their cytosolic domains, 
sharing less than 10% homology in the N-terminal 70 residues and between amino 
acids 305-375 in the loop.  These regions are suggested to mediate cell- or PS-specific 
functions by interacting differently with cytosolic proteins.  Biochemical studies suggest 
that presenilins are not subject to sulfation, glycosylation or acylation.  However, serine 
residues in the cytosolic domain of PS1 and in the N terminal region of PS2 are sites 
for phosphorylation.  PS1 phosphorylation is mediated by protein kinase C and cMAP-
dependent protein kinase or inhibition of protein phosphatase 1 or 2A (De Strooper et 
al., 1997).  
 
4.1.2 Localization of Presenilins 
Presenilins are expressed in many tissues and detectable at low levels in the brain.  
Full length PS1 and PS2 is localized to membranous compartments such as the ER 
and Golgi network, where they undergo endoproteolysis to yield stable N- and C-
terminal fragments (Selkoe, 1998).  The fragments appear to be highly regulated as 
mice overexpressing PS1 fail to increase fragment production, suggesting degradation 
of the presenilins via a nonspecific proteolytic pathway (Thinakaran et al., 1996).  The 
PS1 fragments are transported to Golgi vesicles where they assemble together to form 
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heterodimers, which are considered to be their primary form (Steiner et al., 1998, 
Farquhar et al., 2003).     
 
4.1.3 Presenilin 1 function 
PS1 plays a role in a number of processes such as protein processing and cell 
signalling.  Most notably, it is known to form part of the enzyme complex, γ-secretase 
which cleaves APP to yield the Aβ peptide.  Indeed, mice lacking PS1 demonstrated 
70-80% decrease in Aβ40 and Aβ42 levels and a corresponding increase in their 
precursors, C99 and C-terminal fragment.  Two hypotheses may explain how 
presenilins regulate APP proteolysis at the γ-secretase cleavage site.  Presenilins may 
complex with C99 and C83 and modulate protease access to the peptide bond at Aβ40 
and Aβ42.  PS1 and PS2 have in fact been found been shown to co-precipitate with the 
N-glycosylated form of APP.  When the cytoplasmic domain of APP was deleted, this 
did not prevent co-precipitation with presenilins which suggests that its interaction 
could involve the transmembrane domains of the proteins, regions which may enable 
APP proteolysis. 
 
4.1.4 Presenilin mutations 
Mutations in PSEN1 are the most common cause of FAD (Sherrington et al., 1995) 
many of which occur in single-kindred families.  The majority of these missense 
mutations are located within transmembrane II or immediately adjacent to the predicted 
loop domain, accounting for at least 50% of the known PS1 mutations.  These 
mutations cause an early AD phenotype where the average age of onset is about 40 
years, with one of the youngest ages of onset being 28 years.  The location of the point 
mutations appears to influence age of onset, for instance, individuals with mutations in 
exon 8, have an average of onset of 43 years whilst other mutations outside this region 
lead to an average of onset of 48 years.  Exon 8 encodes for a region of a predicted 
TM domain 6 (TM-6) and the largest cytoplasmic loop of PS1.  Other mutations have 
also been localised to exon 5 which encodes the second predicted TM domain (TM-2) 
and the largest luminal loops of PS1.  In addition, exon 9 is another location of interest, 
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which encodes for a region of HL-6.  These so-called ‘’hotspots’’ are found in critical 
functional or conformational domains in PS1, which may affect interactions with other 
proteins.  Interestingly fewer PS2 mutations have been discovered, (Rogaev et al., 
1995, Levy-Lahad et al., 1995).   
 
One particular presenilin 1 mutation that occurs in intron 4, leads to the production of  
truncated deletion transcripts, and an in-frame insertion transcript due to alternative 
splicing using a cryptic splice site in intron 4 (De Jonghe et al., 1999).  This mutation is 
common in the British population, who were found to develop AD in their mid-thirties 
and died in their mid-forties.  A genotype analysis of polymorphic dinucleotide repeat 
markers found that many of the patients carrying this mutations share one common 
allele at one of these markers.   
 
Individuals presenting with the PSEN1 point mutation at position 278 suffer from 
spastic paraparesis (Assini et al., 2003), speech production deficits and frontal 
behavioural disturbances (Kennedy et al., 1995), without the cognitive dysfunction 
usually associated with AD (Kwok et al., 1997).  Indeed, a study of 2 AD cases with the 
R278I mutation, under the age of 55 years experienced no significant loss of episodic 
memory but exhibited symptoms of early language impairment (Godbolt et al., 2004), 
while individuals with R278K mutations showed increased Aβ40/Aβ42 ratio in cultured 
fibroblasts, implying that mutations at position 278 encourages amyloidogenesis (Assini 
et al., 2003).  
 
Another hotspot for mutation is found in PS1 where Methionine 146 is commonly 
substituted with another hydrophobic residue, such as Valine, Leucine and Isoleucine, 
which corresponds to any nucleotide change at the first or third position of the codon 
(Jorgensen et al., 1996).  
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Much if not all the research of AD involving these familial mutations has been carried 
out in the brain, as traditionally, AD is considered a brain-related disorder because the 
production of amyloid is considered to be a neuronal phenomenon.  In AD, the brain 
appears to be most vulnerable to the effects of these mutations which leads to adverse 
effects on mental functions.  However several studies have since detected amyloid 
deposition or APP695 expression outside of the CNS.  These studies and their 
relevance will be outlined in the following sections.   
 
4.1.5 APP expression outside the CNS 
Expression of the APP695 isoform is not restricted to the brain but is also widely 
expressed in other tissues, such as thymus, heart, muscle, kidney, adipose tissue, skin 
and intestine.  This widespread expression suggests that APP may not only effect 
neurons but also other somatic cell types, expanding its potential physiological 
functions beyond that of neuronal networks (Puig and Combs, 2013).  Aberrant 
deposition of amyloid is not only associated with dementia but also a series of diseases 
termed amyloidosis, in which amyloid-like peptides can be abnormally deposited in 
organs or tissue as fine fibrils (Kazmi, 2013).  At least twenty-eight different kinds of 
human proteins in addition to APP, are found to be amyloidogenic in vivo and are 
associated with pathological disorders such as prion diseases, type II diabetes and 
familial, systemic and sporadic amyloidosis (Westermark et al., 2007).  
 
4.1.5.1 APP function in adipose and intestine 
APP and its cleavage products are detectable in human adipocytes and macrophages 
(Lee et al., 2008b, Puig et al., 2012a).  Obesity has been shown to influence APP 
levels in vivo in human adipose tissue, in correlation with hyperinsulinemia, insulin 
resistance and increase expression of pro-inflammatory genes, such as macrophage 
inflammatory protein-1α and IL-6 (Lee et al., 2008b, Puig et al., 2012a).  Inflammatory 
TNFα increases APP levels in 3T3 adipocytes corroborating in vivo studies carried out 
in a rodent model of diet-induced obesity (Sommer et al., 2009, Puig et al., 2012a). 
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4.1.5.2 APP function in muscle 
APP has also been shown to localise to the synaptic compartments of mouse skeletal 
muscle and cultured murine myogenic cells (Akaaboune et al., 2000a).  APP 
expression is detectable early in muscle fibre development, accumulating at 
neuromuscular junctions (NMJs).  NMJs which lack APP exhibit abnormal localization 
of pre- and postsynaptic proteins with few synaptic vesicles at presynaptic junctions, 
resulting in increased synaptic dysfunction (Wang et al., 2005).  In murine intestine, 
APP is localized in enterocytes, neurons and smooth muscle.  Dietary cholesterol and 
saturated fats have been shown to increase APP and amyloid in columnar epithelial 
cells in mice (Galloway et al., 2007).   
 
Aβ peptide is also detectable within the Golgi and rough endoplasmic reticulum of 
enterocytes.  Within the intestine, APP appears to modulate motility, barrier integrity 
and nutrient absorption within neurons, macrophages and epithelial cells.  APP 
knockout mice demonstrate a weakened intestinal inflammatory profile, which suggests 
that APP may regulate host-microbe interactions or vulnerability to gastrointestinal 
inflammatory disease (Puig et al., 2012b).  From a pathological viewpoint, aberrant 
amyloid aggregation is also present in Inclusion Body Myositis (IBM), which is a 
common myopathy affecting skeletal muscle cells (Askanas and Engel, 2002).  IBM 
patients exhibit gradual muscle weakness, impaired innervation of muscle and muscle 
fibre degeneration (Minniti et al., 2009). 
 
4.1.5.3 APP function in skin 
APP expression is abundant in basal keratinocytes of the epidermis, melanocytes and 
melanoma cells (Herzog et al., 2004).  Aβ deposits have been detected under the 
epidermal/ dermal junction and adjacent to small blood vessels (Joachim et al., 1989).  
Here, APP may influence cell adhesion to components of the extracellular matrix and 
may function as a membrane receptor to regulate kinesin-1, an axonal transport protein 
(Lazarov et al., 2005).  In addition, APP has been shown to regulate copper 
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homeostasis, and is associated with oxidative stress and apoptosis in human 
keratinocytes via its ability to reduce Cu2+ to Cu+ in vitro (Kagan et al., 2002).  
 
In addition to AD pathogenesis, APP has been associated with skin disorders.  For 
example, APP is upregulated in keratinocytes in psoriasis (Siemes et al., 2004), in 
which aberrant keratinocyte proliferation and differentiation are observed 
(Romanowska et al., 2009).  Increased production of Aβ in the keratinocytes of 
psoriasis patients increases transcription of the pro-inflammatory enzyme 
kynureninase.  Increased APP expression has also been reported in advanced 
melanoma, whilst down-regulation of APP leads to the terminal differentiation of human 
melanoma cell lines (Botelho et al., 2010). 
 
4.1.5.4 APP expression within fibroblasts 
APP processing has been observed in cultured skin fibroblasts, regulated by PKC 
activity. Phorbol ester-induced PKC activation of FAD-derived skin fibroblasts 
increased levels of sAPPα and decreased levels of Aβ (Vestling et al., 1999).  PKC can 
up-regulate ADAM10/ 17 (which has α-secretase activity) thereby influencing the non-
amyloidogenic pathway, increasing levels of sAPPα and subsequently decreasing Aβ 
production (Ebsen et al., 2013).  Basal amyloid levels were elevated in these 
fibroblasts, possibly due to reduced PKC activity.  FAD-derived fibroblasts also show 
distinct metabolic profiles when compared to non-AD controls; including increased 
lactate production and abnormal glucose uptake (Gasparini et al., 1998).   
 
Patient-derived fibroblasts have provided a great source of information concerning the 
role of APP outside of the CNS.  Studies dating from the 1980’s, have observed 
physiological differences in FAD-derived fibroblasts when compared against aged 
matched controls.  These fibroblasts show abnormalities in energy metabolism (Sims et 
al., 1987), alterations in calcium content (Peterson and Goldman, 1986) and increased 
sensitivity to free radicals (Tesco et al., 1992).  Interestingly, fibroblasts taken from DS 
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patients showed decreased growth rate and increased protein content (Segal and 
McCoy, 1974).  In addition, SAD and FAD–derived fibroblasts exhibit reduced 
adhesiveness to plastic when compared to non-disease fibroblasts (Ueda et al., 1989).  
This finding is supported by other studies that have demonstrated abnormal 
cytoskeletal proteins, vimentin fibres, aberrant degradation of fodrin and aberrant 
calcium responses (Takeda et al., 1990, Takeda et al., 1991, Tatebayashi et al., 1995). 
 
Oxidative stress within diseased fibroblasts is of particular relevance to AD.  ROS 
generation is known to cause tissue damage, however cells possess mechanisms to 
scavenge these free radicals, such as the expression of manganese superoxide 
dismutase (MnSOD) (Tesco et al., 1992).  The gene encoding MnSOD is located on 
chromosome 21 and is overexpressed in DS due to trisomy 21.  Pathological changes 
common to both AD and DS strongly imply a possible role of free radicals in disease 
pathogenesis.  Furthermore, fibroblasts taken from SAD patients showed impaired 
oxidative metabolism (Gasparini et al., 1998, Gibson et al., 1996).  Cultured skin 
fibroblasts taken from SAD and FAD have previously been subjected to oxidative 
stress in order to observe their responses.  SOD activity was higher in FAD than SAD 
fibroblasts, resulting in increased conversion of superoxide to hydrogen peroxide.  
Deficiency of cytochrome oxidase complex IV has also been reported in AD platelet 
mitochondria (Parker et al., 1990) suggesting that the scavenging system may be 
involved in increased ROS vulnerability.  Decreased Cox activity was also observed in 
SAD-derived fibroblasts (Curti et al., 1997), which may lead to an increase in ROS 
leakage from the respiratory chain (Benzi et al., 1992).  Decreased Cox activity in AD 
cybrids (SHSY5Y and AD platelets) was found to lead to increased ROS generation 
(Davis et al., 1997b). 
 
More recently, genetic profiles of SAD-derived fibroblasts were compared with stressed 
healthy fibroblasts controls.  AD cells experienced elevated unrepaired 8-oxo-guanine 
(8-OdG), a type of DNA base modification, providing evidence of chronic oxidative 
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stress.  (Ramamoorthy et al., 2012).  Altered gene expression was also detected 
between the two cell lines, with a number of genes previously associated with AD 
found to be altered.  For example, IL-6 is differentially expressed amongst different 
ethnic groups reflecting varied AD risk amongst these ethnicities.  A specific 
polymorphism in 3’ flanking region of the IL-6 gene correlates negatively with AD in 
some populations (Papassotiropoulos et al., 1999).  However, in Caucasians, this 
polymorphism is associated with an increased risk of developing sporadic AD (Bhojak 
et al., 2000).  Another gene associated with AD is the PRKAA1 gene which encodes for 
the α1 subunit of the mammalian (adenosine monophosphate-activated protein kinase 
(AMPK).  AMPK  regulates cholesterol and glucose metabolism, and is also activated 
in response to DNA damage, regulates ROS autophagy and mitochondrial function 
(Wang et al., 2012).  The exact relationship between AMPK and AD is unclear, but 
APP processing occurs in the membrane where changes in the cholesterol component 
may exert an effect.  Furthermore, there is an association of high serum cholesterol in 
midlife and where there is increased incidence of AD (Wollmer, 2010). 
 
These studies suggest that fibroblasts from both familial and sporadic AD patients 
exhibit metabolic differences when compared to age-matched controls.  As some of 
these changes are also observed in sporadic AD-derived fibroblasts this finding 
suggests that there may be common changes in metabolic pathways shared between 
both forms of AD.  Moreover, differences observed in both in culture and tissues 
outside of the CNS suggest that the effects of APP misprocessing are not limited to the 
brain but may also involve metabolic dysregulation in multiple peripheral tissues.  
 
4.1.6 Aims and objectives 
The aim of this study was to examine whether dermal fibroblasts taken from AD 
patients with confirmed familial mutations exhibit perturbed energy metabolism.  
Studies described in section 4.1.5.4 have previously demonstrated significant 
differences in patient derived fibroblasts in cellular metabolism, increased production of 
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Aβ in vitro and most interestingly, oxidative stress in comparison to controls.  In order 
to determine the metabolic changes present in FAD-derived fibroblasts (carrying the 
London V717I, PS1 mutations M146I and PS1 mutation Intron 4), glucose uptake from 
the media was measured.  In addition, AD-derived fibroblasts were assessed for any 
changes in mitochondrial function, which may contribute to their susceptibility to 
oxidative stress using the Seahorse analyzer.  They were also subjected to oxidative 
stress to study their responses in terms of cellular toxicity.  Changes observed in 
fibroblasts could inform research into AD as this study will highlight the consequences 
of altered APP processing, not only in neuronal cultures but also in cells from the 
periphery.  In addition, normal dermal fibroblast cells were treated with Aβ 1-42 to 
determine whether amyloid has any effects on healthy non-neuronal cell lines.   
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4.2 Methods and materials 
4.2.1 Human Dermal Fibroblast culture (hDFa) 
Human dermal fibroblasts (Gibco,, Thermo Fisher Scientific, Paisley, UK) and FAD-
derived fibroblasts (a kind gift from UCL Institute of Neurology) were cultured in 
Dulbecco’s minimal essential medium (DMEM) containing 4.5g/l glucose with Glutamax 
(Gibco, Invitrogen, Paisley, UK), with 100U/ml Penicillin and 100μg/ml Streptomycin 
and 10% FBS. 
 
Cells were initially resurrected from liquid nitrogen by warming them at 37°C until the 
cells had thawed.  The cell suspension was then mixed in pre-warmed media and 
pelleted at 180g for 7 minutes, after which point, the media was removed and the cell 
pellet re-suspended in 1ml media and then were seeded at 5000 cells/cm2 of surface 
area of culture vessel.  Fibroblasts were left to grow undisturbed at 37°C, 5% CO2 for 3 
days after which point media was refreshed every 2 days.  When cells reached 
approximately 90% confluence they were passaged. 
 
For passaging cells, media was decanted and cells washed twice in PBS.  Cells were 
detached in Trypsin-EDTA (0.01%) with any remaining attached cells detached by 
gentle agitation of the flask.  Fibroblasts were then pelleted and passaged at a ratio of 
1:4/ 1:6.  Media was refreshed every two days, and then when cells approached 80% 
confluence, media was refreshed every day.  Cells were grown at 37°C, 5% CO2.  For 
freezing, cells were pelleted and then re-suspended in 10% DMSO made in FCS, 
before being stored at -80°C overnight.  Cells were then stored in liquid nitrogen for 
long term storage.    
 
4.2.2 Metabolic studies between FAD-derived and control fibroblast cell lines 
4.2.2.1 Cell proliferation study 
FAD-derived fibroblasts and control fibroblast cell lines were plated at 7.5 x 105 cells/ 
well into a 96-wellplate and incubated for 24, 48 and 72 hours at 37°C, after which time 
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the media was replaced with Cell Titer Blue reagent.  The cells were incubated for 2 
hours and the Abs620 and background Abs690 read on a platereader.  Once the 
background readings were subtracted from the Abs590 readings, proliferation of patient 
derived cells was determined as a percentage of the control cell line. 
 
4.2.2.2 Glucose uptake 
To study glucose uptake from the media, both diseased and control fibroblasts were 
seeded into 12 well plates at a seeding density of 5.5 x 104 per well.  After 24 and 48 
hours, media was collected from three wells and pooled to be clarified by centrifugation 
(10000rpm for 5 minutes).  Cells from the three wells were pooled and cell lysates 
obtained (section 2.2.2.1).  The glucose in the conditioned media was quantified using 
the Glucose HK assay (section 3.3.4.4) and normalised to total cellular protein.  Media 
samples were diluted 1:20 in deionized water to obtain absorbance readings that lay 
within the linear range of the glucose standard curve.   
 
4.2.2.3 Aβ ELISA 
Extracellular amyloid 1-42 production was determined as described in section 
3.2.3.3.2.  Media samples (24 and 48 hours) obtained for glucose studies was vacuum 
evaporated to one fifth of the original volume.  Aβ standards were diluted in fibroblast 
culture media and samples and standards incubated overnight in Aβ1-42 detection 
antibody.  Aβ concentrations were corrected to total cellular protein.  
 
4.2.2.4 Analysing mitochondrial function  
4.2.2.4.1 Optimization of seeding density 
Optimization of hDF cells on the Seahorse analyzer was carried out as discussed in 
Chapter 3 with some modifications.  Fibroblasts were plated from 2x104 to 7x104 
cells/well into XF 24 microplates.  These ranges of cell numbers were chosen as 
recommended in the literature (Zhang et al., 2012b).  Assay media was prepared 
containing 25mM glucose and 1mM sodium pyruvate (as recommended in the 
manufacturer’s protocol).  
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4.2.2.4.2 Optimization of mitochondrial inhibitors 
Control dermal fibroblasts were seeded at the optimal density across the XF microplate 
for titration of compounds.  Optimisation was carried out as described in section 3.2.7.  
OCR readings were normalized using protein concentration (see section 2.2.2.1) and 
the average OCR plotted against increasing concentration of compound. 
 
4.2.2.4.3 Performing the MitoStress Test 
The Mito Stress test was performed as described in section 3.2.4.3.4.  The three FAD-
derived fibroblasts cell lines and control hDF cells were seeded across the plate in five 
replicate wells.  Mitochondrial inhibitors were prepared (at the optimized 
concentrations) in the assay media and loaded into the cartridge.  After the 
experimental run was complete, the protein concentration (see section 2.2.2.1) was 
determined.  
 
Results were analysed using the Seahorse Wave 2.0 software, protein concentrations 
were used to normalize OCR readings for each well.  The data was used to generate a 
MitoStress report (MitoStress report generator software, Seahorse Biosciences, 
Massachusetts, USA).  The data from repeat experiments was collated and analysed 
using Graph Pad Prism 6.0 (La Jolla, CA, USA).   
 
4.2.2.3 Oxidative stress response studies 
Fibroblasts were treated with hydrogen peroxide (H2O2) in order to induce oxidative 
stress.  Previous studies have suggested that FAD-derived fibroblasts cells exhibit an 
oxidative phenotype as well as sensitivity to oxidative stress.  Therefore, these cells 
were tested for their responses to H2O2 in terms of cell survival. 
 
4.2.2.3.1 Optimization of seeding density and hydrogen peroxide concentration 
Initially control dermal fibroblasts were seeded at 5000 cells/well into a 96-wellplate.  
On the following day, fresh hydrogen peroxide (Sigma-Aldrich, Poole UK) was diluted 
in different media to determine dose response curve.  H2O2 was diluted in phenol red-
free DMEM with 2mM l-glutamine to the following concentrations: 6400µM, 3200µM, 
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1600µM, 800µM, 400µM, 200µM, 100µM 50µm and 25µM.  Cells were treated for 1 
hour after which time, media was replaced with complete growth media.  The 96-
wellplate was placed into the incubator for 18 hours.   
 
4.2.2.3.2 MTT assay 
After this period, cell viability was assessed using the MTT assay (see section 
3.2.4.4.2).  A dose response curve was constructed by plotting log10 of H2O2 
concentrations against percentage cell viability compared to untreated fibroblasts. 
 
4.2.2.3.3 Statistical analysis 
Statistical analysis was performed using Graph Pad Prism 6.0 (La Jolla, CA, USA).  
When comparing amyloid treated cells to untreated controls, two-way analysis of 
variance (ANOVA) was performed with post hoc Bonferroni’s/Dunnett’s comparisons. 
Studies involving comparisons between different cell lines, a two way ANOVA was 
performed with Dunnett’s multiple comparisons/ Students T test.  Dose response 
curves of cell lines with hydrogen peroxide were constructed using nonlinear 
regression with a variable slope, from which the IC50 of each cell line was calculated.  
IC50 values were compared to the control cell line using a two tailed, unpaired Student’s 
T test. 
 
4.2.2.4 Amyloid treatment studies 
Previous studies have examined the effects of exogenous Aβ1-42 on cell lines.  
Studies have shown metabolic effects (discussed in section 4.4) in response to amyloid 
treatment.  Therefore it was of interest to investigate the effects of amyloid on normal 
dermal fibroblasts.  
 
4.2.2.4.1 Optimization of cell seeding density 
Control fibroblasts were initially plated at 2x105 cells/ well in triplicate and then serially 
diluted 1:2 to 3.125 x 103  cells/ well into two 96 well plates.  The cells were incubated 
for 24 and 48 hours after which time; cell proliferation was measured using Cell Titer 
Blue reagent (see section 3.2.4.1).  The fibroblasts were then placed back into the 
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incubator for 3 hours after which time the A620 and A690 readings were measured.  The 
optimal seeding density was selected as the density at which the absorbance changed 
gradually over time without saturation. 
 
4.2.2.4.2 Amyloid treatment of hDF 
Human dermal fibroblasts were seeded into 96-wellplates (Corning) at 7.5x104 cell/ 
well.  On the following day, human Aβ1-42, pre-treated with hexofluoroisopropanol (to 
induced amyloid aggregation, forming oligomers was prepared in HEPEs at a stock 
concentration of 100µM.  This stock was diluted 1:10 to 10µM, which was then serially 
diluted 1:2 in culture media to the following concentrations, 10µM, 5µM, 2.5µM, 
1.25µM, 625nM, 312.5nM, 156nM and finally 78nM.  100µl of each amyloid preparation 
was applied in triplicate to the fibroblasts and the cells incubated for 48 hours.   
 
4.2.2.4.3 Cell viability 
After 48 hours, the media was aspirated and clarified whilst cells were briefly washed in 
fresh PBS before being incubated in 100µl of Cell Titer Blue reagent (see section 
3.2.4.1) for 2 hours to determine cell viability.   
 
4.2.2.4.4 Glucose uptake  
Media clarified from section 4.2.4.3 was assessed for glucose concentration using the 
Glucose HK assay kit (section 3.2.4.2).  Samples were diluted 1:20 in deionized to fit 
within the linear region of the glucose standard curve. 
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4.3 Results  
FAD-derived dermal fibroblasts were obtained from UCL Institute of Neurology carrying 
familial mutations in either PSEN1 or APP (Table 4.1), of which the mutations M146I, 
V717I and Intron 4 were picked for study. 
Gene Mutation Passage 
received 
Mutation 
description 
Mean age 
of onset 
Average 
age of 
death 
PSEN1 R278I P6 AGA -> ATA 49.5 - 
PSEN1 Y115H P6 TAT -> CAT 38.5 41.5 
PSEN1 M139V P4 ATG-> GTG 40.7 48.6 
PSEN1 Y115C P4 TAT -> TGT 44.2 55.0 
PSEN1 Intron 4 P4 Point mutation 
leading to 3 
transcripts * 
35.6 42.0 
 
PSEN1 M146I P2 ATG -> ATA 46.7 55.4 
APP V717I P4 London mutation, 
GTC -> ATC 
53.2 63.2 
Table 4.1. Table of patient mutations available for study.  *point mutation which can 
leading to 3 different transcripts which encode for either two truncated PS1 proteins or 
full length PS1 with extra Threonine residue. 
 
 
4.3.1 Cell proliferation 
Cell lines were initially assessed for cell proliferation rate using the MTT assay, 
compared to the control cell line (see Figure 4.2).  Cells were seeded for 24, 48 and 72 
hours to determine if there were any significant differences in growth rates at these 
time points.  No significant differences were observed at 24 or 48 hours.  However, at 
the 72 hour time point, there was an increase in the proliferation of cells containing 
fibroblasts carrying the APP717I mutation (140 ± 16.5%, p value = 0.0291) compared 
to control and an increase in growth of M146I cell line (139.2 ± 12.4%, p value = 
0.0366) when compared to control dermal fibroblasts.  
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Figure 4.2.  Graph of cell growth of fibroblast cell lines using the MTT assay.  Viability 
was measured using MTT/Cell Titer blue.  Results are expressed as a percentage cell 
growth compared with control fibroblasts ± SEM, (n=3).  P values <0.05 (*). 
 
 
4.3.2 Glucose uptake 
AD-derived fibroblasts were also tested for their ability to take up glucose from the 
media after 24 and 48 hours (see Figure 4.3), using the Glucose HK assay.  Glucose 
levels in the media were normalised to total levels of protein/well to account for any 
differences in the proliferation of cells.  There was a general trend of mutant cell lines 
utilising less glucose than the control cell line but no significant changes in glucose 
uptake were observed. 
Figure 4.3.  Graph showing the amount of glucose remaining in media after 24 and 48 
hours using the Glucose HK assay.  Results are presented as a percentage of the 
control cell line, ± SEM (n=3), normalised to total cellular protein. 
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4.3.3 Aβ ELISA 
Amounts of Aβ1-42 secreted into the media were assessed for fibroblast cell lines after 
24 and 48 hours of incubation.  FAD-derived fibroblasts have been reported to secrete 
amounts of  amyloid than compared to control cell lines(Citron et al., 1994).  It was 
expected they would secrete small amounts of the peptide, so media samples were 
vacuum evaporated five times the original volume.  Results from the amyloid ELISA 
showed non-detectable amounts of peptide (concentrations were below the limit of the 
assay, data not shown). 
 
4.3.4 Analysing mitochondrial function 
Optimization experiments were carried out using control dermal fibroblast cell lines.  
Cells were seeded to study mitochondrial function using the Seahorse Mito Stress Kit.  
Protocols provided by the manufacturer, recommend assay media to supplementation 
with 25mM glucose and 1mM sodium pyruvate, which is essential to be able to record 
a maximal OCR response.   
Optimization of compounds on the Seahorse analyser with fibroblasts seeded at 20000 
to 70000 cells per well across the plate.  Basal OCR (Figure 4.4) and ECAR readings 
(Figure 4.5) were measured four times after setting up a looped protocol of mixing, 
waiting and measuring.  The OCR measurements over time were constant throughout 
the experiment but ECAR readings were higher at the higher seeding densities.  
Generally, all OCR readings were stable, with increasing cell density leading to 
increases in OCR readings as expected.  The ECAR readings (Figure 4.5) showed 
differences between the different seeding densities.  ECAR readings for cells seeded at 
20000 cells showed the lowest ECAR along with the lowest OCR measurements.  
Seeding 30000 cells gave an abnormal response in ECAR which was unexpected.  
Ideally, the optimal seeding density of any cell line should exhibit consistently low 
ECAR values at rest, with OCR readings expected to between 100 to 500pmoles/min.  
The chosen seeding density for fibroblasts was 50000 cells, which gives an average 
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OCR of 144 ± 6.4 and average ECAR of 12.9 ± 2.6 mpH/ min.  This low OCR indicates 
a cell type of low metabolic activity, which was evident by slow growth.  
Figure 4.4.  Basal OCR measurements of control hDF seeded at different densities. 
Figure 4.5.  ECAR readings of the same cells seeded over time. 
 
 
Following optimisation of the seeding density, the concentration of mitochondrial 
inhibitors was optimised.  Optimized concentrations are tabulated in Table 4.2. 
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Mitochondrial inhibitor  Optimal concentration (µM) 
Oligomycin 1 
FCCP 5 
Antimycin A 0.5 
Rotenone 0.5 
Table 4.2.  Table of the optimal concentrations of inhibitors calculated. 
 
 
The Mito Stress assay was performed in accordance with the manufacturer’s 
instructions.  After the run was complete, all readings were normalized to protein 
concentrations and measurements of OCR were analysed using the Seahorse 
MitoStress Report to determine the metabolic profiles of each cell line.  Data was 
analysed in Graph Pad 6.0 using one way ANOVA and unpaired Students T test to 
compare the metabolic measurements of each cell line to each other.  
 
Figure 4.6 shows a typical metabolic profile of the hDF cell line produced from the 
MitoStress test.  The readings are presented as percentage of the basal OCR for each 
cell line.  These cell lines respond to oligomycin by reducing OCR and demonstrate an 
increased OCR in response to FCCP.  The following rotenone and antimycin A 
injection a modest fall in OCR is observed. 
Figure 4.6.  Graph of one MitoStress experiment of the hDF cell lines.  Results are 
represented as percentage of basal OCR readings for each cell line.  
 
Figure 4.7 shows the metabolic measurements calculated by analyzing the OCR 
readings in the MitoStress report V2.  Results are presented as average OCR 
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readings, normalised against protein.  Multiple Student’s Tests with post hoc Holm-
Sidak method (p<0.05) was performed between the different cell lines for the different 
metabolic measurements calculated, which revealed no signficance between any of the 
cell lines.  Results also show some variation between experimental runs, despite 
protein normalization.  
 
 
Figure 4.7.  Graph of the metabolic parameter calculated OCR readings recorded from 
the MitoStress test.  Results are presented as OCR readings, normalised to total 
protein per well ± SEM, (n=3).   
 
 
4.3.5 Oxidative stress of human dermal fibroblasts 
As oxidative stress is associated with AD and other neurodegenerative disorders, the 
next step was to determine the responses of dermal fibroblasts (both control and AD-
derived) to oxidative stress.  One common method to induce oxidative stress is to treat 
cells with hydrogen peroxide (H2O2).  H2O2 is a strong oxidizing agent, which is highly 
unstable.  When applied to organic material, it can break down to form highly reactive 
OH- radicals, which can interact with proteins and DNA.  Therefore, the effects of 
hydrogen peroxide on fibroblasts were assessed using the MTT assay to study cell 
growth.  Previous studies have shown that the effects of hydrogen peroxide on 
fibroblasts are both dose-dependent and cell density-dependent.  To this end, fibroblast 
cells were seeded at 5000 cells/well across a 96-well plate.  Decreasing concentrations 
of hydrogen peroxide diluted in, phenol-red free DMEM with 2mM l-glutamine.  Cells 
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were incubated for 1 hour in H2O2 and then cells allowed to recover after 18 hours to 
assess for cell viability in normal medium.  To calculate the IC50, one point had to be 
excluded as this was distorting the data.  Interestingly, at all densities tested, cell 
viability does not decrease at 800µM, but increases slightly.  This variation occurs 
during all experiments suggesting that this is not due to technical error, but may reflect 
a positive response in fibroblasts. 
 
For the analysis of stress responses in patient derived cells, cell viability was measured 
using the MTT assay, and calculated as a percentage of the untreated control (Figure 
4.8).  IC50 values were calculated for each patient derived line and compared to the 
control (Table 4.2).  Statistical analyses of the IC50 values suggest that there was no 
significant difference in the IC50 values between the control and patient derived 
fibroblasts.  There was also considerable variation between repeat experiments. 
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Figure 4.8.  Non-linear regression curve fit demonstrating the dose response of AD-
derived fibroblasts treated with increasing concentrations of H2O2 (n=3).  Cell viability 
was measured using the MTT assay.  IC50 values were calculated using GraphPad 
Prism 6.0 (see Table 4.3).  Results are displayed a percentage of the untreated cell line 
± SEM, (n=3).   
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Table 4.3.  Table of the average IC50 calculated using Graph Pad Prism 6.0.  A two 
tailed, unpaired T- test (with Welch’s correction) showed no significant differences 
between mutations and control HDF. 
 
 
4.3.6 Amyloid treatment of hDF 
Normal dermal fibroblasts were treated with a range of oligomeric Aβ1-42 
concentrations to determine its effects on this non-neuronal cell type.  
 
4.3.6.1 Cell viability 
Human dermal fibroblasts were treated with increasing concentrations of Aβ1-42 for 48 
hours, after which time cell viability was assessed by Cell Titer Blue (Figure 4.9).  At all 
concentrations, no cellular toxicity was observed.  At the lower concentrations of 78nM 
and 156nM, there were no significant changes in viability.  However at 312.5nM of 
amyloid, there was a significant increase of 109.6 ± 4.9%, (P<0.05) in resazurin 
absorbance.  Significant increases in resazurin absorbance were also observed at 
62.5nm (112.5 ± 1.4 %, (P<0.05) 125nM (109.8 ± 2.1, (P<0.05). 5µM 112 ± 3.6% 
(P<0.05) 10µM and 121.6% ±0.634% (P<0.05). 
Cell type Average IC50 (µM) T test analysis compared 
against Control HDF 
P value 
Control HDF 
 
584.9 ± 122.6 - - 
APPV717I 583.9 ± 223.9 
 
NS 0.4612 
M146I 714.6 ± 330.3 
 
NS 0.7412 
 
Intron 4 669.7 ± 40 
 
NS 0.5679 
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Figure 4.9.  Graph showing the cell viability of dermal fibroblasts treated with increasing 
concentrations of Aβ1-42, represented as a percentage of control (± SEM n=3). p 
<0.05 (*), p < 0.005 (**), p< 0.0001(****). 
 
 
4.3.6.2 Glucose uptake 
The glucose remaining in the media from dermal fibroblasts treated with Aβ1-42 was 
determined using the Glucose HK assay after 48 hours (Figure 4.10).  There was a 
significant reduction in glucose uptake at 312.5nm, where there was 113.3 ± 2.0 % 
(p<0.05) more glucose in the media, when compared to untreated controls.  However, 
there was no significant difference at any of the other concentrations tested.  
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Figure 4.10.  Graph showing the amount of glucose remaining in the media in Aβ1-42 –
treated dermal fibroblasts compared to untreated controls.  Cell viability was measured 
using Cell Titer Blue.  Results are presented as a percentage ± SEM compared to non-
treated controls (n=3), p<0.05(*). 
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4.4 Discussion 
Since the emergence of iPSCs technology in 2006, researchers have used these cells 
to create cellular models of genetic disorders by taking patient somatic cells and 
reprogramming them back into induced pluripotent stem cells.  Several studies have 
utilised FAD and SAD derived fibroblasts to create neuronal cultures and to study early 
AD development (Israel et al., 2012, Kondo et al., 2013, Qiang et al., 2011, Yagi et al., 
2011).  All of these studies have focussed on characterising iPSC-derived neurons.  
However, a recent study has analysing neural precursor cells (hNPCs) prior to 
differentiation (Sproul et al., 2014) found significant differences in amyloid processing 
between AD and control NPCs.  As NPCs are also a more homogenous population, 
this study suggested that hNPCs could provide a better system to identify novel 
molecules, potentially important for early events in AD and might allow better cross 
comparisons between control and FAD cells.  This study demonstrated that FAD 
derived fibroblasts and their reprogrammed NPCs counterparts have a higher 
Aβ42/Aβ40 ratio than equivalent control cells, suggesting pathogenic proteolytic 
processing of endogenous APP in these cells.  As patient derived fibroblasts represent 
an unadulterated patient cell line, these cells may provide useful tools for identification 
of novel molecules for the treatment of AD as well as pathways that may lead to the 
development of disease. 
 
4.4.1 Characterizing FAD-derived fibroblast metabolism 
The above study provides an interesting rationale for studying alterations observed in 
FAD-derived fibroblasts in terms of their metabolism.  Previous studies have observed 
changes in cell adhesion, vimentin distribution (Takeda et al., 1990) calcium regulation 
(Peterson et al., 1985), oxidative metabolism (Peterson and Goldman, 1986), 
potassium channel activity (Etcheberrigaray et al., 1993) and the phosphotidylinositide 
cascade including PKC (Bruel et al., 1991, Govoni et al., 1993).  Initial observations 
here in this study suggested that there were significant differences in the proliferation of 
some fibroblast lines.  In addition, whilst results were insignificant, there was a trend for 
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reduced glucose uptake in these cells and a trend for increased sensitivity to oxidative 
stress which again was not significant.  The reduction in glucose uptake has been 
observed in proliferating APP-expressing SHSY5Y cell lines which suggests some 
common mechanism of the effects of amyloid on both these cell lines.  As such, the 
amount of secreted Aβ1-42 from these fibroblasts was assessed.  Unfortunately, no 
amyloid could be detected as concentrations were below the limit of detection even 
after vacuum evaporation of the media.  This contradicts previous studies which found 
FAD- derived fibroblasts secreting low levels of amyloid, which were more than that of 
control fibroblasts (Scheuner et al., 1996b, Scheuner et al., 1996a, Duff et al., 1996, 
Citron et al., 1994).  DS derived fibroblasts were reported to secrete low levels of Aβ1-
40 but Aβ1-42 levels were undetectable (Shi et al., 2012a).  Future experiments will 
therefore assess Aβ1-40 secretion from fibroblasts, as well as the secretion of sAPPα 
and sAPPβ fragments.  Investigating Aβ1-42 release after stressing fibroblasts with 
hydrogen peroxide may also be an option to consider studying. 
 
Mitochondrial dysfunction has been observed in the brains of AD patients as well as 
AD transgenic mice.  As metabolic dysfunction has previously been described within 
patient derived fibroblasts, this would suggest that either APP/ PSEN1 mutations are 
able to drive dysfunction within these cells or that bodies of AD patients due to chronic 
stress.  To this end, mitochondrial function was studied extensively in AD-derived 
fibroblasts using the Seahorse analyser.  However, no significant differences were 
observed suggesting that these cells are not suffering from mitochondrial stress.  A 
previous study has shown that mitochondria isolated from AD-derived fibroblasts are 
more susceptible to free radicals (Kumar et al., 1994).  Therefore, future experiments 
will determine the responses of patient derived cells in response to oxidative stress, (by 
using hydrogen peroxide treatment) on the Seahorse analyser.  It should also be noted 
that the Mito Stress test was conducted in high glucose media (25mM).  Future 
experiments will be performed using a range of glucose concentrations to determine its 
effects on mitochondrial function.  Further kits available from Seahorse Biosciences 
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would also allow the determination of glycolysis stress as well as lipid metabolism.  
Interestingly, skin fibroblasts from AD patients have been demonstrated to show 
changes in cholesterol metabolism (Pani et al., 2009).  To fully rule out metabolic 
dysfunction in these cells other pathways should also be determined.   
 
4.4.2 Effects of exogenous Aβ1-42 on fibroblasts 
As a number of studies have demonstrated increases in the secretion and ratio of Aβ1-
42/40 in FAD-derived fibroblasts (Sproul et al., 2014, Duff et al., 1996, Scheuner et al., 
1996a, Tamaoka et al., 1994), it was of great interest to determine the effects of 
exogenous Aβ1-42 on these cells.  The secretion of Aβ from platelets and leukocytes 
following their activation, led to autocrine or paracrine effects on cells throughout the 
body (Li et al., 1999, Chen et al., 1995).  Aberrant Aβ metabolism is consistently 
detected in plasma of AD mutation carriers, where platelets are suggested to be the 
major source of APP.  Studies of patients with platelets with low α-granule content 
demonstrate a reduction in APP expression, which led to a reduction in plasma APP 
levels (Li et al., 1994) supports this theory.  The physiological role of this secreted APP 
from platelets is poorly characterised, but in AD, it is hypothesised to be deposited into 
the brain.  The mechanism by which amyloid may be delivered into the brain may 
involve complexes containing HDL and VHDL in association with ApoJ (Koudinov et al., 
1994).  With respect to the immune system, lymphocytes, monocytes, neutrophils, 
macrophage and microglia have been confirmed to express and secrete APP (Konig et 
al., 1992).  Stimulated T-lymphocytes secrete the larger APP isoforms as well as 
APP695, which may be associated with non-adherence and adherence in the immune 
system.  Microglia produce APP, which can interact with different extracellular matrix 
components, and may influence APP secretion as well as intracellular APP 
metabolism, implying a role in microglial mobility (Monning et al., 1995).  FAD-derived 
lymphocytes are also reported to secrete Aβ (and other APP cleavage products) 
suggesting that these cells could be another source of Aβ found in blood.  Changes in 
calcium homeostasis are considered to play a role in AD pathology, in fact in stimulated 
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lymphocytes, Aβ amplifies intracellular calcium signalling, although this effect was 
ameliorated in sporadic and FAD –derived lymphocytes (Eckert et al., 1994).   
 
Recent studies in our laboratory have also investigated the effect of exogenous 
amyloid on a range of cells.  Tarczyluk et al. (2015) demonstrated that human stem 
cell-derived neuron and astrocyte cultures treated with oligomeric Aβ1-42 display 
hypometabolism, with regards to the utilisation of substrates such as glucose, pyruvate, 
lactate and glutamate.  In addition, astrocytes within these cultures stored significantly 
higher levels of glycogen in comparison to controls.  Significant changes in NAD+/ 
NADH, ATP and GSH levels were observed, suggesting a disturbance in the energy 
redox axis.  Other studies in our laboratory (Dr Eric Hill, Personal communication) have 
demonstrated that following treatment of the mouse myoblast cell line C2C12 cell line 
with amyloid, these cells exhibited increased cell viability, decreased glucose uptake 
and increased glycogen storage.   
 
Treatment of normal dermal fibroblasts with Aβ1-42 at the low concentrations tested 
did not cause cell death but led to a significant decrease in glucose uptake within these 
cells.  This suggests some metabolic effect which in line with previous studies 
discussed above.  In contrary, at high concentrations of Aβ1-42 cells exhibited 
increased growth and increased glucose usage.  Aβ monomers are known to exert 
neurotrophic and neuroprotective effects (Giuffrida et al., 2009, Yankner et al., 1990, 
Chen and Dong, 2009).  Therefore, the form of Aβ1-42 used in this study should be 
verified to identify which form of amyloid could be affecting fibroblast metabolism.  
Such observations strongly imply that the metabolic and proliferative effects of amyloid 
are not neuronal-specific and that AD is possibly one consequence of pathological APP 
misprocessing.  Use of the Seahorse analyzer to study mitochondrial function and 
glycolysis in response to amyloid treatment would be ideal to further study fibroblast 
responses. 
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As numerous studies have demonstrated the production of APP and its cleavage 
products in skeletal muscle, skin cells, blood and gut, this further supports the idea that 
APP is expressed, metabolised and secreted by cells outside of the brain where its 
cleavage products may play physiological roles under non-pathological conditions that 
become perturbed in AD.  As such, future studies should further investigate the utility of 
patient derived cells in order to study the biological roles of APP within tissues. 
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Chapter 5: Conclusions and future work 
The cell lines used for the study of endogenous APP expression in this thesis provide 
an interesting insight into the effects of APP on cellular metabolism.  This study is novel 
is in that it attempts to establish a link between APP overexpression/ mutant APP 
expression with reduced glucose uptake and mitochondrial function.  APP 
overexpression has been a common route of generating AD models by transfecting the 
APP gene under the control of a non-native / viral promoter into host cells.  This has 
led to the production of a plethora of AD in vivo and in vitro models, which has 
increased our knowledge of AD pathology, but their relevance to human disease has 
been questioned.  For example, the use of rodents to induce AD-like symptoms by 
expressing multiple human genes has yielded results which may not relate to the 
natural development of dementia.  A further point to note is that mouse amyloid does 
not aggregate as it does in humans, and so the effects of amyloid deposition may lead 
to responses that are rodent-specific.  The promoter used is also of great importance, 
as the use of viral promoters can lead to unnaturally high levels of protein expression, 
which could exaggerate the pathology of AD.  Taking these findings into account, the 
human synapsin I promoter which is native to neuronal phenotypes was used to control 
APP expression.  This promoter is relatively weak in comparison to viral promoters 
such as CMV and may more naturally represent more mildly elevated levels of APP.  
However, the lack of significance in many of the assays used to assess clones 
suggests that the level of APP expression may not have been sufficient to drive 
significant pathology. 
 
The use of patient fibroblasts provides an interesting opportunity to identify changes 
associated with mutations in APP expressed at natural levels.  It also allows for the 
identification of early changes that may occur in non-neuronal cell lines that may be 
relevant to AD.  However, the study of these cell lines did not reveal any overt 
pathological phenotypes in comparison to control cell lines.   
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The approaches used in this study are potentially hampered by a number of issues with 
the methodology used.  Alternative strategies could be employed to investigate 
metabolism in AD.  Future work will further aim to characterise the SHSY5Y lines in 
terms of the number and location of APP genes inserted into the cell line.  Techniques 
such as inverse PCR sequencing and Southern blotting could be used to determine 
where and how many copies of the APP gene had integrated into the cellular genome 
of each clone.  Using the SHSY5Y cell line to express a mutant form of APP may be an 
over simplification of studying APP metabolism in neuronal cell lines.  In the SweAPP-
expressing cell lines, the native wtAPP695 gene are still expressed by the cell, which 
may affect processing of the exogenous protein.  Therefore, future work should 
consider knocking out the native wtAPP695 expression prior to integrating the 
SweAPP695 mutation. 
 
As there is little control of the level of APP expression a useful tool would be to develop 
an inducible model such as the Tet-on system to control both the timing and level of 
APP expression in response to an exogenous additives such as doxycycline.  As such, 
changes in APP expression and metabolism could be simultaneously monitored.  
Alternatively, knocking in the BACE1 gene or even knockdown of the α-secretase 
activity could be considered to drive amyloid production.   
 
In addition, cell lines should be fully characterised in terms of their APP metabolism, 
including analysis of the forms of soluble APP as well as Aβ1-40/42 ratios and crucially, 
levels of BACE1 activity.  The levels of Aβ1-42 produced by the cell may be limited by 
the expression levels of BACE1.  This could then be used to gain a better 
understanding of the effects of APP processing on cellular metabolism.  
Pharmacological inhibition of BACE or γ secretases could also be used to modulate 
APP processing and the effects on metabolism determined.   
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Future work with the cell lines developed will utilise the Glycolysis stress kit available 
from Seahorse Biosciences in order to investigate glycolytic pathways, which may 
operate within these cells and be affected by APP processing.  The use of cellular 
stressors such as Aβ or oxidative stress could also be used in combination with the 
Seahorse bioanalyser, could also be used to monitor the subtle effects of stress on 
cellular metabolism.  Conversely potential neuroprotective agents such as 
hydroxybutyrate or NMN could also be analysed using this system. 
 
iPS cells are increasingly used as tools to model AD.  These stem cells can be 
generated from ‘normal’ controls as well as from people who carry genotypes 
associated with AD making them highly attractive models.  They also overcome the 
ethical issues faced with hESCs and have already been used to study ALS, spinal 
muscular atrophy and familial dysautonomia (Hu et al., 2010).  Since their discovery, 
iPSC lines have been successfully generated independently in different laboratories 
and are comparable to hESCs in their morphology and gene-expression profiles (Park 
et al., 2008a).  
 
These cells can be differentiated into neuronal cell types but it was reported that the 
neural differentiation of iPSCs is variable and less efficient when compared to hESC 
differentiation A number of groups have also suggested that there is large variability 
and unpredictability in the differentiation such cell lines (Hu et al. (2010).  More 
recently, studies have successfully cultured neurons from DS patient fibroblasts, which 
produce more amyloid 1-42 and form amyloid plaques (Shi et al., 2012a).  These cells 
also demonstrate network functionality and can therefore provide a system to model 
the functional effects of APP overexpression/misprocessing.  In addition, 
phosphorylated tau was found to aberrantly accumulate in the dendrites and cell bodies 
of DS-derived neurons compared to control neurons (Shi et al., 2012a). 
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Emergence of iPSC cells derived from AD patients has rendered the use of cell lines 
such as the SHSY5Y cell lines almost obsolete in terms of studying AD development.  
Current studies already show both tau and amyloid pathology in cells derived from AD 
patients.  This would not be possible to replicate naturally in SHSY5Y cells.  
Furthermore, neuronal cultures derived from patient cells do not need to be genetically 
manipulated in terms of molecular cloning as they already carry a specific mutation, 
and have been thoroughly genotyped and karyotyped to ensure that they represent a 
‘normal’ cell line.   
 
Caution should be taken when using iPSCs as numerous studies have described 
differences in the fibroblasts taken from AD patients (Chapter 4).  These have the 
potential to be carried through to subsequent iPSC clones.  A number of studies have 
suggested that iPSCs have a ‘phenotypic memory’ of their previous cell line and may 
continue to express genes associated with their previous state (Ohi et al., 2011).  
Therefore, epigenetic changes present in patient cells may contribute to the 
phenotypes observed in the cells after differentiation and need to be considered.  
Questions also remain over when AD begins.  FAD patients probably express APP 
inappropriately during development and may therefore suffer the effects of AD before 
birth.  In this way the effects of APP misprocessing on development should also be 
considered (Sproul et al. 2014).  Alzheimer’s disease is considered to develop over a 
number of decades.  As such short term cultures may not reveal changes in cells at 
physiological levels of expression.  However, experiments in our laboratory have 
demonstrated that iPSC derived neurons can be maintained in culture for over a year 
(Dr David Nagel; personal communication).  As such long term effects of APP 
misprocessing could be studied during which time the low levels of expression may 
elicit changes in metabolism. 
 
There are no easy answers as to how best to model AD.  Instead a range of models 
should be considered and their translation into humans should be treated with caution.  
230 
 
However, it is clear that AD cannot be considered a brain specific phenomenon and 
future research should attempt to understand the role of APP in a range of tissues.  
This may eventually reveal its natural functions within the body and how it is changes in 
its processing lead to disease. 
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7.0 Appendices 
7.1 Sequencing for Pittsburgh/ jAPP695 in pcDNA3.1 
Sample Primer Construct Comment 
1 Pcdna 100- seq EM3 DH5 mini 23-916 
2 App 613 for EM3 DH5 mini correct 
3 App1004 EM3 DH5 mini G-T at 2124 
4 PCDNA+70 rev EM3 DH5 mini g-t at 2124 
5 Pcdna 100- seq EM4 MTR mini correct 
6 App 613 for EM4 MTR mini correct 
7 App1004 EM4 MTR mini G – T at 2124 
8 PCDNA+70 rev EM4 MTR mini G – T at 2124 
9 Pcdna 100- seq EM7 MTR mini correct 
10 App 613 for EM7 MTR mini correct 
11 App1004 EM7 MTR mini G – T at 2124 
12 PCDNA+70 rev EM7 MTR mini G – T at 2124 
13 HindIII primer 
(Ex apps alt for) 
Franks APP donor 
plasmid 
correct 
14 App 613 for Franks APP donor 
plasmid 
correct 
15 App1004 Franks APP donor 
plasmid 
G -> T at 2124 
16 APP 1545 Franks APP donor 
plasmid 
G -> T at 2124 
17 APP2040 for Franks APP donor 
plasmid 
Ok, did not get 
sequence until at 2290, 
after mutation 
18 App165 rev Franks APP donor 
plasmid 
Unrecognised 
19 APP695rev Franks APP donor 
plasmid 
1150-1923 
20 Ex apps alt for Pittsburgh APP donor 
plasmid 
25-834 , downstream 
mismatching 
21 App 613 for Pittsburgh APP donor 
plasmid 
Upstream sequence 
does not match, 883-
1568 
22 App1004 Pittsburgh APP  
donor plasmid 
1050-2092 
23 APP 1545 Pittsburgh APP donor 
plasmid 
1579-2361 
 
24 APP2040 for Pittsburgh APP donor 
plasmid 
2081- end of gene 
25 App165 rev Pittsburgh APP donor 
plasmid 
Mismatching 
26 APP695rev Pittsburgh APP donor 
plasmid 
1071-2049 
 
 
270 
 
7.2 Gel extraction 
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7.3 PCR Purification 
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7.4 QIAGEN Miniprep protocol 
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7.5 Transfection of COS7 with Lipofectamine LTX 
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7.5 PierceNet BCA protein assay 
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7.6 Antibodies for Western blotting 
 
Antibody Dilution Company 
Mouse anti-APP695 1:2000 Invitrogen 
Mouse anti- Aβ (6E10) 1:1000 Covance 
Rabbit anti-β actin 1:1000 Sigma Aldrich 
Goat anti-rabbit HRP 1:5000 Dako 
Rabbit anti-mouse HRP 1:5000 Cell Signalling 
 
7.7 Recipe for making buffers (Western blotting) 
 
10x Tris buffered saline (TBS):  Trizma base (Sigma) 
     NaCl  
     Make up to final volume of 1L distilled water 
     Adjust pH to 8.0 with 6N HCl 
      
10% Tween:    5ml Tween-20 
     45ml distilled water 
TBS-T (1L):     100ml 10x TBS 
     10ml 10% Tween 
     890ml distilled water  
 
10x Transfer buffer (TB):   72.08g Glycine (Sigma) 
     15.52g Trizma base (Sigma) 
     5g SDS (Sigma) 
     Dissolve in 1L distilled water 
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7.8 DNA/ Protein Ladder sizing 
 
PageRuler Prestained Protein Ladder 
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7.9 List of primers used 
 
Purpose Annealing 
temp (°C)  
Primer 
 
Sequencing 
of the 
pcDNA3 
plasmid 
 
- 
pcDNA -100 seq 5’ CAAATGGGCGGTAGGCG  
3’ 
pcDNA+70 5’ GGTCAAGGAAGGCACGG 3’ 
Sequencing 
the donor 
plasmids 
 
- 
APP2040 5’ CGGCTACGAAAATCCAACC 3’ 
APP165 Rev 5’ GGTTTTGGTCCCTGATGG 3’ 
Sequencing 
the APP 
gene 
- APP613 5’ GACTCGGATGTCTGGTGG 3’ 
APP1004 5’ TGAGAGAATGGGAAGAGGC 3’ 
APP 1545 5’ TCAGTTACGGAAACGATGC 3’ 
Introducing 5’ 
HindIII RS  
 
55 
Ex Alt APP for 
5’TCCCAAGCTTGCCACCATGCTGCCCGGT
TTGGC 3’ 
Introducing 3’ 
XbaI RS 
APP695rev  
5’ 
AGCTTCTAGACTAGTTCTGCATCTGCTCAA
A 3’ 
Introducing 
the Swedish 
mutations 
55 SweAPP695 rev  
5’ TCGGAATTCTGCATCCAGATTCACTTC 3’ 
PCR of APP 
for entry into 
pCR8 
66 APP P8 TOPO For G 5’ 
TTGCCACCATGCTGCCCG 3’ 
APP 8 Rev 3 STOP  
5’ CTAGTTAAGACTAGTTCTGCATCTGCTC 
3’ 
PCR of 
SYN1 for 
entry into 
pENTR5’  
 Syn1 pentr5 For g 
5’AGGCGGTATCCTGCAGAGGG 3’ 
Syn1 pentr Rev 5’ GATCCCTGCGCTCTCAGG 
3’ 
Colony 
screening of 
pcDNA3/ 
pcDNA3.1 
55 BGH REV 5’ TAGAAGGCACAGTCGAGG 3’ 
T7 promoter 5’TTAATACGACTCACTATAGGG 
3’ 
Colony 
screening of 
pLenti6.4 
constructs 
55 pLenti6.4 for seq 5’ 
GATTGGGGGGTACAGTGC 3’ 
WPRE Rev SQ 5’ 
CCACATAGCGTAAAAGGAGC 3’ 
Colony 
screening of 
pCR8/ 
pENTR5’ 
vectors 
 M13 For (-20) 5’ GTAAAACGACGGCCAGT 3’ 
M13 Rev  5’ AACAGCTATGACCATG 3’ 
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7.10 Recombination of TOPO vector into final destination vector 
 
 
7.11 293FT resurrection and culture 
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280 
 
7.12 Lenti-X GoStix  
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7.13 QuickTiter Lentivirus Titer test (Lentivirus-associated HIV p24) 
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7.14 Aβ1-42 ELISA 
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